Document:

Exhibit 10.1

 

EXECUTION VERSION

 

 

TERM LOAN AGREEMENT

 

dated as of

 

August 11, 2022,

 

among

 

V.F. CORPORATION,

 

the
LENDERS party hereto

 

and

 

JPMORGAN CHASE BANK,
N.A.,

as Administrative Agent

 

 

 

WELLS FARGO SECURITIES,
LLC,

JPMORGAN CHASE BANK, N.A.,

PNC BANK NATIONAL ASSOCIATION,

TD SECURITIES (USA) LLC,

TRUIST
SECURITIES, INC.

 

and

 

U.S. BANK NATIONAL
ASSOCIATION,

as Joint Lead Arrangers and Joint Bookrunners

 

WELLS FARGO BANK,
NATIONAL ASSOCIATION,

as Syndication Agent

 

PNC BANK NATIONAL
ASSOCIATION,

TD BANK, N.A.,

TRUIST BANK

 

and

 

U.S. BANK NATIONAL
ASSOCIATION

as Documentation Agents

 

 

     

     

    

TABLE
OF CONTENTS

 

Page

 

	ARTICLE I
	 	 
	Definitions and Terms
	 
	SECTION 1.01.  Definitions	1
	SECTION 1.02.  Classification of Loans and Borrowings	24
	SECTION 1.03.  Rules of Interpretation	24
	SECTION 1.04.  Interest Rates; Benchmark Notification	26
	SECTION 1.05.  Divisions	26
	 	 
	ARTICLE II
	 	 
	The Credits
	 
	SECTION 2.01.  Commitments	27
	SECTION 2.02.  Loans and Borrowings	27
	SECTION 2.03.  Requests for Borrowings	27
	SECTION 2.04.  Funding of Borrowings	28
	SECTION 2.05.  Interest Elections	29
	SECTION 2.06.  Termination, Reduction and Increase of Commitments	30
	SECTION 2.07.  Repayment of Loans; Evidence of Debt	31
	SECTION 2.08.  Prepayment of Loans	32
	SECTION 2.09.  Fees	33
	SECTION 2.10.  Interest	33
	SECTION 2.11.  Payments Generally; Pro Rata Treatment; Sharing
    of Set-offs	34
	SECTION 2.12.  Defaulting Lenders	36
	SECTION 2.13.  Extension Offers	36
	SECTION 2.14.  Use of Proceeds	36
	 	 
	ARTICLE III
	 	 
	Change in Circumstances
	 
	SECTION 3.01.  Increased Cost and Reduced Return	38
	SECTION 3.02.  Alternate Rate of Interest	39
	SECTION 3.03.  Illegality	42
	SECTION 3.04.  Compensation	42
	SECTION 3.05.  Taxes	43
	SECTION 3.06.  Designation and Change of Lending Offices	45
	SECTION 3.07.  Substitution of Lenders	45

 

    i 

     

    

	 	 
	ARTICLE IV
	 	 
	Conditions to Making Loans
	 
	SECTION 4.01.  Conditions of Closing	46
	SECTION 4.02.  Conditions to Making Loans	47
	 	 
	ARTICLE V
	 	 
	Representations and Warranties
	 
	SECTION 5.01.  Corporate Existence and Power	48
	SECTION 5.02.  Corporate and Governmental Authorization; No
    Contravention	48
	SECTION 5.03.  Binding Effect	48
	SECTION 5.04.  Financial Information	48
	SECTION 5.05.  Litigation	49
	SECTION 5.06.  Compliance with ERISA	49
	SECTION 5.07.  Environmental Matters	49
	SECTION 5.08.  Taxes	49
	SECTION 5.09.  Margin Stock	50
	SECTION 5.10.  Investment Company	50
	SECTION 5.11.  Full Disclosure	50
	SECTION 5.12.  No Consents, Etc	50
	SECTION 5.13.  Anti-Corruption Laws and Sanctions	50
	 	 
	ARTICLE VI
	 	 
	Affirmative Covenants
	 
	SECTION 6.01.  Financial Reports, Etc	51
	SECTION 6.02.  Payment of Taxes	53
	SECTION 6.03.  Maintenance of Properties; Insurance	54
	SECTION 6.04.  Compliance with Laws	54
	SECTION 6.05.  Books and Records	54
	SECTION 6.06.  Existence	54
	 	 
	ARTICLE VII
	 	 
	Negative Covenants
	 
	SECTION 7.01.  Financial Covenant	55
	SECTION 7.02.  Liens	55
	SECTION 7.03.  Indebtedness of Subsidiaries	56
	SECTION 7.04.  Consolidations, Mergers and Sales of Assets	57
	SECTION 7.05.  Use of Proceeds	57

 

    ii 

     

    
	 	 
	ARTICLE VIII
	 	 
	Events of Default and Acceleration
	 
	SECTION 8.01.  Events of Default	57
	SECTION 8.02.  Administrative Agent to Act	60
	SECTION 8.03.  Cumulative Rights	60
	SECTION 8.04.  No Waiver	60
	SECTION 8.05.  Allocation of Proceeds	60
	 	 
	ARTICLE IX
	 	 
	The Administrative Agent
	 
	SECTION 9.01.  Appointment and Authority	61
	SECTION 9.02.  Rights as Lender	61
	SECTION 9.03.  Exculpatory Provisions	62
	SECTION 9.04.  Reliance by Administrative Agent	63
	SECTION 9.05.  Delegation of Duties	63
	SECTION 9.06.  Resignation of Administrative Agent	63
	SECTION 9.07.  Acknowledgments of Lenders	64
	SECTION 9.08.  No Other Duties, Etc	67
	SECTION 9.09.  Administrative Agent May File Proofs of Claim	67
	SECTION 9.10.  Certain ERISA Matters	67
	SECTION 9.11.  Posting of Communications	69
	 	 
	ARTICLE X
	 	 
	Miscellaneous
	 
	SECTION 10.01.  Assignments and Participations	70
	SECTION 10.02.  Notices; Effectiveness; Electronic Communication	73
	SECTION 10.03.  Right of Set-off; Adjustments	75
	SECTION 10.04.  Survival	75
	SECTION 10.05.  Expenses	75
	SECTION 10.06.  Amendments and Waivers	76
	SECTION 10.07.  Counterparts; Electronic Execution	77
	SECTION 10.08.  Termination	78
	SECTION 10.09.  Indemnification; Limitation of Liability	79
	SECTION 10.10.  Severability	80
	SECTION 10.11.  Integration	80
	SECTION 10.12.  Governing Law; Waiver of Jury Trial	80
	SECTION 10.13.  Confidentiality	81
	SECTION 10.14.  “Know Your Customer” Checks; Certain
    Notices	82
	SECTION 10.15.  Interest Rate Limitation	83
	SECTION 10.16.  No Fiduciary Relationship	83

 

    iii 

     

    
	SECTION 10.17.  Acknowledgement and Consent to Bail-In of Affected
    Financial Institutions	84

  

    iv 

     

    

Schedule:

 

	Schedule 2.01	Commitments

Exhibits:

 

	Exhibit A	Form of Assignment and Assumption
	Exhibit B	Form of Borrowing Notice
	Exhibit C	Form of Interest Election Request
	Exhibit D	Form of Accession Agreement
	Exhibit E	Form of Compliance Certificate

    v 

     

    

TERM
LOAN AGREEMENT dated as of August 11, 2022, among V.F. CORPORATION, a Pennsylvania corporation (the “Company”); the
LENDERS from time to time party hereto; and JPMORGAN CHASE BANK, N.A., as Administrative Agent.

 

WITNESSETH:

 

WHEREAS
the Company has requested that the Lenders make available to the Company a term loan facility of up to US$1,000,000,000 (which may be
increased to US$1,100,000,000), the proceeds of which are to be used for general corporate purposes; and

 

WHEREAS
the Lenders are willing to make the term loan facility available to the Company upon the terms and conditions set forth herein.

 

NOW,
THEREFORE, the Company, the Lenders and the Administrative Agent hereby agree as follows:

 

ARTICLE
I

Definitions and Terms

 

SECTION
1.01.  Definitions.  For the purposes of this Agreement, the following terms shall have the respective meanings
set forth below:

 

“ABR
Borrowing” means any Borrowing comprised of ABR Loans.

 

“ABR
Loan” means any Loan that bears interest at a rate determined by reference to the Alternate Base Rate.

 

“Accession
Agreement” has the meaning specified in Section 2.06(d).

 

“Adjusted
Daily Simple SOFR” means an interest rate per annum equal to (a) Daily Simple SOFR plus (b) 0.10% per annum; provided
that if Adjusted Daily Simple SOFR as so determined would be less than zero, such rate shall be deemed to be zero.

 

“Adjusted
Term SOFR” means, for any Interest Period, an interest rate per annum equal to (a) Term SOFR for such Interest Period plus
(b) 0.10% per annum; provided that if Adjusted Term SOFR as so determined would be less than zero, such rate shall be deemed to
be zero.

 

“Administrative
Agent” means JPMorgan, in its capacity as administrative agent for the Lenders hereunder, or any successor appointed in accordance
with Section 9.06.  Unless the context requires otherwise, the term “Administrative Agent” shall include any Affiliate
of JPMorgan through which JPMorgan shall perform any of its obligations in such capacity hereunder or under the other Loan Documents.

 

    2 

     

    

“Administrative
Questionnaire” means an administrative questionnaire in a form supplied by the Administrative Agent.

 

“Affected
Financial Institution” means (a) any EEA Financial Institution or (b) any UK Financial Institution.

 

“Affiliate”
means, as to any Person, any other Person directly or indirectly controlling, controlled by, or under direct or indirect common control
with, such Person.  A Person shall be deemed to be “controlled by” any other Person if such other Person possesses,
directly or indirectly, power to direct or cause the direction of the management and policies of such Person whether by contract or otherwise.

 

“Agreement”
means this Term Loan Agreement, as the same may hereafter be amended, supplemented or otherwise modified from time to time.

 

“Alternate
Base Rate” means, for any day, a rate per annum equal to the greatest of (a) the Prime Rate in effect on such day, (b) the
NYFRB Rate in effect on such day plus 1⁄2 of 1.00% per annum and (c) the Adjusted Term SOFR for a one month Interest
Period as published two U.S. Government Securities Business Days prior to such day (or if such day is not a U.S. Government Securities
Business Day, the immediately preceding U.S. Government Securities Business Day) plus 1.00% per annum.  For purposes
of clause (c) above, the Adjusted Term SOFR for any day shall be based on the Term SOFR Reference Rate at approximately 5:00 a.m., Chicago
time, on such day (or any amended publication time for Term SOFR Reference Rate, as specified by the CME Term SOFR Administrator in the
Term SOFR Reference Rate methodology).  If the Alternate Base Rate is being used as an alternate rate of interest pursuant
to Section 3.02 (for the avoidance of doubt, only until an amendment hereto has become effective pursuant to Section 3.02(b)), then the
Alternate Base Rate shall be the greater of clauses (a) and (b) above and shall be determined without reference to clause (c) above;
provided that the Alternate Base Rate shall not be less than 1%.  Any change in the Alternate Base Rate due to a change
in the Prime Rate, the NYFRB Rate or the Adjusted Term SOFR shall be effective from and including the effective date of such change in
the Prime Rate, the NYFRB Rate or the Adjusted Term SOFR, as the case may be.

 

“Ancillary
Document” has the meaning set forth in Section 10.07(b).

 

“Anti-Corruption
Laws” means all laws, rules, and regulations of any jurisdiction applicable to the Company or any of its Subsidiaries from
time to time concerning or relating to bribery or corruption.

 

“Applicable
Lending Office” means, as to any Lender, the office or offices described as such in such Lender’s Administrative Questionnaire,
or such other office of such Lender (or an Affiliate of such Lender) as such Lender may from time to time specify to the Administrative
Agent and the Company by written notice in accordance with the terms hereof as the office by which its Loans are to be made and maintained.

 

“Applicable
Rate” means, for any day with respect to any ABR Loan, any Term SOFR Loan or, if applicable pursuant to Section 3.02, any Daily
Simple SOFR Loan

 

    3 

     

    

or with respect to the Ticking Fee,
as the case may be, the applicable rate per annum set forth under the caption “ABR Spread”, “Term SOFR/Daily Simple
SOFR Spread” or “Ticking Fee Rate” in the table below, as the case may be, in each case based upon the ratings by S&P
and Moody’s applicable on such date to the Index Debt:

 

	Category
	Ratings
S&P / Moody’s
	Term
SOFR/Daily Simple SOFR Spread
	ABR
Spread
	Ticking
Fee Rate

	1	≥A / A2	0.700%	0.000%	0.070%
	2	A- / A3	0.750%	0.000%	0.070%
	3	≤BBB+ / Baa1	0.875%	0.000%	0.070%

 

For
purposes of the foregoing, (i) if either S&P or Moody’s shall not have in effect a rating for the Index Debt (other than
by reason of the circumstances referred to in the last sentence of this definition), then such rating agency shall be deemed to have
established a rating in Category 3, (ii) if the ratings established or deemed to have been established by Moody’s and S&P
for the Index Debt shall fall within different Categories, the Applicable Rate shall be the applicable rate per annum corresponding to
the higher (or numerically lower) of such Categories unless one of the ratings is two Categories lower than the other, in which case
the Applicable Rate shall be determined by reference to Category 2 and (iii) if the ratings established or deemed to have been established
by S&P and Moody’s for the Index Debt shall be changed (other than as a result of a change in the rating system of S&P
or Moody’s), such change shall be effective as of the date on which it is first announced by the applicable rating agency.  Each
change in the Applicable Rate shall apply during the period commencing on the effective date of such change and ending on the date immediately
preceding the effective date of the next such change.  If the rating system of S&P or Moody’s shall change, or if
either such rating agency shall cease to be in the business of rating corporate debt obligations, the Company and the Lenders shall negotiate
in good faith to amend this definition to reflect such changed rating system or the unavailability of ratings from such rating agency
and, pending the effectiveness of any such amendment, the Applicable Rate shall be determined by reference to the ratings most recently
in effect prior to such change or cessation.

 

“Approved
Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or
an Affiliate of an entity that administers or manages a Lender.

 

“Arrangers”
means Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., PNC Bank National Association, TD Securities (USA) LLC, Truist Securities, Inc.
    and U.S. Bank National Association,
in their capacities as joint lead arrangers and joint bookrunners of the term loan facility provided for herein.

 

“Assignment
and Assumption” means an Assignment and Assumption in the form of Exhibit A hereto (with blanks appropriately filled in) delivered
to the Administrative Agent in connection with an assignment of a Lender’s interest under this Agreement pursuant to Section 10.01.

 

“Authorized
Representative” means any of the Chairman of the Board of Directors, President, Chief Executive Officer, Chief Financial Officer,
Vice President-

 

    4 

     

    

Treasurer, or any other Vice President
of the Company, or any other Person expressly designated by the written authorization of any of the foregoing as an Authorized Representative.

 

“Availability
Period” means the period from and including the Closing Date to, but excluding, the earlier of the Commitment Outside Date
and the date of termination of the Commitments.

 

“Available
Tenor” means, as of any date of determination and with respect to the then-current Benchmark, any tenor for such Benchmark
(or component thereof) or payment period for interest calculated with reference to such Benchmark (or component thereof), as applicable,
that is or may be used for determining the length of an Interest Period for any term rate or otherwise for determining any frequency
of making payments of interest calculated pursuant to this Agreement as of such date and not including, for the avoidance of doubt, any
tenor for such Benchmark that is then-removed from the definition of “Interest Period” pursuant to Section 3.02(b)(iv).

 

“Bail-In
Action” means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any
liability of an Affected Financial Institution.

 

“Bail-In
Legislation” means (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European
Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country
from time to time which is described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of the
United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom
relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than
through liquidation, administration or other insolvency proceedings).

 

“Bankruptcy
Event” means, with respect to any Person, that such Person has become the subject of a voluntary or involuntary bankruptcy
or insolvency proceeding, or has had a receiver, conservator, trustee, administrator, custodian, assignee for the benefit of creditors
or similar Person charged with the reorganization or liquidation of its business appointed for it; provided that a Bankruptcy
Event shall not result solely by virtue of (a) any ownership interest, or the acquisition of any ownership interest, in such Person by
a Governmental Authority; provided that such ownership interest does not result in or provide such Person with immunity from the
jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such
Person (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any agreements made by such Person, or (b) any Undisclosed
Administration.

 

“Benchmark”
means, initially, Term SOFR; provided that if a Benchmark Transition Event and the related Benchmark Replacement Date have occurred
with respect to Term SOFR or the then-current Benchmark, then “Benchmark” means the applicable

 

    5 

     

    

Benchmark Replacement to the extent
that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section 3.02(b)(i).

 

“Benchmark
Replacement” means, for any Available Tenor, the first alternative set forth in the order below that can be determined by the
Administrative Agent for the applicable Benchmark Replacement Date:

 

(1)       Adjusted
Daily Simple SOFR; and

 

(2)       the
sum of: (a) the alternate benchmark rate that has been selected by the Administrative Agent and the Company as the replacement for the
then-current Benchmark for the applicable Corresponding Tenor giving due consideration to (i) any selection or recommendation of a replacement
benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body and/or (ii) any evolving or then-prevailing
market convention for determining a benchmark rate as a replacement for the then-current Benchmark for syndicated credit facilities denominated
in the US Dollars at such time in the United States and (b) the related Benchmark Replacement Adjustment.

 

If the Benchmark
Replacement as determined pursuant to clause (1) or (2) above would be less than the Floor, the Benchmark Replacement will be deemed
to be the Floor for the purposes of this Agreement and the other Loan Documents.

 

“Benchmark
Replacement Adjustment” means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement
for any applicable Interest Period and Available Tenor for any setting of such Unadjusted Benchmark Replacement the spread adjustment,
or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected
by the Administrative Agent and the Company for the applicable Corresponding Tenor giving due consideration to (i) any selection or recommendation
of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the
applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body on the applicable Benchmark Replacement Date and/or (ii)
any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such
spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for syndicated credit facilities
denominated in the US Dollars at such time in the United States.

 

“Benchmark
Replacement Conforming Changes” means, with respect to any Benchmark Replacement and/or any Term SOFR Loan, any technical,
administrative or operational changes (including changes to the definition of “Alternate Base Rate”, the definition of “Business
Day”, the definition of “Interest Period”, the definition of “U.S. Government Securities Business Day”,
timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or
continuation notices, length of lookback periods, the applicability of breakage provisions, and other technical, administrative or operational
matters) that the Administrative Agent decides (in consultation with the Company) may be appropriate to reflect the adoption and

 

    6 

     

    

implementation of the applicable Benchmark
and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if
the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative
Agent determines that no market practice for the administration of such Benchmark exists, in such other manner of administration as the
Administrative Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents).

 

“Benchmark
Replacement Date” means, with respect to any Benchmark, the earlier to occur of the following events with respect to such then-current
Benchmark:

 

(1)       in
the case of clause (1) or (2) of the definition of “Benchmark Transition Event”, the later of (a) the date of the public
statement or publication of information referenced therein and (b) the date on which the administrator of such Benchmark (or the published
component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such
component thereof); or

 

(2)       in
the case of clause (3) of the definition of “Benchmark Transition Event”, the first date on which such Benchmark (or the
published component used in the calculation thereof) has been determined and announced by the regulatory supervisor for the administrator
of such Benchmark (or such component thereof) to be no longer representative; provided that such non-representativeness will be
determined by reference to the most recent statement or publication referenced in such clause (3) and even if any Available Tenor of
such Benchmark (or such component thereof) continues to be provided on such date.

 

For
the avoidance of doubt, (i) if the event giving rise to the Benchmark Replacement Date occurs on the same day as, but earlier than, the
Reference Time in respect of any determination, the Benchmark Replacement Date will be deemed to have occurred prior to the Reference
Time for such determination and (ii) the “Benchmark Replacement Date” will be deemed to have occurred in the case of clause
(1) or (2) with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all
then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).

 

“Benchmark
Transition Event” means, with respect to any Benchmark, the occurrence of one or more of the following events with respect
to such then-current Benchmark:

 

(1)
a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used
in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark
(or such component thereof), permanently or indefinitely; provided that, at the time of such statement or publication, there is
no successor administrator that will continue

 

    7 

     

    

to provide
any Available Tenor of such Benchmark (or such component thereof);

 

(2)
a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published
component used in the calculation thereof), the Federal Reserve Board, the NYFRB, the CME Term SOFR Administrator, an insolvency official
with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator
for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator
for such Benchmark (or such component), in each case, which states that the administrator of such Benchmark (or such component) has ceased
or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; provided
that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available
Tenor of such Benchmark (or such component thereof); or

 

(3)
a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published
component used in the calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are no
longer, or as of a specified future date will no longer be, representative.

 

For
the avoidance of doubt, a “Benchmark Transition Event” will be deemed to have occurred with respect to any Benchmark if a
public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such
Benchmark (or the published component used in the calculation thereof).

 

“Benchmark
Unavailability Period” means, with respect to any Benchmark, the period (if any) (x) beginning at the time that a Benchmark
Replacement Date pursuant to clause (1) or (2) of that definition has occurred if, at such time, no Benchmark Replacement has replaced
such then-current Benchmark for all purposes hereunder and under any other Loan Document in accordance with Section 3.02(b) and (y) ending
at the time that a Benchmark Replacement has replaced such then-current Benchmark for all purposes hereunder and under any other Loan
Document in accordance with Section 3.02(b).

 

“Beneficial
Ownership Regulation” means 31 C.F.R. § 1010.230.

 

“Benefit
Arrangement” means at any time an employee benefit plan within the meaning of Section 3(3) of ERISA which is not a Plan or
a Multiemployer Plan and which is maintained or otherwise contributed to by any member of the ERISA Group.

 

“Benefit
Plan” means (a) an “employee benefit plan” (as defined in ERISA) that is subject to Title I of ERISA, (b) a
“plan” as defined in and subject to Section 4975

 

    8 

     

    

of the Code or (c) any Person whose
assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the
assets of any such “employee benefit plan” or “plan”.

 

“Borrowing”
means Loans of the same Type made, converted or continued on the same date and, in the case of Term SOFR Loans, as to which a single
Interest Period is in effect.

 

“Borrowing
Minimum” means US$5,000,000.

 

“Borrowing
Multiple” means US$1,000,000.

 

“Borrowing
Notice” means a request by the Company for a Borrowing in accordance with Section 2.03, in the form of Exhibit B hereto.

 

“Business
Day” means any day that is not a Saturday, Sunday or other day on which commercial banks in New York City are authorized
or required by law to remain closed; provided that when used in connection with a Term SOFR Loan or a Daily Simple SOFR Loan
and any interest rate setting, fundings, disbursements, settlements or payments of any Term SOFR Loans or Daily Simple SOFR Loans, or
any other dealings in respect of such Loans referencing Adjusted Term SOFR or Adjusted Daily Simple SOFR, the term “Business Day”
shall also exclude any day that is not a U.S. Government Securities Business Day.

 

“Capital
Leases” means all leases which have been capitalized in accordance with GAAP as in effect, subject to Section 1.03(a), from
time to time.

 

“Change
of Control” means, at any time:

 

(a)
any person or group of persons (within the meaning of Section 13 or 14 of the Exchange Act), other than the Trust, shall have acquired
beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act ) of 35% or more of the outstanding shares of Voting Securities
of the Company; or

 

(b)
as of any date a majority of the Board of Directors of the Company consists of individuals who were not either (i) directors of the Company
as of the corresponding date of the previous year, (ii) selected or nominated to become directors by the Board of Directors of the Company
of which a majority consisted of individuals described in clause (i), or (iii) selected or nominated to become directors by the Board
of Directors of the Company of which a majority consisted of individuals described in clauses (i) and (ii).

 

“Change
in Law” means the occurrence, after the date of this Agreement, of any of the following: (a) the adoption or taking effect
of any applicable law, rule, regulation or treaty, (b) any change in any applicable law, rule, regulation or treaty or in the interpretation
or administration thereof by any Governmental Authority or (c) the making or issuance of any request or directive (whether or not having
the force of law) of any Governmental Authority; provided that, notwithstanding anything herein to the

 

    9 

     

    

contrary, (i) the Dodd-Frank Wall Street
Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and
(ii) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking
Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to
Basel III, shall in each case be deemed to be a “Change in Law”, regardless of the date enacted, adopted, promulgated or
issued.

 

“Claims”
has the meaning specified in Section 2.11(c).

 

“Closing
Date” means the date as of which this Agreement is executed by the parties hereto and on which the conditions set forth in
Section 4.01 have been satisfied (or waived in accordance with Section 10.02).

 

“CME
Term SOFR Administrator” means CME Group Benchmark Administration Limited as administrator of the forward-looking term Secured
Overnight Financing Rate (SOFR) (or a successor administrator).

 

“Code”
means the Internal Revenue Code of 1986, as amended from time to time, and any regulations promulgated thereunder.

 

“Commitment
Outside Date” means December 30, 2022.

 

“Commitments”
means, with respect to each Lender, the commitment of such Lender to make Loans, expressed as an amount representing the maximum aggregate
amount of the Loans to be made by such Lender, as such commitment may be reduced or increased from time to time pursuant to Section 2.06
or assignments by or to such Lender pursuant to Section 10.01.  The initial amount of each Lender’s Commitment is set
forth on Schedule 2.01, or in the Assignment and Assumption or the Accession Agreement pursuant to which such Lender shall have assumed
or provided its Commitment, as the case may be.  The aggregate amount of the Commitments as of the Closing Date is US$1,000,000,000.

 

“Communications”
means, collectively, any notice, demand, communication, information, document or other material provided by or on behalf of the Company
or the Administrative Agent pursuant to any Loan Document or the transactions contemplated therein that is distributed to or by the Administrative
Agent or any Lender by means of electronic communications in accordance with this Agreement, including through the Platform.

 

“Company”
has the meaning specified in the preamble hereto.

 

“Company
Materials” has the meaning specified in Section 6.01.

 

“Consolidated
Net Capitalization” means, as of the last day of any fiscal quarter, the sum of Consolidated Net Indebtedness plus Consolidated
Net Worth.

 

    10 

     

    

“Consolidated
Net Indebtedness” means, as of the last day of any fiscal quarter, all Funded Indebtedness of the Company and its Subsidiaries,
determined on a consolidated basis in accordance with GAAP, minus Unrestricted Cash; provided that Consolidated Net Indebtedness
shall not be less than zero.

 

“Consolidated
Net Worth” means, as of the last day of any fiscal quarter, the consolidated stockholders’ equity of the Company and
its Subsidiaries, determined on a consolidated basis in accordance with GAAP.

 

“Corresponding
Tenor” with respect to any Available Tenor means, as applicable, either a tenor (including overnight) or an interest payment
period having approximately the same length (disregarding business day adjustment) as such Available Tenor.

 

“Daily
Simple SOFR” means, for any day (a “SOFR Rate Day”), a rate per annum equal to SOFR for the day that is five U.S.
Government Securities Business Days prior to (a) if such SOFR Rate Day is a U.S. Government Securities Business Day, such SOFR Rate Day
or (ii) if such SOFR Rate Day is not a U.S. Government Securities Business Day, the U.S. Government Securities Business Day immediately
preceding such SOFR Rate Day, in each case, as such SOFR is published by the SOFR Administrator on the SOFR Administrator’s Website.  

 

“Daily
Simple SOFR Borrowing” means any Borrowing comprised of Daily Simple SOFR Loans.

 

“Daily
Simple SOFR Loan” means any Loan that bears interest at a rate determined by reference to Adjusted Daily Simple SOFR.

 

“Debtor
Relief Laws” means the Bankruptcy Code of the United States, and all other liquidation, conservatorship, bankruptcy, assignment
for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the
United States or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally.

 

“Declining
Lender” has the meaning specified in Section 2.13(a).

 

“Default”
means any event or condition which, with the giving or receipt of notice or lapse of time or both, unless cured or waived, would constitute
an Event of Default hereunder.

 

“Defaulting
Lender” means any Lender that (a) has failed, within two Business Days of the date required to be funded or paid, (i) to fund
any portion of its Loans or (ii)  to pay to the Administrative Agent or any Lender any other amount required to be paid by
it hereunder, unless, in the case of clause (i) above, such Lender notifies the Administrative Agent in writing that such failure is
the result of such Lender’s good faith determination that a condition precedent to funding (specifically identified in such writing,
including, if applicable, by reference to a specific Default or Event of Default) has not been satisfied, (b) has notified the Company
or the Administrative Agent in writing, or has made

 

    11 

     

    

a public statement to the effect, that
it does not intend or expect to comply with any of its funding obligations under this Agreement (unless such writing or public statement
indicates that such position is based on such Lender’s good faith determination that a condition precedent (specifically identified
in such writing, including, if applicable, by reference to a specific Default or Event of Default) to funding a Loan cannot be satisfied),
(c) has failed, within three Business Days after request by the Administrative Agent, made in good faith, to provide a certification
in writing from an authorized officer of such Lender that it will comply with its obligations to fund prospective Loans; provided
that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon the receipt by the Administrative Agent of
such certification in form and substance reasonably satisfactory to it, or (d) has become, or has a Lender Parent that has become,
the subject of a Bankruptcy Event or a Bail-In Action.

 

“Dividing
Person” has the meaning assigned to such term in the definition of “Division Successor”.

 

“Division”
has the meaning specified in Section 1.05.

 

“Division
Successor” means any Person that, upon the consummation of a Division of any other Person (a “Dividing Person”),
holds all or any portion of the assets, liabilities and/or obligations previously held by such Dividing Person immediately prior to the
consummation of such Division.  A Dividing Person that retains any of its assets, liabilities and/or obligations after a Division
shall be deemed a Division Successor upon the occurrence of such Division.

 

“Documentation
Agents” means PNC Bank National Association, TD Bank, N.A., Truist Bank and U.S. Bank National Association.

 

“EEA
Financial Institution” means (a) any credit institution or investment firm established in any EEA Member Country which is subject
to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution
described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary
of an institution described in clause (a) or (b) of this definition and is subject to consolidated supervision with its parent.

 

“EEA
Member Country” means any member state of the European Union, Iceland, Liechtenstein and Norway.

 

“EEA
Resolution Authority” means any public administrative authority or any Person entrusted with public administrative authority
of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.

 

“Electronic
Signature” means an electronic signature, sound, symbol or process attached to, or associated with, a contract or other record
and adopted by a Person with the intent to sign, authenticate or accept such contract or record.

 

    12 

     

    

“Eligible
Assignee” means (a) a Lender and (b) any other Person (other than a natural person, or a holding company, investment vehicle
or trust for, or owned and operated for the primary benefit of, a natural person) approved by (i) the Administrative Agent (which approval
shall be subject to the last sentence of Section 10.01(b) and shall not be unreasonably withheld or delayed) and (ii) unless an Event
of Default under Section 8.01(a), 8.01(b), 8.01(g) or 8.01(h) has occurred and is continuing, the Company (such approval not to
be unreasonably withheld or delayed); provided that, notwithstanding the foregoing, “Eligible Assignee” shall not
include the Company or any of its Subsidiaries or other Affiliates.

 

“Environmental
Laws” means any federal, state, local or foreign statute, law, ordinance, code, rule, regulation, order, decree, permit or
license by any Governmental Authority regulating, relating to, or imposing liability or standards of conduct concerning, any environmental
matters or conditions or environmental protection or conservation, including without limitation, the Comprehensive Environmental Response,
Compensation, and Liability Act of 1980, as amended; the Superfund Amendments and Reauthorization Act of 1986, as amended; the Resource
Conservation and Recovery Act, as amended; the Toxic Substances Control Act, as amended; the Clean Air Act, as amended; the Clean Water
Act, as amended; together with all regulations promulgated thereunder, and any other “Superfund” or “Superlien”
law.

 

“ERISA”
means the Employee Retirement Income Security Act of 1974, as amended from time to time, and any successor statute and all rules and
regulations promulgated thereunder.

 

“ERISA
Group” means the Company, any Subsidiary and all members of a controlled group of corporations and all trades or businesses
(whether or not incorporated) under common control which, together with the Company or any Subsidiary, are treated as a single employer
under Section 414 of the Code.

 

“Erroneous
Payment Return Deficiency” has the meaning set forth in Section 9.07(b)(iii).

 

“Erroneous
Payment Deficiency Assignment” has the meaning set forth in Section 9.07(b)(iii).

 

“EU
Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor
person), as in effect from time to time.

 

“Events
of Default” has the meaning set forth in Section 8.01.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder.

 

“Excluded
Taxes” means any of the following Taxes imposed on or with respect to any Lender or the Administrative Agent or required to
be withheld or deducted from a payment to any Lender or the Administrative Agent: (a) Taxes imposed on its net

 

    13 

     

    

income (however denominated), and franchise
or similar Taxes (including branch profit Taxes) imposed on it, in each case (i) by the jurisdiction under the laws of which such Lender
or the Administrative Agent is organized or in which its principal office (or in the case of a Lender, its Applicable Lending Office)
is located or any political subdivision thereof and (ii) by reason of any present or former connection between such Lender or the Administrative
Agent and the jurisdiction imposing such Taxes, other than solely as a result of this Agreement or any other Loan Document or any transaction
contemplated hereby, (b) in the case of a Lender, any U.S. federal withholding Tax imposed on such payment, but not excluding (i) any
portion of such Tax that exceeds the U.S. federal withholding Tax that would have been imposed on such a payment to such Lender under
the laws in effect on the date on which such Lender first becomes a party to this Agreement or the date on which such Lender changed
its lending office and (ii) any portion of such Tax that does not exceed the amount payable to the assignor of such Lender immediately
before such Lender became a party to this Agreement or changed its lending office, (c) any U.S. federal withholding Tax imposed under
FATCA and (d) Taxes attributable to such Lender’s failure to comply with Section 3.05(e).

 

“Extending
Lender” has the meaning specified in Section 2.13(a).

 

“Extension
Agreement” means an Extension Agreement, in form and substance reasonably satisfactory to the Administrative Agent, among the
Company, the Administrative Agent and one or more Extending Lenders, effecting an Extension Permitted Amendment and such other amendments
hereto and to the other Loan Documents as are contemplated by Section 2.13.

 

“Extension
Offer” has the meaning set forth in Section 2.13(a).

 

“Extension
Permitted Amendment” means an amendment to this Agreement and the other Loan Documents effected in connection with an Extension
Offer pursuant to Section 2.13, providing for an extension of the Maturity Date applicable to the Loans of the Lenders consenting
thereto (such Loans being referred to as the “Extended Loans”) and, in connection therewith, if the parties to such
amendment shall so agree, (a) a change in the rate of interest accruing on such Extended Loans, (b) the inclusion of fees to be payable
to the Extending Lenders in respect of such Extension Offer or their Extended Loans, (c) an addition of any affirmative or negative covenants
applicable to the Company and its Subsidiaries; provided that any such additional covenant with which the Company and its Subsidiaries
shall be required to comply for the benefit of the Extending Lenders shall also be for the benefit of all other Lenders, and/or (d) any
other amendment to this Agreement or the other Loan Documents to the extent such amendment would otherwise be permitted pursuant to,
and is adopted in accordance with the consent requirements of, Section 10.06 and such amendment and the related Extension Agreement comply
with Section 2.13(b).

 

“Facility
Termination Date” means the date on which all of the following shall have occurred: (a) all of the Commitments shall have expired
or shall have been terminated and the principal of and interest on each Loan and all fees payable hereunder shall have been paid in full
and (b) the Company shall have fully, finally and irrevocably

 

    14 

     

    

paid and satisfied in full all other
obligations of the Company under the Loan Documents (other than obligations consisting of continuing indemnities and other contingent
obligations of the Company that may be owing to the Administrative Agent, the Lenders or any of the other Indemnified Parties pursuant
to the Loan Documents and expressly survive termination of this Agreement).

 

“FATCA”
means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively
comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any
agreement entered into pursuant to Section 1471(b)(1) of the Code and any intergovernmental agreements between the United States and
another country that modify the provisions of the foregoing or law or regulation in any jurisdiction implementing such intergovernmental
agreement.

 

“Federal
Funds Effective Rate” means, for any day, the rate calculated by the NYFRB based on such day’s federal funds transactions
by depository institutions, as determined in such manner as shall be set forth on the NYFRB’s Website from time to time, and published
on the next succeeding Business Day by the NYFRB as the effective federal funds rate; provided that if such rate shall be less
than zero, such rate shall be deemed to be zero for all purposes of this Agreement.

 

“Federal
Reserve Board” means the Board of Governors of the Federal Reserve System of the United States of America (or any successor
body).

 

“Floor”
means the benchmark rate floor, if any, provided in this Agreement initially (as of the execution of this Agreement, the modification,
amendment or renewal of this Agreement or otherwise) with respect to Adjusted Term SOFR or, if applicable pursuant to Section 3.02,  Adjusted
Daily Simple SOFR.

 

“Foreign
Lender” means any Lender that is not a US Person.

 

“Fund”
means any Person (other than a natural person or a holding company, investment vehicle or trust for, or owned and operated for the primary
benefit of, a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans
and similar extensions of credit in the ordinary course of its business.

 

“Funded
Indebtedness” means with respect to any Person, without duplication, (a) all indebtedness in respect of borrowed money, (b)
all obligations under Capital Leases, (c) the deferred purchase price of any property or services that are in the nature of money borrowed,
and (d) indebtedness evidenced by a promissory note, bond, debenture or similar written obligation for the payment of money (including
non-contingent, past-due obligations under reimbursement agreements and conditional sales or similar title retention agreements), other
than (i) trade payables and accrued expenses incurred in the ordinary course of business, and (ii) indebtedness secured by cash deposits
subject to a legal right of set-off and not classified as a liability under GAAP.

 

    15 

     

    

“Funding
Date” means, with respect to any Loan or any Borrowing, the date on which such Loan, or the Loans comprising such Borrowing,
is or are made pursuant to Section 2.01.

 

“GAAP”
means generally accepted accounting principles in the United States, being those principles of accounting set forth in pronouncements
of the Financial Accounting Standards Board, the American Institute of Certified Public Accountants, or which have other substantial
authoritative support and are applicable in the circumstances, as in effect, subject to Section 1.03(a), from time to time.

 

“Governmental
Authority” means any federal, state, municipal, national or other governmental department, commission, board, bureau, court,
central bank, agency or instrumentality or political subdivision thereof or any entity or officer exercising executive, legislative,
judicial, taxing, regulatory or administrative functions of or pertaining to any government or any court, in each case whether associated
with a state of the United States of America, the United States of America or a foreign entity or government (including any supra-national
body exercising such powers or functions, such as the European Union or the European Central Bank).

 

“Guarantee”
by any Person means any obligation, contingent or otherwise, of such Person directly or indirectly guaranteeing any Indebtedness of any
other Person and, without limiting the generality of the foregoing, any obligation, direct or indirect, contingent or otherwise, of such
Person (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness (whether arising by virtue
of partnership arrangements, by agreement to keep-well, to purchase assets, goods, securities or services, to take-or-pay, or to maintain
financial statement conditions or otherwise) and the purpose of such contracts is to provide credit support in the nature of a guaranty
or (b) entered into for the purpose of assuring in any other manner the holder of such Indebtedness of the payment thereof or to protect
such holder against loss in respect thereof (in whole or in part); provided that the term “Guarantee” shall not include
endorsements for collection or deposit in the ordinary course of business.  The term “Guarantee” used as a verb
has a corresponding meaning.

 

“Increasing
Lenders” has the meaning specified in Section 2.06(d).

 

“Indebtedness”
means, as to any Person, without duplication, (a) all Funded Indebtedness of such Person, (b) all Funded Indebtedness of any other Person
secured by any Lien on any property or asset owned or held by such Person, regardless of whether the indebtedness secured thereby shall
have been assumed by such Person or is non-recourse to the credit of such Person, other than indebtedness secured by cash deposits subject
to a legal right of set-off and not classified as a liability under GAAP, and (c) all Funded Indebtedness of any other Person Guaranteed
by such Person.

 

“Indemnified
Party” has the meaning specified in Section 10.09(a).

 

“Indemnified
Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation
of the Company

 

    16 

     

    

under this Agreement or any other Loan
Document and (b) to the extent not otherwise described in clause (a) of this definition, Other Taxes.

 

“Index
Debt” means senior, unsecured, long-term Indebtedness for borrowed money of the Company that is not guaranteed by any other
Person or subject to any other credit enhancement.

 

“Information”
has the meaning specified in Section 10.13.

 

“Interest
Election Request” means a request by the Company to convert or continue a Borrowing in accordance with Section 2.05, in
the form of Exhibit C hereto.

 

“Interest
Payment Date” means (a) with respect to any ABR Loan and, if applicable pursuant to Section 3.02, any Daily Simple SOFR
Loan, the last day of each March, June, September and December and the Maturity Date and (b) with respect to any Term SOFR Loan,
the last day of the Interest Period applicable to the Borrowing of which such Loan is a part and, in the case of a Term SOFR Borrowing
with an Interest Period of more than three months’ duration, each day prior to the last day of such Interest Period that shall
occur at an interval of three months’ duration after the first day of such Interest Period.

 

“Interest
Period” means with respect to any Term SOFR Borrowing, the period commencing on the date of such Borrowing and ending on (a)
the numerically corresponding day in the calendar month that is one, three or six months thereafter, in each case as the Company
may elect; provided that (i) if any Interest Period would end on a day other than a Business Day, such Interest Period shall
be extended to the next succeeding Business Day unless such next succeeding Business Day would fall in the next calendar month, in which
case such Interest Period shall end on the next preceding Business Day and (ii) any Interest Period that commences on the last Business
Day of a calendar month (or on a day for which there is no numerically corresponding day in the last calendar month of such Interest
Period) shall end on the last Business Day of the last calendar month of such Interest Period.  For purposes hereof, the date
of a Borrowing initially shall be the date on which such Borrowing is made and thereafter shall be the effective date of the most recent
conversion or continuation of such Borrowing.

 

“JPMorgan”
means JPMorgan Chase Bank, N.A. and its successors.

 

“Lender
Parent” means, with respect to any Lender, any Person as to which such Lender is, directly or indirectly, a subsidiary.

 

“Lender-Related
Person” means the Administrative Agent, each Arranger, the Syndication Agent, each Documentation Agent and each Lender, and
each Related Party of any of the foregoing Persons.

 

“Lenders”
means the Persons listed on Schedule 2.01, any other Person that shall have become a Lender pursuant to an Assignment and Assumption
or Section 2.06(d), other than any such Person that shall have ceased to be a party hereto pursuant to an Assignment and Assumption.  

 

    17 

     

    

“Liabilities”
means any losses, claims, damages or liabilities of any kind.

 

“Lien”
means any interest in property securing any obligation owed to, or a claim by, a Person other than the owner of the property, whether
such interest is based on the common law, statute or contract, and including but not limited to the lien or security interest arising
from a mortgage, encumbrance, pledge, security agreement, conditional sale or trust receipt or a lease, consignment or bailment for security
purposes.  For the purposes of this Agreement, the Company and any Subsidiary shall be deemed to be the owner of any property
which it has acquired or holds subject to a conditional sale agreement, financing lease, or other arrangement pursuant to which title
to the property has been retained by or vested in some other Person for security purposes.

 

“Loan
Documents” means this Agreement, each Accession Agreement and, other than for purposes of Section 10.06,  the Notes.

 

“Loans”
means the loans made by the Lenders to the Company pursuant to this Agreement.

 

“Margin
Stock” shall have the meaning specified for such term in Regulation U of the Federal Reserve Board.

 

“Material
Adverse Effect” means a material adverse effect on (a) the business, financial position or results of operations of the Company
and its Subsidiaries, taken as a whole, (b) the ability of the Company to pay or perform its material obligations, liabilities and indebtedness
under the Loan Documents as such payment or performance becomes due and payable in accordance with the terms thereof, or (c) the rights,
powers and remedies of the Administrative Agent or any Lender under any Loan Document or the validity, legality or enforceability thereof.

 

“Material
Plan” means, at any time, a Plan or Plans having aggregate Unfunded Liabilities in excess of US$100,000,000.

 

“Maturity
Date” means the date that is the second anniversary of the earlier of (a) the Commitment Outside Date and (b) the Funding Date
(or, if there shall be more than one Funding Date, the latest Funding Date to occur hereunder), as such date may be extended pursuant
to Section 2.13; provided that, as to the Loans of any Lender that is a Declining Lender in respect of any Extension Permitted
Amendment effected pursuant to Section 2.13 (and any assignee thereof, other than any assignee that is an Extending Lender in respect
of such Extension Permitted Amendment), the term “Maturity Date” shall be the Maturity Date as in effect immediately prior
to the effectiveness of the applicable Extension Agreement; provided further that if any such day is not a Business Day, the Maturity
Date shall be the next preceding Business Day.

 

“MNPI”
means material information concerning the Company or any of the Subsidiaries or any of its or their respective securities that has not
been disseminated in a manner making it available to investors generally, within the meaning of Regulation FD under the Exchange Act.  For
purposes of this definition, “material information” means information concerning the Company, the Subsidiaries or any of
its or their respective

 

    18 

     

    

securities that could reasonably be
expected to be material for purposes of the United States federal and state securities laws.

 

“Moody’s”
means Moody’s Investors Service, Inc., and any successor to its rating agency business.

 

“Multiemployer
Plan” means at any time an employee benefit plan within the meaning of Section 4001(a)(3) of ERISA to which any member of the
ERISA Group is then making, or is accruing an obligation to make, contributions or has within the preceding five plan years made contributions,
including for these purposes any Person which ceased to be a member of the ERISA Group during such five-year period.

 

“Notes”
means the promissory notes, if any, executed and delivered pursuant to Section 2.07(e).

 

“NYFRB”
means the Federal Reserve Bank of New York.

 

“NYFRB
Rate” means, for any day, the greater of (a) the Federal Funds Effective Rate in effect on such day and (b) the Overnight Bank
Funding Rate in effect on such day (or for any day that is not a Business Day, for the immediately preceding Business Day); provided
that if none of such rates are published for any day that is a Business Day, the term “NYFRB Rate” shall mean the rate
for a federal funds transaction quoted at 11:00 a.m., New York City time, on such day received to the Administrative Agent from a Federal
funds broker of recognized standing selected by it; provided further that, if any of the aforesaid rates shall be less than zero,
such rate shall be deemed to be zero.

 

“NYFRB’s
Website” means the website of the NYFRB at http://www.newyorkfed.org, or any successor source.

 

“Other
Taxes” has the meaning specified in Section 3.05(b).

 

“Overnight
Bank Funding Rate” means, for any day, the rate comprised of both overnight federal funds and overnight eurodollar transactions
denominated in US Dollars by U.S.-managed banking offices of depository institutions, as such composite rate shall be determined by the
NYFRB as set forth on the NYFRB’s Website from time to time, and published on the next succeeding Business Day by the NYFRB as
an overnight bank funding rate.

 

“Participant”
has the meaning set forth in Section 10.01(d).

 

“Participant
Register” has the meaning set forth in Section 10.01(g).

 

“Payment”
has the meaning set forth in Section 9.07(b)(i).

 

“Payment
Notice” has the meaning set forth in Section 9.07(b)(ii).

 

“PBGC”
means the Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing similar functions.

 

    19 

     

    

“Person”
means an individual, partnership, corporation, limited liability company, limited liability partnership, trust, unincorporated organization,
association, joint venture or a Governmental Authority.

 

“Plan”
means at any time an employee pension benefit plan (other than a Multiemployer Plan) which is covered by Title IV of ERISA or subject
to the minimum funding standards under Section 412 of the Code or Section 302 of ERISA and either (a) is sponsored, maintained, or contributed
to, by any member of the ERISA Group for employees of any member of the ERISA Group or (b) has at any time within the preceding five
years been sponsored, maintained, or contributed to, by any Person which was at such time a member of the ERISA Group for employees of
any Person which was at such time a member of the ERISA Group.

 

“Platform”
means IntraLinksTM, DebtDomain, SyndTrak, ClearPar or any other electronic platform chosen by the Administrative Agent to be its
electronic transmission system.

 

“Prime
Rate” means the rate of interest last quoted by The Wall Street Journal as the “Prime Rate” in the United
States or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Federal
Reserve Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the “bank prime loan” rate or,
if such rate is no longer quoted therein, any similar rate quoted therein (as determined by the Administrative Agent in its reasonable
discretion, in consultation with the Company) or any similar release by the Federal Reserve Board (as determined by the Administrative
Agent in its reasonable discretion, in consultation with the Company).  Each change in the Prime Rate shall be effective from
and including the date such change is publicly announced as being effective.

 

“Proceeding”
means any claim, litigation, investigation, action, suit, arbitration or administrative, judicial or regulatory action or proceeding
in any jurisdiction.

 

“PTE”
means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time
to time.

 

“Public
Lender” has the meaning specified in Section 6.01.

 

“Reference
Time” with respect to any setting of the then-current Benchmark means (a) if such Benchmark is the Term SOFR, 5:00 a.m., Chicago
time, on the day that is two U.S. Government Securities Business Days preceding the date of such setting or (b) otherwise, the time determined
by the Administrative Agent in its reasonable discretion.

 

“Refinancing
Indebtedness” means, in respect of any Indebtedness (the “Original Indebtedness”), any Indebtedness that
extends, renews or refinances such Original Indebtedness (or any Refinancing Indebtedness in respect thereof); provided that (a)
the principal amount of such Refinancing Indebtedness shall not exceed the principal amount of such Original Indebtedness; (b) such Refinancing
Indebtedness shall not constitute an obligation (including pursuant to a Guarantee) of any Subsidiary that shall not have been (or, in
the case of after-acquired Subsidiaries, shall not have been required

 

    20 

     

    

pursuant to the terms of the Original
Indebtedness to become) an obligor in respect of such Original Indebtedness; and (c) such Refinancing Indebtedness shall not be secured
by any Lien on any asset other than the assets that secured such Original Indebtedness (or would have been required to secure such Original
Indebtedness pursuant to the terms thereof).

 

“Register”
has the meaning set forth in Section 10.01(c).

 

“Related
Parties” means, with respect to any specified Person, such Person’s Affiliates and the directors, officers, partners,
trustees, employees, agents and advisors of such Person and of such Person’s Affiliates.

 

“Relevant
Governmental Body” means the Federal Reserve Board, the NYFRB or a committee officially endorsed or convened by the Federal
Reserve Board and/or the NYFRB or, in each case, any successor thereto.

 

“Relevant
Rate” means (a) with respect to any Term SOFR Borrowing, Adjusted Term SOFR and (b) with respect to any Daily Simple SOFR Borrowing,
Adjusted Daily Simple SOFR.

 

“Required
Lenders” means, at any time, Lenders having Loans and Commitments representing in the aggregate more than 50% of the aggregate
outstanding principal amount of the Loans and the aggregate amount of the Commitments of all Lenders at such time.

 

“Resolution
Authority” means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.

 

“S&P”
means S&P Global Ratings, a division of S&P Global Inc., and any successor to its rating agency business.

 

“Sanctioned
Country” means, at any time, a country, region or territory which is the subject or target of comprehensive territorial Sanctions
(at the date of this Agreement, the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic, the Crimea
region of Ukraine, Cuba, Iran, North Korea and Syria).

 

“Sanctioned
Person” means, at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office
of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, the United Nations Security Council,
the European Union, any European Union member state to whose jurisdiction the Company or any Subsidiary of the Company is subject or
Her Majesty’s Treasury of the United Kingdom, (b) any Person located, organized or resident in a Sanctioned Country or (c) any
Person 50% or more owned by any Person or Persons described in the foregoing clause (a) and/or, to the knowledge of the Company, clause (b).

 

“Sanctions”
means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the Office of Foreign
Assets Control of the U.S. Department of the Treasury or the U.S. Department of State or (b) the United Nations Security Council, the
European Union, any European Union member state

 

    21 

     

    

to whose jurisdiction the Company or
any Subsidiary of the Company is subject or Her Majesty’s Treasury of the United Kingdom.

 

“Significant
Subsidiary” means at any time any Subsidiary, except Subsidiaries which at such time have been designated by the Company (by
notice to the Administrative Agent, which may be amended from time to time, which notices shall be made available by the Administrative
Agent to the Lenders upon request) as nonmaterial and which, if aggregated and considered as a single Subsidiary, would not meet the
definition of “significant subsidiary” in Regulation S-X of the Securities and Exchange Commission.

 

“SOFR”
means a rate per annum equal to the secured overnight financing rate as administered by the SOFR Administrator.

 

“SOFR
Administrator” means the NYFRB (or a successor administrator of the secured overnight financing rate).

 

“SOFR
Administrator’s Website” means the NYFRB’s Website or any successor source for the secured overnight financing
rate identified as such by the SOFR Administrator from time to time.

 

“subsidiary”
means, with respect to any Person, any corporation or other Person in which more than 50% of its outstanding Voting Securities or more
than 50% of all equity interests is owned directly or indirectly by such Person and/or by one or more of its Subsidiaries.

 

“Subsidiary”
means any subsidiary of the Company.

 

“Surviving
Company” has the meaning specified in Section 7.04.

 

“Syndication
Agent” means Wells Fargo Bank, National Association.

 

“Taxes”
means any and all present or future taxes, duties, levies, imposts, duties, deductions, withholdings (including backup withholding),
assessments, fees or other charges, in each case in the nature of a tax, imposed by any Governmental Authority, and all liabilities (including
penalties, interest, and expenses) with respect thereto.

 

“Term
SOFR” means, with respect to any Term SOFR Borrowing and for any tenor comparable to the applicable Interest Period, the Term
SOFR Reference Rate at approximately 5:00 a.m., Chicago time, two U.S. Government Securities Business Days prior to the commencement
of such tenor comparable to the applicable Interest Period, as such rate is published by the CME Term SOFR Administrator.

 

“Term
SOFR Borrowing” means any Borrowing comprised of Term SOFR Loans.

 

    22 

     

    

“Term
SOFR Loan” means any Loan that bears interest at a rate determined by reference to Adjusted Term SOFR (other than solely as
a result of clause (c) of the definition of “Alternate Base Rate”).

 

“Term
SOFR Reference Rate” means, for any day and time (such day, the “Term SOFR Determination Day”), with respect
to any Term SOFR Borrowing and for any tenor comparable to the applicable Interest Period, the rate per annum published by the CME Term
SOFR Administrator and identified by the Administrative Agent as the forward-looking term rate based on SOFR.  If by 5:00 a.m.,
Chicago time, two U.S. Government Securities Business Days prior to such Term SOFR Determination Day, the “Term SOFR Reference
Rate” for the applicable tenor has not been published by the CME Term SOFR Administrator and a Benchmark Replacement Date with
respect to Term SOFR has not occurred, then, so long as such day is otherwise a U.S. Government Securities Business Day, the Term SOFR
Reference Rate for such Term SOFR Determination Day will be the Term SOFR Reference Rate as published in respect of the first preceding
U.S. Government Securities Business Day for which such Term SOFR Reference Rate was published by the CME Term SOFR Administrator, so
long as such first preceding U.S. Government Securities Business Day is not more than five U.S. Government Securities Business Days prior
to such Term SOFR Determination Day.

 

“Ticking
Fee” has the meaning set forth in Section 2.09(a).

 

“Transactions”
means the execution, delivery and performance by the Company of each Loan Document and the borrowing of the Loans.

 

“Trust”
means the respective trusts established under those certain deeds of trust dated August 21, 1951, made by John E. Barbey and under the
will of John E. Barbey, deceased.

 

“Type”,
when used in reference to any Loan or Borrowing, refers to whether the rate of interest on such Loan, or on the Loans comprising such
Borrowing, is determined by reference to the Adjusted Term SOFR (other than solely as a result of clause (c) of the definition of “Alternate
Base Rate”), the Alternate Base Rate or, if applicable pursuant to Section 3.02, the Adjusted Daily Simple SOFR.

 

“UK
Financial Institutions” means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to
time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook
(as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions
and investment firms, and certain affiliates of such credit institutions or investment firms.

 

“UK
Resolution Authority” means the Bank of England or any other public administrative authority having responsibility for the
resolution of any UK Financial Institution.

 

“Unadjusted
Benchmark Replacement” means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.

 

    23 

     

    

“Undisclosed
Administration” means, with respect to any Person, the appointment of an administrator, provisional liquidator, conservator,
receiver, trustee, custodian or other similar official by a supervisory authority or regulator under or based on the applicable law in
the country where such Person is subject to home jurisdiction supervision if the applicable law require that such appointment is not
to be publicly disclosed.

 

“Unfunded
Liabilities” means, with respect to any Plan at any time, the amount (if any) by which (a) the value of all benefit liabilities
under such Plan, determined on a plan termination basis using the assumptions prescribed by the PBGC for purposes of Section 4044 of
ERISA, exceeds (b) the fair market value of all Plan assets allocable to such liabilities under Title IV of ERISA (excluding any accrued
but unpaid contributions), all determined as of the then most recent valuation date for such Plan, but only to the extent such excess
represents a potential liability of a member of the ERISA Group to the PBGC or any other Person under Title IV of ERISA.

 

“Unrestricted
Cash” means, as of any date of determination, cash and cash equivalents owned on such date by the Company and its Subsidiaries;
provided that such cash and cash equivalents do not appear (and in accordance with GAAP would not be required to appear) as “restricted”
on any consolidated balance sheet of the Company.

 

“U.S.
Government Securities Business Day” means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities
Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for
purposes of trading in United States government securities.

 

“USA
PATRIOT Act” means the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct
Terrorism Act of 2001.

 

“US
Dollars” or “US$” means the lawful currency of the United States of America.

 

“US
Lender” means any Lender that is a US Person.

 

“US
Person” means a “United States person” as defined in Section 7701(a)(30) of the Code.

 

“Voting
Securities” means shares of capital stock issued by a corporation, or equivalent interests in any other Person, the holders
of which are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar
functions) of such Person, even if the right so to vote has been suspended by the happening of such a contingency.

 

“Wholly
Owned Subsidiary” means any Subsidiary all of the shares of capital stock or other ownership interests of which (except directors’
qualifying shares and, in the case of any Subsidiary organized in a jurisdiction outside of the United States, shares not exceeding 5%
of total shares) are at the time directly or indirectly owned by the Company.

 

    24 

     

    

“Write-Down
and Conversion Powers” means (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such
EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and
conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the
applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial
Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities
or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had
been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation
that are related to or ancillary to any of those powers.

 

SECTION
1.02.  Classification of Loans and Borrowings.  For purposes of this Agreement, Loans may be classified and
referred to by Type (e.g., a “Term SOFR Loan”).  Borrowings also may be classified and referred to by Type
(e.g., a “Term SOFR Borrowing”).

 

SECTION
1.03.  Rules of Interpretation.  (a)  All accounting terms not specifically defined herein shall
have the meanings assigned to such terms, and shall be interpreted in accordance with, GAAP as in effect from time to time; provided
that if the Company notifies the Administrative Agent that the Company wishes to amend any covenant in Article VII (including
any defined term as used in such Article) to eliminate the effect of any change in GAAP or in the application thereof on the operation
of such covenant (or if the Administrative Agent notifies the Company that the Required Lenders wish to amend any covenant in Article
VII (including any defined term as used in such Article) for such purpose), then the Company’s compliance with such covenant shall
be determined on the basis of GAAP as in effect and applied immediately before the relevant change in GAAP or in the application thereof
became effective, until either such notice is withdrawn or such covenant is amended in a manner satisfactory to the Company and the Required
Lenders. Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein shall be construed,
and all computations of amounts and ratios referred to herein shall be made, without giving effect to (i) any election under Accounting
Standards Codification 825-10-25 (or any other Accounting Standards Codification or Financial Accounting Standard having a similar result
or effect) to value any Indebtedness or other liabilities of the Company or any Subsidiary at “fair value” as defined therein,
(ii) any treatment of Indebtedness in respect of convertible debt instruments under Accounting Standards Codification 470-20 (or any
other Accounting Standards Codification or Financial Accounting Standard having a similar result or effect) to value any such Indebtedness
in a reduced or bifurcated manner as described therein, and such Indebtedness shall at all times be valued at the full stated principal
amount thereof and (iii) any treatment of any lease (or similar arrangement conveying the right to use) as a capital lease where such
lease (or similar arrangement) would not have been required to be so treated under GAAP as in effect on December 31, 2017, as a result
of the effectiveness of the Financial Accounting Standards Board Accounting Standards Codification 842 (or any other Accounting Standards
Codification having a similar result or effect) (and related interpretations).

 

    25 

     

    

(b)  The
headings, subheadings and table of contents used herein or in any other Loan Document are solely for convenience of reference and shall
not constitute a part of any such document or affect the meaning, construction or effect of any provision thereof.

 

(c)  Except
as otherwise expressly provided, references in any Loan Document to articles, sections, paragraphs, clauses, annexes, appendices, exhibits
and schedules are references to articles, sections, paragraphs, clauses, annexes, appendices, exhibits and schedules in or to such Loan
Document.

 

(d)  All
definitions set forth herein or in any other Loan Document shall apply to the singular as well as the plural form of such defined term,
and all references to the masculine gender shall include reference to the feminine or neuter gender, and vice versa, as the context may
require.

 

(e)  When
used herein or in any other Loan Document, words such as “hereunder”, “hereto”, “hereof” and “herein”
and other words of like import shall, unless the context clearly indicates to the contrary, refer to the whole of the applicable document
and not to any particular article, section, subsection, paragraph or clause thereof.

 

(f)  References
to “including” mean including without limiting the generality of any description preceding such term, and for purposes
hereof the rule of ejusdem generis shall not be applicable to limit a general statement, followed by or referable to an enumeration
of specific matters, to matters similar to those specifically mentioned.

 

(g)  The
words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all
tangible and intangible assets and properties, including cash, securities, accounts and contract rights. The word “will”
shall be construed to have the same meaning and effect as the word “shall”.

 

(h)  Whenever
interest rates or fees are established in whole or in part by reference to a numerical percentage expressed as “%”, such
arithmetic expression shall be interpreted in accordance with the convention that 1% = 100 basis points.

 

(i)  Each
of the parties to the Loan Documents and their counsel have reviewed and revised, or requested (or had the opportunity to request) revisions
to, the Loan Documents, and any rule of construction that ambiguities are to be resolved against the drafting party shall be inapplicable
in the construing and interpretation of the Loan Documents and all exhibits, schedules and appendices thereto.

 

(j)  Any
reference to an officer of the Company or any other Person by reference to the title of such officer shall be deemed to refer to each
other officer of such Person, however titled, exercising the same or substantially similar functions.

 

(k)  Unless
the context otherwise requires, any definition of or reference to any agreement, instrument or other document herein (including to any
Loan Document) shall be construed as referring to such agreement or other document as from time to time

 

    26 

     

    

amended, restated, supplemented or otherwise
modified (subject to any restrictions on such amendments, restatements, supplements or modifications set forth herein).

 

(l)  Unless
the context otherwise requires, any definition of or reference to any statute, rule or regulation shall be construed as referring hereto
as from time to time amended, supplemented or otherwise modified (including by succession of comparable successor laws).

 

(m)  Unless
the context otherwise requires, any reference herein to any Person shall be construed to include such Person’s successors and assigns
(subject to any restrictions on assignment set forth herein) and, in the case of any Governmental Authority, any other Governmental Authority
that shall have succeeded to any or all functions thereof.

 

SECTION
1.04.  Interest Rates; Benchmark Notification.  The interest rate on any Loan may be derived from an interest
rate benchmark that may be discontinued or is, or may in the future become, the subject of regulatory reform. Upon the occurrence of
a Benchmark Transition Event, Section 3.02(b) provides a mechanism for determining an alternative rate of interest.  The Administrative
Agent does not warrant or accept any responsibility for, and shall not have any liability with respect to, the administration, submission,
performance or any other matter related to any interest rate used in this Agreement, or with respect to any alternative or successor
rate thereto, or replacement rate thereof, including whether the composition or characteristics of any such alternative, successor or
replacement reference rate will be similar to, or produce the same value or economic equivalence of, the existing interest rate being
replaced or have the same volume or liquidity as did any existing interest rate prior to its discontinuance or unavailability.  The
Administrative Agent and its Affiliates and/or other related entities may engage in transactions that affect the calculation of the any
interest rate used in this Agreement or any alternative, successor or alternative rate (including any Benchmark Replacement) and/or any
relevant adjustments thereto, in each case, in a manner adverse to the Company.  The Administrative Agent may select information
sources or services in its reasonable discretion to ascertain any interest rate used in this Agreement, any component thereof, or rates
referenced in the definition thereof, in each case pursuant to the terms of this Agreement, and shall have no liability to the Company,
any Lender or any other Person for damages of any kind, including direct or indirect, special, punitive, incidental or consequential
damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation
of any such rate (or component thereof) provided by any such information source or service.

 

SECTION
1.05.  Divisions.  For all purposes under the Loan Documents, in connection with any division or plan of division
under Delaware law (or any comparable event under a different jurisdiction’s laws) (a “Division”): (a) if any
asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it
shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) if any new Person comes into existence,
such new Person shall be deemed to have been organized and acquired on the first date of its existence by the holders of its equity interests
at such time.

 

    27 

     

    

ARTICLE
II

The Credits

 

SECTION
2.01.  Commitments.  Subject to the terms and conditions set forth herein, each Lender agrees to make Loans
to the Company from time to time during the Availability Period in US Dollars, provided that (a) the principal amount of each
Loan made by any Lender shall not exceed such Lender’s Commitment as in effect immediately prior to the making of such Loan and
(b) all Loans made pursuant to this Section 2.01 shall be made on no more than three Funding Dates.  Amounts repaid or prepaid
in respect of Loans may not be reborrowed.

 

SECTION
2.02.  Loans and Borrowings.  (a)  Each Loan shall be made as part of a Borrowing consisting of
Loans of the same Type made by the Lenders ratably in accordance with their respective Commitments.  The failure of any Lender
to make any Loan required to be made by it shall not relieve any other Lender of its obligations hereunder; provided that the
Commitments of the Lenders are several and no Lender shall be responsible for any other Lender’s failure to make Loans as required.

 

(b)  Subject
to Sections 3.02 and 3.03, each Borrowing shall be comprised entirely of Term SOFR Loans, ABR Loans or, if applicable pursuant to
Section 3.02, Daily Simple SOFR Loans, in each case, as the Company may request in accordance herewith.  Each Lender at its
option may make any Loan by causing any domestic or foreign branch or Affiliate of such Lender to make such Loan; provided that
any exercise of such option (x) shall not affect the obligation of the Company to repay such Loan in accordance with the terms of this
Agreement and (y) shall be subject to Section 3.06.

 

(c)  At
the commencement of each Interest Period for any Term SOFR Borrowing, such Borrowing shall be in an aggregate amount that is an integral
multiple of the Borrowing Multiple and not less than the Borrowing Minimum; provided that any Term SOFR Borrowing that results
from a continuation of an outstanding Borrowing of such Type may be in an aggregate amount that is equal to such outstanding Borrowing.  At
the time that each ABR Borrowing or Daily Simple SOFR Borrowing is made, such Borrowing shall be in an aggregate amount that is an integral
multiple of the Borrowing Multiple and not less than the Borrowing Multiple.  Notwithstanding the foregoing, any Borrowing
may be in an aggregate amount that is equal to the entire balance of the Commitments.  Borrowings of more than one Type may
be outstanding at the same time; provided that there shall not at any time be more than a total of 10 Term SOFR Borrowings outstanding.

 

(d)  Notwithstanding
any other provision of this Agreement, the Company shall not be entitled to request, or to elect to convert or continue, any Borrowing
if the Interest Period requested with respect thereto would end after the Maturity Date.

 

SECTION
2.03.  Requests for Borrowings.  To request a Borrowing, the Company shall submit to the Administrative Agent,
by email (in .pdf or .tif format), a completed Borrowing Notice signed by an Authorized Representative (a) in the case of a Term
SOFR Borrowing, not later than 1:00 p.m., New York City time, three U.S.

 

    28 

     

    

Government Securities Business Days
before the date of the proposed Borrowing (or one U.S. Government Securities Business Day in the case of any Term SOFR Borrowing to be
made on the Closing Date), (b) in the case of an ABR Borrowing, not later than 12:00 noon, New York City time, on the date of the
proposed Borrowing or (c) if applicable pursuant to Section 3.02, in the case of a Daily Simple SOFR Borrowing, not later than 1:00 p.m.,
New York City time three U.S. Government Securities Business Days before the date of the proposed Borrowing.  Each such Borrowing
Notice shall specify the following information in compliance with Section 2.02:

 

(i)
the Type of such Borrowing;

 

(ii)
the principal amount of such Borrowing;

 

(iii)
the date of such Borrowing, which shall be a Business Day;

 

(iv)
in the case of a Term SOFR Borrowing, the initial Interest Period to be applicable thereto, which shall be a period contemplated by the
definition of the term “Interest Period”; and

 

(v)
the location and number of the Company’s account to which funds are to be disbursed.

 

If
no election as to the Type of Borrowing is specified, then the requested Borrowing shall be an ABR Borrowing. If no Interest Period is
specified with respect to any requested Term SOFR Borrowing, then the Company shall be deemed to have selected an Interest Period of
one month’s duration.  Promptly following receipt of a Borrowing Notice in accordance with this Section (but in any event,
if received not later than 3:00 p.m., New York City time, on the same Business Day such Borrowing Notice is received by the Administrative
Agent), the Administrative Agent shall advise each Lender of the details thereof and of the amount of such Lender’s Loan to be
made as part of the requested Borrowing.

 

SECTION
2.04.  Funding of Borrowings.  (a)  Each Lender shall make each Loan to be made by it hereunder
on the proposed date thereof by wire transfer of immediately available funds in US Dollars by (i) in the case of a Term SOFR Borrowing
or, if applicable pursuant to Section 3.02, a Daily Simple SOFR Borrowing, 10:00 a.m., New York City time, and (ii) in the case of an
ABR Borrowing, 1:00 p.m., New York City time, in each case to the account of the Administrative Agent most recently designated by the
Administrative Agent for such purpose by notice to the Lenders.  The Administrative Agent will make such Loan proceeds available
to the Company by promptly remitting the amounts so received, in like funds, to the account designated in the applicable Borrowing Notice.  If
a Borrowing shall not occur on such date because any condition precedent herein specified shall not have been met, the Administrative
Agent shall return the amounts so received to the respective Lenders.

 

(b)  Unless
the Administrative Agent shall have received notice from a Lender prior to the proposed date of any Borrowing that such Lender will not
make available to the Administrative Agent such Lender’s share of such Borrowing, the

 

    29 

     

    

Administrative Agent may assume that
such Lender has made such share available on such date in accordance with paragraph (a) of this Section and may, in reliance upon such
assumption, make available to the Company on such date a corresponding amount in US Dollars.  In such event, if a Lender has
not in fact made its share of the applicable Borrowing available to the Administrative Agent, then the applicable Lender and the Company
severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount with interest thereon, for each day
from and including the date such amount is made available to the Company to but excluding the date of payment to the Administrative Agent,
at (i) in the case of such Lender, the greater of (x) the NYFRB Rate and (y) a rate determined by the Administrative Agent
in accordance with banking industry rules on interbank compensation or (ii) in the case of the Company, the interest rate applicable
to the subject Loan pursuant to Section 2.10. If the Company and such Lender shall both pay such interest to the Administrative Agent
for the same or an overlapping period, the Administrative Agent shall promptly remit to the Company the amount of such interest paid
by the Company for such period. If such Lender pays such amount to the Administrative Agent, then such amount shall constitute such Lender’s
Loan included in such Borrowing. Any payment by the Company shall be without prejudice to any claim the Company may have against a Lender
that shall have failed to make such payment to the Administrative Agent.

 

SECTION
2.05.  Interest Elections.  (a)  Each Borrowing initially shall be of the Type specified in the
applicable Borrowing Notice and, in the case of a Term SOFR Borrowing, shall have an initial Interest Period as specified in such Borrowing
Notice or as otherwise provided in Section 2.03.  Thereafter, the Company may elect to convert such Borrowing to a different
Type or to continue such Borrowing and, in the case of a Term SOFR Borrowing, may elect Interest Periods therefor, all as provided in
this Section and on terms consistent with the other provisions of this Agreement.  The Company may elect different options
with respect to different portions of the applicable affected Borrowing, in which case each such portion shall be allocated ratably among
the Lenders holding the Loans comprising such Borrowing and the Loans comprising each such portion shall be considered a separate Borrowing.
Notwithstanding any other provision of this Section, the Company shall not be permitted to elect an Interest Period for a Term SOFR
Borrowing that does not comply with Section 2.02(b).

 

(b)  To
make an election pursuant to this Section, the Company shall submit to the Administrative Agent, by email (in .pdf or .tif format), a
completed Interest Election Request signed by an Authorized Representative by the time and date that a Borrowing Notice would be required
under Section 2.03 if the Company were requesting a Borrowing of the Type resulting from such election to be made on the effective date
of such election.  Each Interest Election Request shall specify the following information in compliance with Section 2.02:

 

(i)
the Borrowing to which such Interest Election Request applies and, if different options are being elected with respect to different portions
thereof, the portions thereof to be allocated to each resulting Borrowing (in which case the information to be specified pursuant to
clauses (iii) and (iv) below shall be specified for each resulting Borrowing);

 

    30 

     

    

(ii)
the effective date of the election made pursuant to such Interest Election Request, which shall be a Business Day;

 

(iii)
the Type of the resulting Borrowing; and

 

(iv)
if the resulting Borrowing is to be a Term SOFR Borrowing, the Interest Period to be applicable thereto after giving effect to such election,
which shall be a period contemplated by the definition of the term “Interest Period”.

 

If by any such
Interest Election Request the Company requests a Term SOFR Borrowing but does not specify an Interest Period, then the Company shall
be deemed to have selected an Interest Period of one month’s duration.

 

(c)  Promptly
following receipt of an Interest Election Request, the Administrative Agent shall advise each Lender of the details thereof and of such
Lender’s portion of each resulting Borrowing.

 

(d)  If
the Company fails to deliver a timely Interest Election Request with respect to a Term SOFR Borrowing prior to the end of the Interest
Period applicable thereto, then, unless such Borrowing is prepaid in accordance with the provisions of Section 2.08, at the end of such
Interest Period such Borrowing shall be continued as a Borrowing of the applicable Type for an Interest Period of one month.

 

(e)  Notwithstanding
any contrary provision hereof, if an Event of Default has occurred and is continuing and the Administrative Agent, at the request of
the Required Lenders, so notifies the Company, then, so long as an Event of Default is continuing (i) no outstanding Borrowing may be
converted to or continued as a Term SOFR Borrowing and (ii) unless repaid, each Term SOFR Borrowing shall be converted to an ABR
Borrowing at the end of the Interest Period applicable thereto.  The foregoing is without prejudice to the other rights and
remedies available hereunder upon an Event of Default.

 

SECTION
2.06.  Termination, Reduction and Increase of Commitments.  (a)  Unless previously terminated, (i)
the Commitment of each Lender shall reduce automatically and without further action upon the making by such Lender of any Loan by an
amount equal to the principal amount of such Loan and (ii) the Commitments shall terminate automatically and without further action on
the Commitment Outside Date.

 

(b)  The
Company may, upon prior written notice to the Administrative Agent specifying the effective date thereof, terminate, or from time to
time permanently reduce, the Commitments; provided that each such reduction of the Commitments shall be in an amount that
is not less than the Borrowing Minimum and an integral multiple of the Borrowing Multiple (or, if less, the entire remaining amount of
the Commitments).

 

(c)  Promptly
following receipt of notice from the Company pursuant to paragraph (b) of this Section, the Administrative Agent shall advise the
Lenders of the contents thereof.  Each notice delivered by the Company pursuant to this Section shall be irrevocable; provided
that a notice of termination of the Commitments may state that such notice is conditioned upon the effectiveness of other credit
facilities or the completion of

 

    31 

     

    

other transactions, in which case such
notice may be revoked or extended by the Company (by notice to the Administrative Agent on or prior to the specified prepayment date)
if such condition is not satisfied or the satisfaction of such condition is delayed.  Any termination or reduction of the Commitments
shall be permanent.  Each reduction of the Commitments shall be made ratably among the Lenders in accordance with their respective
Commitments.

 

(d)  (i)The
Company, the Administrative Agent and any Lender or any other Person qualifying as an Eligible Assignee or any combination of such Lenders
and such Persons (collectively, “Increasing Lenders”), may (in their sole discretion) enter into one or more amendment
agreements substantially in the form of Exhibit D hereto (each an “Accession Agreement”) without further approval
of the other Lenders, pursuant to which the Increasing Lenders agree to establish or increase, as the case may be, Commitments in an
aggregate amount for all Commitments so established or increased pursuant to this paragraph during the term of this Agreement not to
exceed US$100,000,000; provided that:

 

(A)
each such increase shall be in an amount equal to US$20,000,000 or an integral multiple of US$5,000,000 in excess thereof;

 

(B)
if requested by any Increasing Lender, the Company shall execute and deliver to the Administrative Agent (1) board resolutions of the
Company certified by its secretary or assistant secretary authorizing such increase and (2) a legal opinion of either the General Counsel
of the Company or special counsel to the Company as to the due authorization, execution and delivery of this Agreement, as modified by
such increase, the enforceability thereof and the absence of conflicts with the organizational documents and material agreements of the
Company, all in form and substance substantially similar to such opinions delivered on the Closing Date in satisfaction of Section 4.01(a)(ii);

 

(C)
the Company shall deliver to the Administrative Agent a certificate of an Authorized Representative certifying that no Default or Event
of Default then exists or would arise as a result of any such increase; and

 

(D)
if such Increasing Lender is not already a Lender hereunder, each Increasing Lender shall be subject to the approval of the Administrative
Agent (which approval shall not be unreasonably withheld, delayed or conditioned).

 

(ii)
Upon the execution, delivery and acceptance of the documents required by this Section 2.06(d), each Increasing Lender shall have
all the rights and obligations of a Lender under this Agreement.

 

SECTION
2.07.  Repayment of Loans; Evidence of Debt.  (a)  The Company hereby unconditionally promises to
pay to the Administrative Agent for the account of each Lender the then unpaid principal amount of each Loan of such Lender on the
Maturity Date.

 

(b)  Each
Lender shall maintain in accordance with its usual practice an account or accounts evidencing the Indebtedness of the Company to such
Lender resulting

 

    32 

     

    

from each Loan of such Lender, including
the amounts of principal and interest payable and paid to such Lender from time to time hereunder.

 

(c)  The
Administrative Agent shall maintain accounts in which it shall record (i) the amount of each Loan made hereunder, the Type of such
Loan and, in the case of any Term SOFR Loan, the Interest Period applicable thereto, (ii) the amount of any principal or interest
due and payable or to become due and payable from the Company to each Lender hereunder and (iii) the amount of any sum received
by the Administrative Agent hereunder for the account of the Lenders or any of them and each Lender’s share thereof.  The
information contained in such accounts will be made available to the Company at reasonable times and upon reasonable request.

 

(d)  The
entries made in the accounts maintained pursuant to paragraph (b) or (c) of this Section shall be prima facie evidence
of the existence and amounts of the obligations recorded therein; provided that the failure of any Lender or the Administrative
Agent to maintain such accounts or any error therein shall not in any manner affect the obligation of the Company to repay the Loans
in accordance with the terms of this Agreement.

 

(e)  Any
Lender may request that Loans of such Lender be evidenced by a promissory note.  In such event, the Company shall prepare,
execute and deliver to such Lender a promissory note payable to such Lender (or, if requested by such Lender, to such Lender and its
registered assigns) and in a form approved by the Company and the Administrative Agent.  Thereafter, the Loans evidenced by
such promissory note and interest thereon shall at all times (including after assignment pursuant to Section 10.01) be represented by
one or more promissory notes in such form payable to the payee named therein (or, if such promissory note is a registered note, to such
payee and its registered assigns).

 

SECTION
2.08.  Prepayment of Loans.  (a)  The Company shall have the right at any time and from time to
time to prepay any Borrowing in whole or in part, subject to Section 3.04 (but otherwise without premium or penalty) and the requirements
of this Section.

 

(b)  The
Company shall notify the Administrative Agent of any prepayment of a Borrowing hereunder (i) in the case of a Term SOFR Borrowing,
not later than 1:00 p.m., New York City time, three Business Days before the date of such prepayment, (ii) in the case of an ABR
Borrowing, not later than 12:00 noon, New York City time, on the date of such prepayment and (iii) in the case of a Daily Simple SOFR
Borrowing (if applicable pursuant to Section 3.02), not later than 12:00 noon, New York City time, three Business Days before the date
of such prepayment.  Each such notice shall be irrevocable, shall be submitted by email (in .pdf or .tif format) and shall
specify the prepayment date, the Borrowing or Borrowings to be prepaid and the principal amount of each Borrowing or portion thereof
to be prepaid; provided that, a notice of prepayment may state that such notice is conditioned upon the effectiveness of other
credit facilities or the completion of other transactions, in which case such notice may be revoked or extended by the Company (by notice
to the Administrative Agent on or prior to the specified effective date) if such

 

    33 

     

    

condition is not satisfied or the satisfaction
of such condition is delayed.  Promptly following receipt of any such notice relating to a Borrowing, the Administrative Agent
shall advise the Lenders of the contents thereof.  Each partial prepayment of any Borrowing shall be in an amount that would
be permitted in the case of an advance of a Borrowing of the same Type as provided in Section 2.02.  Each prepayment of
a Borrowing shall be applied ratably to the Loans included in the prepaid Borrowing.  Prepayments shall be accompanied by accrued
interest on the amount prepaid.

 

SECTION
2.09.  Fees.  (a)  The Company agrees to pay to the Administrative Agent, in US Dollars, for the
account of each Lender, a ticking fee (a “Ticking Fee”), which shall accrue at the Applicable Rate on the daily amount
of each Commitment of such Lender, during the period from and including the date that is 91 days after the Closing Date to but excluding
the date on which such Commitment terminates.  Ticking Fees accrued through and including the last day of each March, June,
September and December of each year shall be payable in arrears on the 15th Business Day following such last day, and accrued Ticking
Fees shall also be payable on the date on which the Commitments shall terminate, commencing on the 15th Business Day after the last day
of December 2022.  All Ticking Fees shall be computed on the basis of a year of 360 days and shall be payable for the actual
number of days elapsed (including the first day but excluding the last day).

 

(b)  The
Company agrees to pay to the Administrative Agent, for its own account, fees payable in the amounts and at the times separately agreed
upon in writing between the Company and the Administrative Agent.

 

(c)  The
Company agrees to pay, through the Administrative Agent, upfront fees in the amounts heretofore communicated to the Lenders by the Company
and the Administrative Agent.

 

(d)  All
fees payable hereunder shall be paid on the dates on which due and payable, in immediately available funds, to the Administrative Agent
for distribution, in the case of Ticking Fees and upfront fees, to the Lenders entitled thereto.  Fees paid shall not be refundable
under any circumstances, absent manifest error.

 

SECTION
2.10.  Interest.  (a)  The Loans comprising each ABR Borrowing shall bear interest at the Alternate
Base Rate plus the Applicable Rate.

 

(b)  The
Loans comprising each Term SOFR Borrowing shall bear interest at the Adjusted Term SOFR for the Interest Period in effect for such Borrowing
plus the Applicable Rate.

 

(c)  The
Loans comprising each Daily Simple SOFR Borrowing (if such Type of Borrowing is applicable pursuant to Section 3.02) shall bear interest
at the Adjusted Daily Simple SOFR plus the Applicable Rate.

 

(d)  Notwithstanding
the foregoing, if any principal of or interest on any Loan or any fee or other amount payable by the Company hereunder is not paid when
due and payable, whether at stated maturity, upon acceleration or otherwise, such overdue

 

    34 

     

    

amount shall bear interest, to the fullest
extent permitted by applicable law, after as well as before judgment, at a rate per annum equal to (i) in the case of overdue principal
of any Loan or any interest on any Loan, 2% per annum plus the rate otherwise applicable to such Loan as provided in the preceding paragraphs
of this Section or (ii) in the case of any other amount, 2% per annum plus the rate applicable to ABR Loans as provided in paragraph (a)
of this Section.

 

(e)  Accrued
interest on each Loan shall be payable in arrears on each Interest Payment Date for such Loan; provided that (i) interest
accrued pursuant to paragraph (d) of this Section shall be payable on demand, (ii) in the event of any repayment or prepayment
of any Loan, accrued interest on the principal amount repaid or prepaid shall be payable on the date of such repayment or prepayment
and (iii) in the event of any conversion of any Term SOFR Loan prior to the end of the current Interest Period therefor, accrued
interest on such Loan shall be payable on the effective date of such conversion.  All interest shall be payable in US Dollars.

 

(f)  All
interest hereunder shall be computed on the basis of a year of 360 days, except that interest computed by reference to the Alternate
Base Rate at times when the Alternate Base Rate is based on the Prime Rate shall be computed on the basis of a year of 365 days
(or 366 days in a leap year), and, in each case, shall be payable for the actual number of days elapsed (including the first day
but excluding the last day).  All interest hereunder on any Loan shall be computed on a daily basis based upon the outstanding
principal amount of such Loan as of the applicable date of determination.  The applicable Alternate Base Rate, Adjusted Term
SOFR or Daily Simple SOFR shall be determined by the Administrative Agent, and such determination shall be conclusive absent manifest
error.

 

SECTION
2.11.  Payments Generally; Pro Rata Treatment; Sharing of Set-offs.  (a)  The Company shall make
each payment required to be made by it hereunder or under any other Loan Document (whether of principal, interest, fees, amounts payable
under Sections 3.01, 3.04 or 3.05 or otherwise) prior to 2:00 p.m., New York City time, on the date when due, in immediately available
funds, without set-off or counterclaim.  Any amounts received after such time on any date may be deemed, in the discretion
of the Administrative Agent, to have been received on the next succeeding Business Day for purposes of calculating interest thereon.  All
such payments shall be made to the Administrative Agent for the account of the Lenders to such account as the Administrative Agent shall
from time to time specify in one or more notices delivered to the Company, except that payments to be made pursuant to Sections 3.01,
3.04, 3.05, 10.05 and 10.09 shall be made directly to the Persons entitled thereto and payments pursuant to other Loan Documents shall
be made to the Persons specified therein.  Each such payment shall be made in US Dollars.  The Administrative Agent
shall distribute any such payments received by it for the account of any other Person to the appropriate recipient promptly following
receipt thereof.  If any payment under any Loan Document shall be due on a day that is not a Business Day, the date for payment
shall be extended to the next succeeding Business Day and, in the case of any payment accruing interest, interest thereon shall be payable
for the period of such extension.  Any payment required to be made by the Administrative Agent hereunder shall be deemed to
have been made by the time required

 

    35 

     

    

if the Administrative Agent shall, at
or before such time, have taken the necessary steps to make such payment in accordance with the regulations or operating procedures of
the clearing or settlement system used by the Administrative Agent to make such payment.

 

(b)  If
at any time insufficient funds are received by and available to the Administrative Agent to pay fully all amounts of principal, interest
and fees then due and payable hereunder, such funds shall be applied (i) first, towards payment of interest and fees then
due and payable hereunder, ratably among the parties entitled thereto in accordance with the amounts of interest and fees then due and
payable to such parties and (ii) second, towards payment of principal then due and payable hereunder, ratably among the parties
entitled thereto in accordance with the amounts of principal then due and payable to such parties.

 

(c)  If
any Lender shall, by exercising any right of set-off or counterclaim or otherwise, obtain payment in respect of any principal of or interest
on any of its Loans (collectively “Claims”) resulting in such Lender receiving payment of a greater proportion of
the aggregate amount of its Claims than the proportion received by any other Lender with respect to its Claims, then the Lender receiving
such greater proportion shall purchase (for cash at face value) participations in the Claims of the other Lenders to the extent necessary
so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amounts of their respective
Claims; provided that (i) if any such participations are purchased and all or any portion of the payment giving rise thereto
is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest,
unless the Lender from which such payment is recovered is required to pay interest thereon, in which case each Lender returning funds
to such Lender shall pay its pro rata share of such interest and (ii) the provisions of this paragraph shall not be construed to
apply to any payment made by the Company pursuant to and in accordance with the express terms of this Agreement or any other Loan Document
(for the avoidance of doubt, as it may be amended from time to time), including Section 2.13, or any payment obtained by a Lender as
consideration for the assignment of or sale of a participation in any of its Claims to any assignee or participant, other than to the
Company or any Subsidiary or Affiliate thereof (as to which the provisions of this paragraph shall apply).  The Company consents
to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a participation pursuant
to the foregoing arrangements may exercise against it rights of set-off and counterclaim with respect to such participation as fully
as if such Lender were a direct creditor of the Company in the amount of such participation.

 

(d)  Unless
the Administrative Agent shall have received notice from the Company prior to the date on which any payment is due for the account of
the Lenders hereunder that the Company will not make such payment, the Administrative Agent may assume that the Company has made such
payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders the amount due.  In
such event, if the Company has not in fact made such payment, then each of the Lenders severally agrees to repay to the Administrative
Agent forthwith on demand the amount so distributed to such Lender with interest thereon, for each day from and including the date such
amount is distributed to it to but excluding the date of payment to the Administrative

 

    36 

     

    

Agent, at the greater of (x) the
NYFRB Rate and (y) a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation.

 

(e)  If
any Lender shall fail to make any payment required to be made by it under this Agreement to or for the account of the Administrative
Agent, then the Administrative Agent may, in its discretion (notwithstanding any contrary provision hereof), (i) apply any amounts thereafter
received by it for the account of such Lender for the benefit of the Administrative Agent, to satisfy such Lender’s obligations
to it until all such unsatisfied obligations are fully paid, and/or (ii) hold any such amounts in a segregated account as cash collateral
for, and for application to, any future funding obligations of such Lender, in the case of each of clauses (i) and (ii) above, in any
order as determined by the Administrative Agent in its discretion.

 

SECTION
2.12.  Defaulting Lenders.  Notwithstanding any provision of this Agreement to the contrary, if any Lender
becomes a Defaulting Lender, then the following provisions shall apply for so long as such Lender is a Defaulting Lender:

 

(a)       Ticking
Fees shall cease to accrue on the Commitment of such Defaulting Lender pursuant to Section 2.09(a); and

 

(b)       the
Commitment and the outstanding Loans of such Defaulting Lender shall not be included in determining whether the Required Lenders or any
other requisite Lenders have taken or may take any action hereunder or under any other Loan Document (including any consent to any amendment,
waiver or other modification pursuant to Section 10.06); provided that any amendment, waiver or other modification requiring the
consent of all Lenders or all Lenders affected thereby shall, except as otherwise provided in Section 10.06, require the consent of such
Defaulting Lender in accordance with the terms hereof.

 

In
the event that the Administrative Agent and the Company agree that a Defaulting Lender has adequately remedied all matters that caused
such Lender to be a Defaulting Lender, then such Lender shall thereupon cease to be a Defaulting Lender (but shall not be entitled to
receive any fees accrued during the period when it was a Defaulting Lender, and all amendments, waivers or modifications effected without
its consent in accordance with the provisions of Section 10.06 and this Section 2.12 during such period shall be binding on it).  The
rights and remedies against, and with respect to, a Defaulting Lender under this Section 2.12 are in addition to, and cumulative and
not in limitation of, all other rights and remedies that the Administrative Agent, each Lender and the Company may at any time have against,
or with respect to, such Defaulting Lender.

 

SECTION
2.13.  Extension Offers.  (a)  The Company may, by written notice to the Administrative Agent, make
offers (collectively, an “Extension Offer”) on equal terms to all the Lenders to enter into an Extension Permitted
Amendment pursuant to procedures reasonably specified by the Administrative Agent and reasonably acceptable to the Company.  Such
notice shall set forth (i) the terms and conditions of the requested Extension Permitted Amendment and (ii) the date on which such Extension
Permitted Amendment is requested to become effective (which shall not be fewer than 10 Business

 

    37 

     

    

Days or more than 30 Business Days after
the date of such notice, unless otherwise agreed to by the Administrative Agent).  Extension Permitted Amendments shall become
effective (A) only with respect to the Loans of the Lenders that accept the applicable Extension Offer (such acceptance being in the
sole and individual discretion of each such Lender and such Lenders being called “Extending Lenders”, and Lenders
that do not accept such Extension Offer being called “Declining Lenders”) and (B) only if Lenders (including any replacement
Lenders referred to in the last sentence of paragraph (c) below) representing at least the Required Lenders accept such Extension Offer.

 

(b)  An
Extension Permitted Amendment shall be effected pursuant to an Extension Agreement executed and delivered by the Company, each applicable
Extending Lender and the Administrative Agent; provided that no Extension Permitted Amendment shall become effective unless the
Company shall have delivered to the Administrative Agent a certificate of an Authorized Representative certifying that (i) no Default
or Event of Default has occurred and is continuing on the date of effectiveness thereof and (ii) on the date of effectiveness thereof,
the representations and warranties of the Company set forth in the Loan Documents are true and correct in all material respects on and
as of such date, except in the case of any such representation and warranty that specifically relates to an earlier date, in which case
such representation and warranty is so true and correct in all material respects on and as of such earlier date and except that the financial
statements referred to in Section 5.04 shall be deemed to be those financial statements most recently delivered to the Administrative
Agent and the Lenders pursuant to Section 6.01.  The Administrative Agent shall promptly notify each Lender of the effectiveness
of each Extension Agreement.  Each Extension Agreement may, without the consent of any Lender other than the applicable Extending
Lenders, effect such amendments to this Agreement and the other Loan Documents, including provisions hereof or thereof that would otherwise
require the consent of all the Lenders, as may be necessary or appropriate, in the opinion of the Administrative Agent, to give effect
to the provisions of this Section, including any amendments necessary to treat the applicable Loans of the applicable Extending Lenders
as a new class of loans hereunder and as the Company and the applicable Extending Lenders may agree to the extent such amendment would
otherwise be permitted pursuant to, and is adopted in accordance with the consent requirements of, Section 10.06; provided that
no such Extension Agreement shall effect any amendment or waiver referred to in Section 10.06(a)(ii)(A), (B) or (C) without the
consent of each Lender affected thereby.  

 

(c)  The
aggregate principal amount of the Loans of each Declining Lender, together with any accrued interest thereon and any accrued fees and
other amounts payable to or for the accounts of such Declining Lender, shall be due and payable on the Maturity Date as in effect immediately
prior to the effectiveness of the applicable Extension Agreement.  Notwithstanding the foregoing provisions of this paragraph,
the Company shall have the right, pursuant to and in accordance with Section 3.07, to replace any Declining Lender with a Lender
or other financial institution that will agree to the applicable Extension Permitted Amendment, and any such replacement Lender shall
for all purposes constitute an Extending Lender as to such Extension Permitted Amendment.

 

    38 

     

    

SECTION
2.14.  Use of Proceeds.  The proceeds of the Loans made hereunder shall be used by the Company for general
working capital needs and other lawful corporate purposes.

 

ARTICLE
III

Change in Circumstances

 

SECTION
3.01.  Increased Cost and Reduced Return.  (a)  If any Change in Law:

 

(i)
shall impose, modify, or deem applicable any reserve, special deposit, assessment, compulsory loan, insurance charge or similar requirement
relating to any extensions of credit or other assets of, or any deposits with or other liabilities or commitments of, any Lender (or
its Applicable Lending Office), including each Commitment of such Lender hereunder;

 

(ii)
shall impose on any Lender (or its Applicable Lending Office) or on the applicable offshore interbank market any other condition (other
than Taxes) affecting this Agreement or any Note or any Loans made by such Lender;

 

(iii)
shall subject any Lender (or its Applicable Lending Office) to any Taxes (other than (A) Indemnified Taxes, (B) Excluded Taxes,
(C) reserve, special deposit, assessment compulsory loan, insurance charge or similar requirements, the compensation for which is
governed solely by Section 3.01(a)(i) or (D) capital adequacy or liquidity requirements, the compensation for which is governed
solely by Section 3.01(b)) on its loans, participations or commitments, or on its assets, deposits, reserves, liabilities or capital,
in each case, attributable thereto;

 

and the result
of any of the foregoing is to increase the cost to such Lender (or its Applicable Lending Office) of making, converting into, continuing
or maintaining any Loan (or of maintaining its Commitment to make Loans) or to reduce any sum received or receivable by such Lender (or
its Applicable Lending Office) under this Agreement or any Note with respect to any Loan, then the Company shall pay to such Lender within
15 days of demand such amount or amounts as will compensate such Lender for such increased cost or reduction.  If any Lender
requests compensation under this paragraph (a), the Company may, by notice to such Lender (with a copy to the Administrative Agent),
suspend the obligation of such Lender to make or continue Loans of the Type with respect to which such compensation is requested, or
to convert Loans of any other Type into Loans of such Type, until the event or condition giving rise to such request ceases to be in
effect; provided that such suspension shall not affect the right of such Lender to receive the compensation so requested.

 

(b)  If
any Lender shall have determined that any Change in Law regarding capital adequacy or liquidity has or would have the effect of reducing
the rate of return on the capital of such Lender or its Lender Parent as a consequence of such Lender’s

 

    39 

     

    

obligations hereunder to a level below
that which such Lender or its Lender Parent could have achieved but for such Change in Law (taking into consideration its policies with
respect to capital adequacy and liquidity), then from time to time within 15 days after demand by such Lender (with a copy to the Administrative
Agent) the Company shall pay to such Lender such additional amount or amounts as will compensate such Lender or its Lender Parent for
such reduction.

 

(c)  Each
Lender shall promptly notify the Company and the Administrative Agent of any event of which it has knowledge which will entitle such
Lender to compensation pursuant to this Section 3.01 and will designate a different Applicable Lending Office if such designation will
avoid the need for, or reduce the amount of, such compensation and will not, in the judgment of such Lender, be otherwise disadvantageous
to it.  Any Lender claiming compensation under this Section 3.01 shall furnish to the Company and the Administrative Agent
a statement setting forth the additional amount or amounts to be paid to it hereunder and the calculation thereof in reasonable detail,
which shall be conclusive in the absence of manifest error.  In determining such amount, such Lender may use any reasonable
averaging and attribution methods.

 

(d)  Failure
or delay on the part of any Lender to demand compensation for any increased costs or reduction in amounts received or receivable or reduction
in return on capital shall not constitute a waiver of such Lender’s right to demand such compensation; provided that the
Company shall not be under any obligation to compensate any Lender under paragraph (a) or (b) above with respect to increased costs or
reduction in return on capital with respect to any period prior to the date that is three months prior to such request if such Lender
knew or could reasonably have been expected to be aware of the circumstances giving rise to such increased costs or reductions in return
on capital and of the fact that such circumstances would in fact result in a claim for increased compensation by reason of such increased
costs or reductions in capital; provided further that the foregoing limitation shall not apply to any increased costs or reductions
in return on capital arising out of the retroactive application of any Change in Law as aforesaid within such three month period.

 

(e)    Notwithstanding
the foregoing provisions of this Section, no Lender shall be entitled to request compensation under this Section for any costs referred
to in paragraph (a)(iii) above or any costs imposed on such Lender under the Dodd-Frank Wall Street Reform and Consumer Protection Act
or Basel III unless it shall be the general policy or practice of such Lender to seek compensation under comparable credit facilities
the documents for which contain provisions comparable to this Section 3.01.

 

SECTION
3.02.  Alternate Rate of Interest.  (a) Subject to Section 3.02(b), if:

 

(i)  the
Administrative Agent determines (which determination shall be conclusive absent manifest error) (A) prior to the commencement of any
Interest Period for a Term SOFR Borrowing, that adequate and reasonable means do not exist for ascertaining the Adjusted Term SOFR (including
because the Term SOFR Reference Rate is not available or published on a current basis) for such Interest

 

    40 

     

    

Period
or (B) at any time, that adequate and reasonable means do not exist for ascertaining the Adjusted Daily Simple SOFR; or

 

(ii)  the
Administrative Agent is advised by the Required Lenders  (A) prior to the commencement of any Interest Period for a Term SOFR
Borrowing, that the Adjusted Term SOFR for such Interest Period will not adequately and fairly reflect the cost to such Lenders of making
or maintaining their Loans included in such Borrowing for such Interest Period or (B) at any time, that the Adjusted Daily Simple SOFR
will not adequately and fairly reflect the cost to such Lenders of making or maintaining their Loans included in any Daily Simple SOFR
Borrowing;

 

then the Administrative
Agent shall give the Company and the Lenders prompt notice thereof (which may be by telephone) and, until (x) the Administrative Agent
notifies the Company and the Lenders that the circumstances giving rise to such notice no longer exist with respect to the relevant Benchmark
and (y) the Company delivers a new Interest Election Request in accordance with the terms of Section 2.05 or a new Borrowing Notice in
accordance with the terms of Section 2.03, any Interest Election Request that requests the conversion of any Borrowing to, or continuation
of any Borrowing as, an affected Term SOFR Borrowing and any Borrowing Notice that requests an affected Term SOFR Borrowing shall instead
be deemed to be an Interest Election Request or a Borrowing Notice, as applicable, for (x) a Daily Simple SOFR Borrowing so long as the
Adjusted Daily Simple SOFR is not also the subject of Section 3.02(a)(i) or 3.02(a)(ii) above or (y) an ABR Borrowing if the Adjusted
Daily Simple SOFR also is the subject of Section 3.02(a)(i) or 3.02(a)(ii) above.  Furthermore, if any Term SOFR Loan or Daily
Simple SOFR Loan is outstanding on the date of the Company’s receipt of the notice from the Administrative Agent referred to in
this Section 3.02(a) with respect to a Relevant Rate applicable to such Loan, then until (x) the Administrative Agent notifies the Company
and the Lenders that the circumstances giving rise to such notice no longer exist with respect to the relevant Benchmark and (y) the
Company delivers a new Interest Election Request in accordance with the terms of Section 2.05 or a new Borrowing Notice in accordance
with the terms of Section 2.03, (1) any Term SOFR Loan shall, on the last day of the Interest Period applicable to such Loan, convert
to, and shall constitute, (x) a Daily Simple SOFR Loan so long as the Adjusted Daily Simple SOFR is not also the subject of Section 3.02(a)(i)
or 3.02(a)(ii) above or (y) an ABR Loan if the Adjusted Daily Simple SOFR also is the subject of Section 3.02(a)(i) or 3.02(a)(ii) above,
on such day, and (2) any Daily Simple SOFR Loan shall on and from such day convert to, and shall constitute an ABR Loan.

 

(b)  (i) Notwithstanding
anything to the contrary herein or in any other Loan Document, if a Benchmark Transition Event and its related Benchmark Replacement
Date have occurred prior to the Reference Time in respect of any setting of the then-current Benchmark, then (x) if a Benchmark Replacement
is determined in accordance with clause (1) of the definition of “Benchmark Replacement” for such Benchmark Replacement Date,
such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any other Loan Document in respect of such
Benchmark setting and subsequent Benchmark settings without any amendment to, or further action or consent of any other party to, this
Agreement or any other Loan Document and (y) if a Benchmark Replacement

 

    41 

     

    

is determined in accordance with clause
(2) of the definition of “Benchmark Replacement” for such Benchmark Replacement Date, such Benchmark Replacement will replace
such Benchmark for all purposes hereunder and under any other Loan Document in respect of any Benchmark setting at or after 5:00 p.m.,
New York City time, on the fifth Business Day after the date notice of such Benchmark Replacement is provided to the Lenders without
any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document so long as the Administrative
Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Required
Lenders.

 

(ii)
Notwithstanding anything to the contrary herein or in any other Loan Document, the Administrative Agent will have the right to make Benchmark
Replacement Conforming Changes from time to time (and in consultation with the Company) and, notwithstanding anything to the contrary
herein or in any other Loan Document, any amendments implementing such Benchmark Replacement Conforming Changes will become effective
without any further action or consent of any other party to this Agreement or any other Loan Document.

 

(iii)
The Administrative Agent will promptly notify the Company and the Lenders of (A) any occurrence of a Benchmark Transition Event, (B)
the implementation of any Benchmark Replacement, (C) the effectiveness of any Benchmark Replacement Conforming Changes, (D) the removal
or reinstatement of any tenor of a Benchmark pursuant to clause (iv) below and (E) the commencement or conclusion of any Benchmark Unavailability
Period.  Any determination, decision or election that may be made by the Administrative Agent or, if applicable, any Lender
(or group of Lenders) pursuant to this Section 3.02(b), including any determination with respect to a tenor, rate or adjustment or of
the occurrence or non-occurrence of an event, circumstance or date, and any decision to take or refrain from taking any action or any
selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from
any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this Section 3.02(b).

 

(iv)  Notwithstanding
anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark
Replacement), (A) if the then-current Benchmark is a term rate (including Term SOFR) and either (1) any tenor for such Benchmark is not
displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent
in its reasonable discretion or (2) the regulatory supervisor for the administrator of such Benchmark has provided a public statement
or publication of information announcing that any tenor for such Benchmark is or will be no longer representative, then the Administrative
Agent may modify the definition of “Interest Period” for any Benchmark settings at or after such time to remove such unavailable
or non-representative tenor and (B) if a tenor that was removed pursuant to clause (A) above either (1) is subsequently displayed on
a screen or information service for a Benchmark (including a

 

    42 

     

    

Benchmark
Replacement) or (2) is not, or is no longer, subject to an announcement that it is or will no longer be representative for a Benchmark
(including a Benchmark Replacement), then the Administrative Agent may modify the definition of “Interest Period” for all
Benchmark settings at or after such time to reinstate such previously removed tenor.

 

(v)  Upon
the Company’s receipt of notice of the commencement of a Benchmark Unavailability Period, the Company may revoke any request for
a borrowing of, conversion to or continuation of Term SOFR Loans to be made, converted or continued during any Benchmark Unavailability
Period and, failing that the Company will be deemed to have converted any request for a Term SOFR Borrowing into a request for a borrowing
of or conversion to (A) a Daily Simple SOFR Borrowing so long as Adjusted Daily Simple SOFR is not also the subject of a Benchmark Transition
Event or (B) an ABR Borrowing if Adjusted Daily Simple SOFR is also the subject of a Benchmark Transition Event.  If any Term
SOFR Borrowing is outstanding on the date of the Company’s receipt of notice of the commencement of a Benchmark Unavailability
Period with respect to the Adjusted Term SOFR, then until such time as a Benchmark Replacement is implemented pursuant to this Section 3.02(b),
(A) any outstanding Term SOFR Borrowing shall, on the last day of the Interest Period applicable to such Borrowing, convert to, and shall
constitute, (x) a Daily Simple SOFR Borrowing so long as Adjusted Daily Simple SOFR is not also the subject of a Benchmark Transition
Event or (y) an ABR Borrowing if Adjusted Daily Simple SOFR is also the subject of a Benchmark Transition Event.

 

SECTION
3.03.  Illegality.  Notwithstanding any other provision of this Agreement, in the event that it becomes unlawful
for any Lender or its Applicable Lending Office to make, maintain, or fund Term SOFR Loans hereunder, then such Lender shall promptly
notify the Company thereof and such Lender’s obligation to make or continue any Term SOFR Loans or to convert other Types of Loans
into Term SOFR Loans shall be suspended until the circumstances giving rise to suspension no longer exist (in which case such Lender
shall again make, maintain, and fund Term SOFR Loans to the Company), and each such Term SOFR Loan then outstanding shall be converted
into an ABR Loan on the last day of the then-current Interest Period with respect thereto.

 

SECTION
3.04.  Compensation.  Upon the request of any Lender (with a copy to the Administrative Agent), the Company
shall promptly pay to such Lender such amount or amounts as shall be sufficient (in the reasonable opinion of such Lender) to compensate
it for any loss (other than lost profit), cost and expense incurred by it as a result of:

 

(a)  any
payment, prepayment, or conversion of a Term SOFR Loan for any reason, including, without limitation, the acceleration of the Loans pursuant
to Section 8.01, on a date other than the last day of the Interest Period for such Loan; or

 

(b)  any
failure by the Company for any reason (including, without limitation, the failure of any condition precedent specified in Article IV
to be satisfied) to

 

    43 

     

    

borrow, convert, continue, or prepay
a Term SOFR Loan on the date for such borrowing, conversion, continuation, or prepayment specified in the relevant Borrowing Notice,
Interest Election Request or notice of prepayment under this Agreement.

 

SECTION
3.05.  Taxes.  (a)  Any and all payments by the Company to or for the account of any Lender or the
Administrative Agent hereunder or under any other Loan Document shall be made free and clear of and without deduction for any Taxes,
other than as required by applicable law.  If  the Company shall be required by applicable law to deduct or withhold
any Taxes from or in respect of any sum payable under this Agreement or any other Loan Document to any Lender or the Administrative Agent,
(i) the Company shall make such deductions, (ii) the Company shall pay the full amount deducted to the relevant taxation authority
or other authority in accordance with applicable law, (iii) if such Tax is an Indemnified Tax, then the sum payable shall be increased
as necessary so that after making all required deductions (including deductions applicable to additional sums payable under this Section
3.05) such Lender or the Administrative Agent receives an amount equal to the sum it would have received had no such deductions been
made and (iv) within 30 days after the date of such payment, the Company shall furnish to the Administrative Agent, at its address
referred to in Section 10.02, the original or a certified copy of a receipt evidencing payment thereof or, if such receipt is not legally
available, any other document evidencing payment thereof that is reasonably satisfactory to such Lender or the Administrative Agent (as
the case may be).

 

(b)  In
addition, the Company agrees to pay any and all present or future stamp or documentary Taxes and any other excise or property Taxes which
arise from any payment made under this Agreement or any other Loan Document or from the execution or delivery of, or otherwise with respect
to, this Agreement or any other Loan Document (hereinafter referred to as “Other Taxes”); provided that, where
such Other Taxes arise from a Loan, the Company shall pay only such Other Taxes as shall be imposed by the United States or any political
subdivision thereof.

 

(c)  The
Company agrees to indemnify each Lender and the Administrative Agent for the full amount of any Indemnified Taxes (including, without
limitation, any Indemnified Taxes imposed or asserted by any jurisdiction on amounts payable under this Section 3.05) payable or paid
by such Lender or the Administrative Agent (as the case may be).  Indemnification shall be made within 15 days of the date
of demand therefor.

 

(d)  Each
Lender severally agrees to indemnify the Administrative Agent for the full amount of (i) Indemnified Taxes attributable to such
Lender (but only to the extent that the Company has not already indemnified the Administrative Agent for such Indemnified Taxes and without
limiting the obligation of the Company to do so), (ii) any Taxes attributable to such Lender’s failure to comply with the
provisions of Section 10.01(g) relating to the maintenance of a Participant Register and (iii) any Excluded Taxes attributable to such
Lender, in each case, that are payable or paid by the Administrative Agent hereunder or in connection with any Loan Document.  Indemnification
shall be made whether or not such Taxes described in clause (i) through (iii) of this paragraph (d) were correctly or legally imposed
or asserted by the relevant Governmental Authority and shall be made within 15 days of the date of demand therefor.  A certificate
as to the amount of

 

    44 

     

    

such payment or liability delivered
to a Lender by the Administrative Agent shall be conclusive absent manifest error.

 

(e)  Each
Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments under this Agreement or any other
Loan Document shall, at the reasonable request of the Company or the Administrative Agent, deliver to the Company (with a copy to the
Administrative Agent), at such time or times prescribed by applicable law, such properly completed and executed documentation prescribed
by applicable law (if any) as is required to permit such payments to be made without withholding or at a reduced rate.  

 

(ef  Without
limiting the foregoing, (i) any US Lender shall provide upon executing this Agreement (and from time to time thereafter upon any reasonable
request of the Company or the Administrative Agent) a duly executed Internal Revenue Service Form W-9 and (ii) any Foreign Lender shall,
to the extent it is legally entitled to do so, provide upon executing this Agreement (and from time to time thereafter upon any reasonable
request of the Company or the Administrative Agent) a duly executed applicable Internal Revenue Service Form W-8 (or in the case of a
Foreign Lender that is not a bank, other customary documentation reasonably satisfactory to the Company establishing eligibility for
the portfolio interest exemption).

 

(g)  If
a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were
to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the
Code, as applicable), such Lender shall deliver to the Company and the Administrative Agent at the time or times prescribed by law and
at such time or times reasonably requested by the Company or the Administrative Agent such documentation prescribed by applicable law
(including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Company
or the Administrative Agent as may be necessary for the Company and the Administrative Agent to comply with their obligations under FATCA
and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct
and withhold from such payment. Solely for the purposes of this Section 3.05(g), “FATCA” shall include any amendments made
to FATCA after the date of this Agreement.

 

(h)  If
any Lender receives a refund or credit from a taxation authority (such credit to include any increase in any foreign tax credit) in respect
of any Indemnified Taxes for which it has been indemnified by the Company or with respect to which the Company has paid additional amounts
hereunder, it shall within 30 days from the date of such receipt pay over the amount of such refund, credit or other reduction (including
any interest paid or credited by the relevant taxing authority or Governmental Authority with respect to such refund, credit or other
reduction) to the Company (but only to the extent of indemnity payments made, or additional amounts paid, by the Company with respect
to the Indemnified Taxes giving rise to such refund or credit), net of all reasonable out-of-pocket third party expenses of such Lender
related to claiming such refund or credit and without interest (other than interest paid by the relevant taxation authority with respect
to such

 

    45 

     

    

refund or credit); provided,
however, that the Company agrees to repay, upon the request of such Lender, the amount paid over to the Company (plus penalties,
interest or other charges) to such Lender in the event such Lender is required to repay such refund or credit to such taxation authority.

 

(i)  Notwithstanding
anything to the contrary in this Section 3.05, if the Internal Revenue Service determines that a Lender is participating in a conduit
financing arrangement as defined in Section 7701(l) of the Code and the regulations thereunder (a “Conduit Financing Arrangement”),
then (i) any Taxes that the Company is required to withhold from payments to the Lender participating in the Conduit Financing Arrangement
shall be excluded from the additional amounts to be paid under paragraphs (a) or (c) of this Section 3.05 and (ii) such Lender shall
indemnify the Company in full for any and all Taxes for which the Company is held liable under Section 1461 of the Code by virtue of
such Conduit Financing Arrangement.

 

SECTION
3.06.  Designation and Change of Lending Offices.  (a)  Each Lender agrees that it will endeavor
in good faith to designate as the office or offices from which it makes Loans one or more of its existing offices not known to it to
be subject to costs or other requirements for which it would be entitled to seek compensation under Section 3.01, 3.03 or 3.05 (or,
where such costs cannot be avoided, that will minimize such costs), insofar as such designation would not result, in the sole judgment
of such Lender, in economic, legal or regulatory disadvantages to such Lender or any such lending office, and subject to overall policy
considerations of such Lender.

 

(b)  Each
Lender agrees that, upon the occurrence of any event giving rise to the operation of Section 3.01, 3.03 or 3.05 with respect to
such Lender, it will, if requested by the Company, use reasonable efforts (subject to overall policy considerations of such Lender) to
designate another lending office for any Loans affected by such event with the object of avoiding the consequences of such event; provided
that such designation is made on terms that, in the sole judgment of such Lender, cause such Lender and its lending office(s) to
suffer no economic, legal or regulatory disadvantage; provided further that nothing in this Section 3.06 shall affect or postpone
any of the obligations of the Company or the rights of any Lender pursuant to Section 3.01, 3.02(a), 3.03 or 3.05.

 

SECTION
3.07.  Substitution of Lenders.  Upon the receipt by the Company from any Lender (an “Affected Lender”)
of a claim under Section 3.01, 3.03 or 3.05, or if any Lender shall become a Declining Lender or a Defaulting Lender, the Company may:
(a) request one or more of the other Lenders to acquire and assume all or part of such Affected Lender’s Loans and Commitment or
(b) replace such Affected Lender by designating another Lender or a financial institution that is willing to acquire such Loans and assume
such Commitment; provided that (i) such replacement does not conflict with any requirement of law, (ii) the Company shall repay
(or the replacement Lender or financial institution shall purchase, at par) all Loans, accrued interest and other amounts owing to such
replaced Lender prior to the date of replacement, (iii) the Company shall be liable to such replaced Lender under Section 3.04 if any
Term SOFR Loan owing to such replaced Lender shall be prepaid (or purchased) other than on the last day of the Interest Period relating
thereto, (iv) the replacement financial institution, if not already a Lender,

 

    46 

     

    

shall be an Eligible Assignee, (v) the
replaced Lender shall be obligated to make such replacement in accordance with the provisions of Section 10.01 (provided that
the Company or replacement Lender shall be obligated to pay the registration and processing fee) and (vi) the Company shall pay all additional
amounts (if any) required pursuant to Section 3.01, 3.03 or 3.05, as the case may be, to the extent such additional amounts were incurred
on or prior to the consummation of such replacement.

 

ARTICLE
IV

Conditions to Making Loans 

 

SECTION
4.01.  Conditions of Closing.  The effectiveness of the obligations of the Lenders to make Loans are subject
to the satisfaction (or waiver in accordance with Section 10.01) of the following conditions:

 

(a)  the
Administrative Agent shall have received on the Closing Date the following:

 

(i)
from each party hereto a counterpart of this Agreement signed on behalf of such party (which, subject to Section 10.07(b), may include
any Electronic Signatures transmitted by emailed. pdf or any other electronic means that reproduces an image of an actual executed signature
page of a counterpart of this Agreement);

 

(ii)
the written opinion or opinions with respect to the Loan Documents and the transactions contemplated thereby of (A) Jennifer S. Sim,
General Counsel of the Company, (B) Davis Polk & Wardwell, special counsel to the Company, and (C) Ballard Spahr LLP, Pennsylvania
counsel for the Company, in each case, dated the Closing Date, addressed to the Administrative Agent and the Lenders and satisfactory
to the Administrative Agent;

 

(iii)
resolutions of the board of directors (or of the appropriate committee thereof) of the Company certified by its secretary or assistant
secretary as of the Closing Date, approving and adopting the Loan Documents to be executed by the Company and authorizing the execution
and delivery thereof;

 

(iv)
specimen signatures of officers or other appropriate representatives executing the Loan Documents on behalf of the Company, certified
by its secretary or assistant secretary;

 

(v)
the organizational documents of the Company certified as of the Closing Date as true and correct by its secretary or assistant secretary;

 

(vi)
a certificate issued as of a recent date by the Secretary of State or other appropriate Governmental Authority of the jurisdiction of
formation of the Company as to the due existence and good standing of the Company; and

 

    47 

     

    

(vii)
a certificate of the Company certifying that (A) as of the Closing Date, each of the representations and warranties set forth in Article
V is true and correct in all material respects, (B) after giving effect to the Closing Date and all Loans to be made on the Closing Date,
if any, there will be no Default or Event of Default under this Agreement, and (C) except as disclosed in any reports or financial statements
publicly filed with the Securities and Exchange Commission prior to the Closing Date, as of the Closing Date there shall not have occurred
a material adverse change since April 2, 2022, in the business, financial position or results of operations of the Company and its Subsidiaries,
taken as a whole;

 

(b)  any
fees and expenses required to be paid on or before the Closing Date shall have been paid, including, to the extent invoiced at least
one Business Day prior to the Closing Date, all fees, charges and disbursements of counsel to the Administrative Agent; and

 

(c)  the
Lenders shall have received all documentation and other information required by bank regulatory authorities under applicable “know
your customer” and anti-money laundering rules and regulations, including the USA PATRIOT Act and the Beneficial Ownership Regulation,
to the extent requested by the Lenders at least three Business Days prior to the Closing Date.

 

Without
limiting the generality of the provisions of Article IX, for purposes of determining satisfaction of the conditions specified in this
Section 4.01, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted, or to be satisfied
with, each document or other matter required hereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless
the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto.

 

SECTION
4.02.  Conditions to Making Loans.  The obligations of the Lenders to make any Loans on any Funding Date are
subject to the satisfaction of the following conditions:

 

(a)
the Administrative Agent shall have received a Borrowing Notice as required by Article II;

 

(b)
the representations and warranties set forth in Article V (other than those set forth in Section 5.05) shall be true and correct
in all material respects on and as of the applicable Funding Date with the same effect as though such representations and warranties
had been made on and as of such Funding Date, except to the extent that such representations and warranties expressly relate to an earlier
date and except that the financial statements referred to in Section 5.04 shall be deemed to be those financial statements most recently
delivered to the Administrative Agent and the Lenders pursuant to Section 6.01 from the date such financial statements are delivered
to the Administrative Agent and the Lenders in accordance with such Section; and

 

    48 

     

    

(c)
at the time of and after giving effect to each such Loan, no Default or Event of Default shall have occurred and be continuing.

 

At
the time of the applicable Borrowing on any Funding Date, the Company shall be deemed to represent that each of the conditions set forth
in this Section 4.02 has been satisfied.

 

ARTICLE
V Representations and Warranties

 

The
Company represents and warrants with respect to itself and its Subsidiaries that:

 

SECTION
5.01.  Corporate Existence and Power.  The Company is duly organized, validly existing and in good standing
under the laws of the jurisdiction of its organization, and has all the corporate or other requisite powers and all material governmental
licenses, authorizations, consents and approvals required to carry on its business as now conducted, except to the extent that the failure
to have any such licenses, authorizations, consents and approvals could not reasonably be expected to result in a Material Adverse Effect.

 

SECTION
5.02.  Corporate and Governmental Authorization; No Contravention.  The execution, delivery and performance
by the Company of this Agreement and the other Loan Documents are within its corporate powers, have been duly authorized by all necessary
corporate action, require no action by or in respect of, or filing with, any Governmental Authority and do not contravene, or constitute
a default under, any provision of applicable law or regulation or of its organizational documents or, except to the extent that any such
contravention or defaults could not reasonably be expected to result in a Material Adverse Effect, of any agreement, judgment, injunction,
order, decree or other instrument binding upon the Company or any of its Subsidiaries or result in the creation or imposition of any
Lien on any asset of the Company or any of its Subsidiaries.

 

SECTION
5.03.  Binding Effect.  This Agreement constitutes a valid and binding agreement of the Company, and each
other Loan Document, when executed and delivered by the Company, will constitute a valid and binding agreement of the Company, in each
case enforceable in accordance with its terms.

 

SECTION
5.04.  Financial Information.  The consolidated balance sheet of the Company and its Subsidiaries as of April
2, 2022, and the related consolidated statements of income, retained earnings and cash flow for the fiscal year then ended, reported
on by PricewaterhouseCoopers LLP and set forth in the Company’s Form 10-K for the fiscal year then ended, fairly present, in conformity
with GAAP, the consolidated financial position of the Company and its Subsidiaries as of such date and their consolidated results of
operations and cash flows for such fiscal year.

 

    49 

     

    

SECTION
5.05.  Litigation.  There is no action, suit or proceeding pending against, or, to the knowledge of the Company,
threatened against or affecting, the Company or any of its Subsidiaries before any court or arbitrator or any Governmental Authority
which could reasonably be expected to result in a Material Adverse Effect, or which in any manner draws into question the validity of
this Agreement or the other Loan Documents.

 

SECTION
5.06.  Compliance with ERISA.  Except to the extent the failure to do so could not reasonably be expected
to result in a Material Adverse Effect, each member of the ERISA Group has fulfilled its obligations under the minimum funding standards
of ERISA and the Code with respect to each Plan and is in compliance in all material respects with the presently applicable provisions
of ERISA and the Code with respect to each Plan.  No member of the ERISA Group has (a) sought a waiver of the minimum funding
standard under Section 412 of the Code in respect of any Plan or Multiemployer Plan, (b) failed to make any contribution or payment to
any Plan or Multiemployer Plan or in respect of any Benefit Arrangement, or made any amendment to any Plan or Benefit Arrangement, which
has resulted or could result in the imposition of a Lien or the posting of a bond or other security under ERISA or the Code or (c) incurred
any liability under Title IV of ERISA other than a liability to the PBGC for premiums under Section 4007 of ERISA, in each case that
could reasonably be expected to have a Material Adverse Effect.

 

SECTION
5.07.  Environmental Matters.  In the ordinary course of its business, the Company conducts periodic reviews,
which it considers prudent and reasonable in light of the nature of the business, of the effect of Environmental Laws on the business,
operations and properties of the Company and its Subsidiaries, in the course of which it identifies and evaluates associated liabilities
and costs (including, without limitation, any capital or operating expenditures required for clean-up or closure of properties presently
or previously owned, any capital or operating expenditures required to achieve or maintain compliance with environmental protection standards
imposed by law or as a condition of any license, permit or contract, any related constraints on operating activities, including any periodic
or permanent shutdown of any facility or reduction in the level of or change in the nature of operations conducted thereat and any actual
or potential liabilities to third parties, including employees, and any related costs and expenses).  On the basis of this
review, the Company has reasonably concluded that Environmental Laws are unlikely to have a Material Adverse Effect.

 

SECTION
5.08.  Taxes.  The Company and its Significant Subsidiaries have filed all United States Federal income tax
returns and all other material tax returns required to be filed by them and have paid all taxes due pursuant to such returns or pursuant
to any assessment received by the Company or any Significant Subsidiary, except (a) for such amounts as may be contested in good faith
by appropriate proceedings or (b) to the extent that any failure to file or pay could not reasonably be expected to result in a Material
Adverse Effect.  The charges, accruals and reserves on the books of the Company and its Subsidiaries in respect of Taxes or
other governmental charges are, in the reasonable opinion of the Company, adequate.  

 

    50 

     

    

SECTION
5.09.  Margin Stock.  The proceeds of the borrowings made hereunder will be used by the Company only for the
purposes expressly authorized herein.  None of such proceeds will be used, directly or indirectly, for the purpose of purchasing
or carrying any Margin Stock or for the purpose of reducing or retiring any Indebtedness which was originally incurred to purchase or
carry Margin Stock or for any other purpose which might constitute any of the Loans a “purpose” credit within the meaning
of Regulation U or Regulation X (12 C.F.R. Part 221) of the Federal Reserve Board; provided, however, that the Company
may purchase (i) its own stock and (ii) Margin Stock so long as, following the application of the proceeds of each borrowing hereunder,
not more than 25% of the value of the assets of the Company and its Subsidiaries on a consolidated basis will be Margin Stock.

 

SECTION
5.10.  Investment Company.  The Company is not required to register as an “investment company”
within the meaning of the Investment Company Act of 1940, as amended.

 

SECTION
5.11.  Full Disclosure.  All information concerning the Company, the Subsidiaries and the transactions contemplated
hereby, other than any forward-looking statements, taken as a whole, that has been or will be made available by the Company to the Administrative
Agent or any Lender is or will be, when furnished, complete and correct in all material respects and does not or will not, when furnished,
contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained
therein not materially misleading in light of the circumstances under which such statements are made, and any forward-looking statements
that have been or will be made available by the Company to the Administrative Agent or any Lender are or will be, when furnished, based
upon assumptions that the Company’s management believes to be reasonable at the time such statements are made.

 

SECTION
5.12.  No Consents, Etc.  Neither the respective businesses or properties of the Company or any Subsidiary,
nor any relationship among the Company or any Subsidiary and any other Person, nor any circumstance in connection with the execution,
delivery and performance of the Loan Documents and the transactions contemplated thereby, is such as to require a consent, approval or
authorization of, or filing, registration or qualification with, any Governmental Authority on the part of the Company as a condition
to the consummation of the Transactions, which, if not obtained or effected, could reasonably be expected to have a Material Adverse
Effect, or if so, such consent, approval, authorization, filing, registration or qualification has been duly obtained or effected, as
the case may be.

 

SECTION
5.13.  Anti-Corruption Laws and Sanctions.  The Company has implemented and maintain in effect policies and
procedures reasonably designed to promote compliance by the Company, its Subsidiaries and their respective directors, officers, employees
and agents with Anti-Corruption Laws and applicable Sanctions, and the Company, its Subsidiaries and, to the knowledge of the Company,
their respective officers, employees, directors and agents, acting in their capacity as such, are in compliance with Anti-Corruption
Laws and applicable Sanctions in all material respects.  None of (a) the Company, any Subsidiary or, to the knowledge of the
Company, any of their respective

 

    51 

     

    

directors, officers or employees, or
(b) to the knowledge of the Company, any agent of the Company or any Subsidiary that will act in any capacity in connection with or benefit
from the credit facility established hereby, is a Sanctioned Person.

 

ARTICLE
VI

Affirmative Covenants

 

Until
the Facility Termination Date, unless the Required Lenders shall otherwise consent in writing:

 

SECTION
6.01.  Financial Reports, Etc.  The Company will deliver to the Administrative Agent, on behalf of the Lenders:

 

(a)
as soon as available and in any event within 90 days after the end of each fiscal year of the Company, a consolidated balance sheet of
the Company and its Subsidiaries as of the end of such fiscal year and the related consolidated statements of income, retained earnings
and cash flows for such fiscal year, setting forth in each case in comparative form the figures for the previous fiscal year, all prepared
in accordance with GAAP and containing opinions of PricewaterhouseCoopers LLP or other independent certified public accountants of nationally
recognized standing, which are unqualified as to the scope of the audit performed and as to the “going concern” status of
the Company;

 

(b)
as soon as available and in any event within 45 days after the end of each of the first three quarters of each fiscal year of the Company,
a consolidated balance sheet of the Company and its Subsidiaries as of the end of such quarter and the related consolidated statements
of income for such quarter and of income and cash flows for the portion of the Company’s fiscal year ended at the end of such quarter,
setting forth in each case in comparative form the figures for the corresponding quarter and the corresponding portion of the Company’s
previous fiscal year, all certified (subject to normal year-end adjustments) as to fairness of presentation and conformity with GAAP
by an Authorized Representative;

 

(c)
simultaneously with the delivery of each set of financial statements referred to in clauses (a) and (b) above, a certificate of an Authorized
Representative substantially in the form of Exhibit E hereto (i) setting forth in reasonable detail the calculations required to establish
whether the Company was in compliance with the requirements of Sections 7.01, 7.02(j) and 7.03(f) as of the last day of the applicable
fiscal year or quarter and (ii) stating whether there exists on the date of such certificate any Default or Event of Default and, if
any Default or Event of Default then exists, setting forth the details thereof and the action which the Company is taking or proposes
to take with respect thereto;

 

    52 

     

    

(d)
forthwith upon the occurrence of any Default or Event of Default, a certificate of an Authorized Representative setting forth the details
thereof and the action which the Company is taking or proposes to take with respect thereto;

 

(e)
promptly upon the mailing thereof to the shareholders of the Company generally, copies of all financial statements, reports and proxy
statements so mailed;

 

(f)
promptly upon the filing thereof, copies of all registration statements (other than the exhibits thereto and any registration statements
on Form S-8 or its equivalent) and reports on Forms 10-K, 10-Q and 8-K (or their equivalents) which the Company shall have filed with
the Securities and Exchange Commission;

 

(g)
if and when any member of the ERISA Group (i) gives or is required to give notice to the PBGC of any “reportable event” (as
defined in Section 4043 of ERISA) with respect to any Plan which might constitute grounds for a termination of such Plan under Title
IV of ERISA, or knows that the plan administrator of any Plan has given or is required to give notice of any such reportable event, a
copy of the notice of such reportable event given or required to be given to the PBGC; (ii) receives notice that it has incurred complete
or partial withdrawal liability under Title IV of ERISA or notice that any Multiemployer Plan is insolvent, has been terminated or is
in “endangered” or “critical” status (within the meaning of Section 432 of the Code or Section 305
of ERISA), a copy of such notice; (iii) receives notice from the PBGC under Title IV of ERISA of an intent to terminate, impose liability
(other than for premiums under Section 4007 of ERISA) in respect of, or appoint a trustee to administer, any Plan, a copy of such notice;
(iv) applies for a waiver of the minimum funding standard under Section 412 of the Code, a copy of such application; (v) gives notice
of intent to terminate any Plan under Section 404l(c) of ERISA, a copy of such notice and other information filed with the PBGC;
(vi) gives notice of withdrawal from any Plan pursuant to Section 4063 of ERISA, a copy of such notice; or (vii) fails to make any
payment or contribution to any Plan or Multiemployer Plan or in respect of any Benefit Arrangement or makes any amendment to any Plan
or Benefit Arrangement which has resulted or could result in the imposition of a Lien or the posting of a bond or other security, a certificate
of an Authorized Representative setting forth details as to such occurrence and the action, if any, which the Company or applicable member
of the ERISA Group is required or proposes to take with respect thereto; provided that no such delivery referred to in clauses
(i) through (vii) above shall be required unless the event described in the applicable clause could reasonably be expected to result
in a Material Adverse Effect;

 

(h)
promptly following a request therefor, any documentation or other information that a Lender reasonably requests in order to comply with
its ongoing obligations under applicable “know your customer” and anti-money laundering rules and regulations, including
the USA PATRIOT Act and the Beneficial Ownership Regulation; and

 

    53 

     

    

(i)
from time to time such additional information regarding the financial position or business of the Company and its Subsidiaries as the
Administrative Agent or any Lender may reasonably request.

 

Documents
required to be delivered pursuant to clauses (a), (b), (f) or (g) of this Section may be delivered electronically and, if so delivered,
shall be deemed to have been delivered on the date on which such documents are posted (or a link thereto is provided) (i) on the
Company’s website on the Internet at www.vfc.com (or such other URL as shall have been
specified by the Company to the Administrative Agent in a written notice), (ii) at www.sec.gov
or (iii) on the Platform, in each case so long as such documents are generally available without charge to the Administrative Agent
and each of the Lenders at such locations; provided that the Company shall notify (which may be by electronic mail) the Administrative
Agent of the posting of any such documents and, upon request, provide to the Administrative Agent by electronic mail electronic versions
(i.e., soft copies) of such documents.  The Administrative Agent shall have no obligation to request the delivery or to maintain
copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Company with any
such request for delivery, and each Lender shall be solely responsible for requesting delivery to it or maintaining its copies of such
documents.

 

The
Company hereby acknowledges that (a) the Administrative Agent will make available to the Lenders materials and/or information provided
by or on behalf of the Company (collectively, the “Company Materials”) by posting the Company Materials on the Platform
and (b) certain of the Lenders (each, a “Public Lender”) may have personnel who do not wish to receive MNPI and who
may be engaged in investment and other market-related activities with respect to securities of the Company or any of its Subsidiaries.  The
Company hereby agrees that (w) all Company Materials that are to be made available to Public Lenders shall be clearly and conspicuously
marked “PUBLIC” which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first
page thereof; (x) by marking Company Materials “PUBLIC”, the Company shall be deemed to have authorized the Administrative
Agent and the Lenders to treat such Company Materials as not containing any MNPI (provided, however, that to the extent
such Company Materials constitute Information, they shall be treated as set forth in Section 10.13); (y) all Company Materials marked
“PUBLIC” are permitted to be made available through a portion of the Platform designated “Public Investor”; and
(z) the Administrative Agent shall be entitled to treat any Company Materials that are not marked “PUBLIC” as being suitable
only for posting on a portion of the Platform not designated “Public Investor”.  Notwithstanding the foregoing,
the Company shall be under no obligation to mark any Company Materials “PUBLIC”.

 

SECTION
6.02.  Payment of Taxes.  The Company will pay, and will cause each Significant Subsidiary to pay, all its
Tax liabilities, except (a) where the same may be contested in good faith by appropriate proceedings or (b) where the failure to do so
could not reasonably be expected to result in a Material Adverse Effect, and the Company will maintain, and will cause each Significant
Subsidiary to maintain, to the extent required under GAAP (or, in the case of a foreign Significant Subsidiary, the accounting standards
applicable thereto), appropriate reserves for the accrual of the same.

 

    54 

     

    

SECTION
6.03.  Maintenance of Properties; Insurance.  Except to the extent that the failure to do so could not reasonably
be expected to result in a Material Adverse Effect, the Company will (a) keep, and will cause each Significant Subsidiary to keep, all
material property useful and necessary in its business in good working order and condition, ordinary wear and tear excepted, and (b)
maintain, and will cause each Significant Subsidiary to maintain (either in the name of the Company or in such Significant Subsidiary’s
own name) with financially sound and reputable insurance companies, insurance on all their property in at least such amounts and against
at least such risks as are usually insured against in the same general area by companies of established repute engaged in the same or
a similar business; provided that the Company shall have the right to self-insure or use a captive insurer in order to meet such
insurance requirements so long as the Company or such captive insurer provides the Administrative Agent and the Lenders with reasonable
proof of financial responsibility.  The Company will furnish to the Administrative Agent and the Lenders, upon written request
from the Administrative Agent, full information as to the insurance carried.

 

SECTION
6.04.  Compliance with Laws.  The Company will comply, and will cause each Subsidiary to comply, in all material
respects with all applicable laws, ordinances, rules, regulations, and requirements of Governmental Authorities (including, without limitation,
Environmental Laws, ERISA, the Trading with the Enemy Act and each of the foreign assets control regulations of the United States Treasury
Department (31 CFR, Subtitle B, Chapter V), the USA PATRIOT Act, the United States Foreign Corrupt Practices Act of 1977 and, in each
case, the rules and regulations thereunder and any other enabling legislation or executive orders relating thereto), except where (a)
the necessity of compliance therewith is contested in good faith by appropriate proceedings or (b) failure to comply therewith could
not reasonably be expected to result in a Material Adverse Effect.  The Company will maintain in effect policies and procedures
reasonably designed to promote compliance by the Company, the Subsidiaries and their respective directors, officers, employees and agents
with Anti-Corruption Laws and applicable Sanctions.

 

SECTION
6.05.  Books and Records.  The Company will maintain proper books of record and account in which full, true
and correct entries in conformity with GAAP consistently applied shall be made of all financial transactions and matters involving the
assets and business of the Company.  The Company will cause the Subsidiaries to maintain books of record and account of all
financial transactions and matters involving the assets and business of the Subsidiaries, from which the Company may prepare consolidated
financial statements in conformity with GAAP consistently applied.

 

SECTION
6.06.  Existence.  The Company will do or cause to be done all things reasonably necessary to preserve, renew
and keep in full force and effect its legal existence; provided that the foregoing shall not prohibit any merger, consolidation
or other transaction permitted under Section 7.04.

 

    55 

     

    

ARTICLE
VII

Negative Covenants

 

Until
the Facility Termination Date, unless the Required Lenders shall otherwise consent in writing:

 

SECTION
7.01.  Financial Covenant.  The Company will not permit the ratio of Consolidated Net Indebtedness to Consolidated
Net Capitalization, as of the last day of any fiscal quarter of the Company, to be greater than (a) on or prior to the fiscal quarter
ending on or about March 31, 2023, 0.70 to 1.00, (b) thereafter and on or prior to the fiscal quarter ending on or about March 31, 2024,
0.65 to 1.00 and (c) thereafter, 0.60 to 1.00.

 

SECTION
7.02.  Liens.  The Company will not, and will not permit any Subsidiary to, incur, create or permit to exist
any Lien with respect to any property or assets now owned or hereafter acquired by the Company or any Subsidiary, other than:

 

(a)  Liens
existing on the date of this Agreement securing Indebtedness outstanding on the date of this Agreement in an aggregate principal amount
not exceeding US$50,000,000;

 

(b)  any
Lien existing on any asset of any Person at the time such Person becomes a Subsidiary (other than as a result of a Division) and not
created in contemplation of such event;

 

(c)  any
Lien on any asset of any Person existing at the time such Person is merged or consolidated with or into the Company or a Subsidiary and
not created in contemplation of such event;

 

(d)  any
Lien existing on any asset prior to the acquisition thereof by the Company or a Subsidiary and not created in contemplation of such acquisition;

 

(e)  any
Lien on any asset securing Indebtedness incurred or assumed for the purpose of financing all or any part of the cost of acquiring such
asset, provided that such Lien attaches to such asset concurrently with or within 180 days after the acquisition thereof;

 

(f)  any
Lien arising out of the refinancing, extension, renewal or refunding of any Indebtedness secured by any Lien permitted by clauses (a)
through (e) above, provided that such Indebtedness is not increased and is not secured by any additional assets;

 

(g)  Liens
arising in the ordinary course of business which (i) do not secure Indebtedness, (ii) do not secure any obligation in an amount exceeding
US$50,000,000 and (iii) do not otherwise in the aggregate materially detract from the value of the assets subject thereto or materially
impair the use thereof in the operations of its business;

 

    56 

     

    

(h)  Liens
on assets of a Subsidiary securing Indebtedness owed to the Company or a Wholly Owned Subsidiary;

 

(i)  Liens
imposed by law for Taxes that are not yet due or are being contested as described in Section 6.02; and

 

(j)  Liens
not otherwise permitted by the foregoing clauses securing Indebtedness in an aggregate principal amount at any time outstanding not to
exceed 15% of Consolidated Net Worth; provided that the sum of the aggregate principal amount of Indebtedness permitted to be
secured by this clause (j) plus the aggregate principal amount of Indebtedness incurred in accordance with Section 7.03(f) at any
time outstanding shall not exceed 20% of Consolidated Net Worth.

 

SECTION
7.03.  Indebtedness of Subsidiaries.  The Company will not permit any Subsidiary to incur, create, assume
or permit to exist any Indebtedness, howsoever evidenced, except:

 

(a)  Indebtedness
of any Person outstanding at the time such Person becomes a Subsidiary (other than as a result of a Division) and not created in contemplation
of such event;

 

(b)  
Indebtedness of any Person outstanding at the time such Person is merged or consolidated with or into a Subsidiary and not created in
contemplation of such event;

 

(c)  
Indebtedness secured by a Lien permitted by Section 7.02 hereof;

 

(d)  
Indebtedness owing to the Company or a Wholly Owned Subsidiary;

 

(e)  Refinancing
Indebtedness in respect of Indebtedness permitted by clause (a), (b) or (c) above (other than, in the case of clause (c), Refinancing
Indebtedness in respect of (i) Indebtedness referred to in Section 7.02(j) or (ii) Indebtedness referred to in Section 7.02(h) insofar
as such Refinancing Indebtedness would be owed to a Person other than the Company or a Wholly Owned Subsidiary); and

 

(f)  Indebtedness
not otherwise permitted by the foregoing clauses of this Section in an aggregate outstanding principal amount for all Subsidiaries at
no time exceeding 15% of Consolidated Net Worth; provided that the sum of the aggregate principal amount of Indebtedness incurred
in accordance with this clause (f) plus the aggregate principal amount of Indebtedness  permitted to be secured in accordance
with Section 7.02(j) at any time outstanding shall not exceed 20% of Consolidated Net Worth.

 

The
foregoing is subject to the further limitation that for purposes of this Section, any preferred stock of a Subsidiary held by a Person
other than the Company or a Wholly Owned Subsidiary shall be included, at the higher of its voluntary or involuntary liquidation value,
in the Indebtedness of such Subsidiary.

 

    57 

     

    

SECTION
7.04.  Consolidations, Mergers and Sales of Assets.  The Company will not (a) consolidate with or merge with
or into any other Person; provided that the Company may consolidate with or merge with or into another Person if (i) (A) the Company
is the corporation surviving such merger and is not a subsidiary of another Person or (B) the Person surviving such merger (the “Surviving
Company”) is organized in the United States or a jurisdiction thereof, is not a subsidiary of another Person and assumes all
of the obligations and liabilities of the Company under and in respect of this Agreement and each other Loan Document, (ii) immediately
after giving effect to such merger, no Default or Event of Default shall have occurred and be continuing and (iii) in the case of clause
(i)(B) above, the Administrative Agent shall have been given reasonable advance notice of such transaction and shall have received such
documents and certificates as the Administrative Agent or its counsel shall reasonably have requested relating to the organization, existence
and good standing of the Surviving Company and the authorization by the Surviving Company of such assumption of obligations and liabilities,
all in form and substance reasonably satisfactory to the Administrative Agent and its counsel; or (b) sell, lease or otherwise transfer,
directly or indirectly, all or substantially all of its assets to any other Person, except for sales, leases and other transfers to a
Wholly Owned Subsidiary.

 

SECTION
7.05.  Use of Proceeds.  The Company will not request any Borrowing, and the Company shall not directly or,
to the knowledge of the Company, indirectly, use the proceeds of any Borrowing (a) in furtherance of an offer, payment, promise to pay,
or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Laws
or (b) for the purpose of funding, financing or facilitating any activities, business or transaction of or with any Sanctioned Person,
or in any Sanctioned Country, except to the extent licensed by the Office of Foreign Assets Control of the U.S. Department of the Treasury
or otherwise authorized under U.S. law.

 

ARTICLE
VIII

Events of Default and Acceleration

 

SECTION
8.01.  Events of Default.  If any one or more of the following events (herein called “Events of Default”)
shall occur for any reason whatsoever (and whether such occurrence shall be voluntary or involuntary or come about or be effected by
operation of law or pursuant to or in compliance with any judgment, decree or order of any court or any order, rule or regulation of
any Governmental Authority), that is to say:

 

(a)
if default shall be made in the due and punctual payment of the principal of any Loan when and as the same shall be due and payable,
whether pursuant to any provision of Article II or Article III, at maturity, by acceleration or otherwise; or

 

(b)
if default shall be made in the due and punctual payment of any interest on any Loan or of any fees or other amounts payable to any of
the Lenders or the

 

    58 

     

    

Administrative
Agent pursuant to any Loan Document within five days of the date on which the same shall be due and payable; or

 

(c)
if default shall be made in the performance or observance of the covenants set forth in (i) Section 6.01(d) with respect to an Event
of Default, (ii) Section 6.06 with respect to the legal existence of the Company or (iii) Article VII; or

 

(d)
if a default shall be made in the performance or observance of, or shall occur under, any covenant, agreement or provision contained
in this Agreement or any other Loan Document (other than as described in clauses (a), (b) or (c) above) and such default shall continue
for 30 or more days after receipt of notice of such default by an Authorized Representative from the Administrative Agent or the Required
Lenders; or

 

(e)
if there shall occur (i) a default, which is not waived or cured within any applicable period of grace, in the payment of any principal
with respect to any Indebtedness (other than the Loans and other than Indebtedness owed to the Company or any Subsidiary) of the Company
or any Subsidiary in an amount not less than US$100,000,000 in the aggregate outstanding, or (ii) any event or condition, including any
default in the payment of interest, fees or other amounts, specified in any agreement or instrument under or pursuant to which any such
Indebtedness may have been issued, created, assumed, guaranteed or secured, and such event or condition shall continue for more than
the period of grace, if any, therein specified, and such event or condition shall permit the holder of any such Indebtedness (or any
agent or trustee acting on behalf of one or more holders) to accelerate the maturity thereof; or

 

(f)
if any representation or warranty contained in any Loan Document, or any representation, warranty or statement of fact in any writing,
certificate, report or statement at any time furnished to the Administrative Agent or any Lender by or on behalf of the Company or any
Subsidiary pursuant to or in connection with any Loan Document, shall be false or misleading in any material respect when given; or

 

(g)
if the Company or any Significant Subsidiary shall be unable to pay its debts generally as they become due; file a petition to take advantage
of any insolvency statute; make an assignment for the benefit of its creditors; commence a proceeding for the appointment of a custodian,
receiver, trustee, liquidator or conservator of itself or of the whole or any substantial part of its property; or file a petition or
answer seeking liquidation, reorganization, arrangement or similar relief any Debtor Relief Laws; or

 

(h)
if a court of competent jurisdiction shall enter an order, judgment or decree appointing a custodian, receiver, trustee, liquidator or
conservator of the Company or any Significant Subsidiary or of the whole or any substantial part of its properties and such order, judgment
or decree continues unstayed and in effect

 

    59 

     

    

for
a period of 60 days, or shall approve a petition filed against the Company or any Significant Subsidiary seeking liquidation, reorganization
or arrangement or similar relief under any Debtor Relief Laws, which petition is not dismissed within 60 days; or if, under the provisions
of any Debtor Relief Laws, a court of competent jurisdiction shall assume custody or control of the Company or any Significant Subsidiary
or of the whole or any substantial part of its properties, which control is not relinquished within 60 days; or if there is commenced
against the Company or any Significant Subsidiary any proceeding or petition seeking liquidation, reorganization, arrangement or similar
relief under any Debtor Relief Laws, which proceeding or petition remains undismissed for a period of 60 days; or if the Company or any
Significant Subsidiary takes any action to indicate its consent to or approval of any such proceeding or petition; or

 

(i)
if (i) any judgment or order where the amount not covered by insurance (or the amount as to which the insurer denies liability) is in
excess of US$100,000,000 is rendered against the Company or any Subsidiary, or (ii) there is any attachment, injunction or execution
against any of the Company’s or the Subsidiaries’ properties for any amount in excess of US$100,000,000, and such judgment,
attachment, injunction or execution remains unpaid, unstayed, undischarged, unbonded or undismissed for a period of thirty (30) days;
or

 

(j)
if any member of the ERISA Group shall fail to pay when due an amount or amounts aggregating in excess of US$100,000,000 which it shall
have become liable to pay under Title IV of ERISA; or notice of intent to terminate a Material Plan shall be filed under Title IV or
ERISA by any member of the ERISA Group, any plan administrator or any combination of the foregoing; or the PBGC shall institute proceedings
under Title IV of ERISA to terminate, to impose liability (other than for premiums under Section 4007 of ERISA) in respect of, or
to cause a trustee to be appointed to administer any Material Plan; or a condition shall exist by reason of which the PBGC would be entitled
to obtain a decree adjudicating that any Material Plan must be terminated; or there shall occur a complete or partial withdrawal from,
or a default, within the meaning of Section 4219(c)(5) of ERISA, with respect to, one or more Multiemployer Plans which could reasonably
be expected to cause one or more members of the ERISA Group to incur a payment obligation in excess of US$100,000,000; or

 

(k)
if a Change of Control shall occur;

 

then,
and in any such event and at any time thereafter during the continuance of such event, if such Event of Default or any other Event of
Default shall have not been waived,

 

(i)  either
or both of the following actions may be taken: the Administrative Agent may with the consent of the Required Lenders, and at the direction
of the Required Lenders shall, (A) declare any obligation of the Lenders to make further Loans terminated, whereupon the obligation of
each Lender to make further Loans hereunder shall terminate immediately, and (B) declare by notice to the Company any or all of the principal
of the Loans to be immediately

 

    60 

     

    

due
and payable, and the same, together with all interest accrued thereon and all other obligations of the Company under the Loan Documents,
shall forthwith become immediately due and payable without presentment, demand, protest, notice or other formality of any kind, all of
which are hereby expressly waived, anything contained herein or in any other Loan Document to the contrary notwithstanding; provided,
however, that notwithstanding the above, if there shall occur an Event of Default under clause (g) or (h) above with respect to
the Company, then the obligation of the Lenders to make Loans hereunder shall automatically immediately terminate and any and all of
the principal of the Loans, together with all interest accrued thereon and all other obligations of the Company under the Loan Documents,
shall be automatically immediately due and payable without the necessity of any action by the Administrative Agent or the Required Lenders
or notice to the Administrative Agent or the Lenders and without presentment, demand, protest, notice or other formality of any kind,
all of which are hereby expressly waived, anything contained herein or in any other Loan Document to the contrary notwithstanding; and

 

(ii)  the
Administrative Agent and each of the Lenders shall have all of the rights and remedies available under the Loan Documents or under any
applicable law.

 

SECTION
8.02.  Administrative Agent to Act.  In case any one or more Events of Default shall occur and not have been
waived, the Administrative Agent may, and at the direction of the Required Lenders shall, proceed to protect and enforce their rights
or remedies either by suit in equity or by action at law, or both, whether for the specific performance of any covenant, agreement or
other provision contained herein or in any other Loan Document, or to enforce the payment of the obligations of the Company under the
Loan Documents or any other legal or equitable right or remedy.

 

SECTION
8.03.  Cumulative Rights.  No right or remedy herein conferred upon the Lenders or the Administrative Agent
is intended to be exclusive of any other rights or remedies contained herein or in any other Loan Document, and every such right or remedy
shall be cumulative and shall be in addition to every other such right or remedy contained herein and therein or now or hereafter existing
at law or in equity or by statute, or otherwise.

 

SECTION
8.04.  No Waiver.  No course of dealing between the Company, on the one hand, and any Lender or the Administrative
Agent, on the other hand, or any failure or delay on the part of any Lender or the Administrative Agent in exercising any rights or remedies
under any Loan Document or otherwise available to it, shall operate as a waiver of any rights or remedies, and no single or partial exercise
of any rights or remedies shall operate as a waiver or preclude the exercise of any other rights or remedies hereunder or of the same
right or remedy on a future occasion.

 

SECTION
8.05.  Allocation of Proceeds.  If an Event of Default has occurred and not been waived, and the maturity
of the Loans has been accelerated pursuant to this Article VIII, all payments received by the Administrative Agent hereunder in
respect

 

    61 

     

    

of any principal of or interest on the
obligations of the Company hereunder, or any other amounts payable by the Company hereunder, shall be applied by the Administrative Agent
in the following order:

 

(a)  amounts
due to the Administrative Agent pursuant to Sections 2.09, 10.05 and 10.09;

 

(b)  amounts
due to the Lenders pursuant to Sections 2.09, 10.05 and 10.09, to be applied for the ratable benefit of the Lenders (based on the amounts
owing to each Lender at such time);

 

(c)  payments
of interest on Loans, to be applied for the ratable benefit of the Lenders (based on the amounts accrued for the account of each Lender
at such time);

 

(d)  payments
of principal of Loans, to be applied for the ratable benefit of the Lenders (based on the amounts owing to each Lender at such time);

 

(e)  payments
of all other amounts due by the Company under any of the Loan Documents, if any, to be applied for the ratable benefit of the parties
entitled thereto (based on the amounts owing to such parties at such time); and

 

(f)  any
surplus remaining after application as provided for herein, to the Company or otherwise as may be required by applicable law.

 

ARTICLE
IX

The Administrative Agent

 

SECTION
9.01.  Appointment and Authority.  Each of the Lenders hereby irrevocably appoints JPMorgan to act on its
behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such
actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof and thereof, together
with such actions and powers as are reasonably incidental thereto.  Except as expressly set forth in Section 9.06, the provisions
of this Article are solely for the benefit of the Administrative Agent and the Lenders, and the Company shall have no rights as third
party beneficiaries of any of such provisions.

 

SECTION
9.02.  Rights as Lender.  The Person serving as the Administrative Agent hereunder shall, if it shall be a
Lender, have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not
the Administrative Agent and the term “Lender” shall, unless otherwise expressly indicated or unless the context otherwise
requires, include the Person serving as the Administrative Agent hereunder in its individual capacity.  Such Person and its
Affiliates may accept deposits from, lend money to, act as the financial advisor or in any other advisory capacity for and generally
engage in any kind of business with the Company

 

    62 

     

    

or any Subsidiary or other Affiliate
thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.

 

SECTION
9.03.  Exculpatory Provisions.  The Administrative Agent shall not have any duties or obligations except those
expressly set forth herein and in the other Loan Documents. Without limiting the generality of the foregoing, the Administrative Agent:

 

(a)
shall not be subject to any fiduciary or other implied duties, regardless of whether a Default or Event of Default has occurred and is
continuing (and it is understood and agreed that the use of the term “agent” herein or in any other Loan Documents (or any
other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express)
obligations arising under agency doctrine of any applicable law, and that such term is used as a matter of market custom and is intended
to create or reflect only an administrative relationship between contracting parties);

 

(b)
shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers
expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing
by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other
Loan Documents); provided that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion
of its counsel, may expose it to liability or that is contrary to any Loan Document or applicable law; and

 

(c)
shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for
the failure to disclose, any information relating to the Company or any of its Affiliates that is communicated to or obtained by the
Person serving as the Administrative Agent or any of its Affiliates in any capacity.

 

The
Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required
Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good
faith to be necessary, under the circumstances as provided in Sections 8.01 and 10.06) or (ii) in the absence of a court of competent
jurisdiction having determined, in a final and non-appealable judgment, that the Administrative Agent’s action or inaction constituted
gross negligence or willful misconduct on the part of the Administrative Agent.  The Administrative Agent shall be deemed not
to have knowledge of any Default or Event of Default unless and until notice (stating it is a “notice of default”) describing
such Default or Event of Default is given to the Administrative Agent by the Company or a Lender.

 

The
Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation
made in or in

 

    63 

     

    

connection with this Agreement or any
other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection
herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth
herein or therein or the occurrence of any Default or Event of Default, (iv) the sufficiency, validity, enforceability, effectiveness
or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document (including, for the avoidance
of doubt, in connection with the Administrative Agent’s reliance on any Electronic Signature transmitted by emailed pdf. or any
other electronic means that reproduces an image of an actual executed signature page) or (v) the satisfaction of any condition set forth
in Article IV or elsewhere herein, other than to confirm receipt of items (which on their face purport to be such items) expressly required
to be delivered to the Administrative Agent.

 

SECTION
9.04.  Reliance by Administrative Agent.  The Administrative Agent shall be entitled to rely upon, and shall
not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing
(including any e-mail transmission of a .pdf or similar electronic copy of any such document or other writing or any electronic message,
Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated
by the proper Person.  The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed
by it to have been made by the proper Person, and shall not incur any liability for relying thereon.  In determining compliance
with any condition hereunder to the making of a Loan that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative
Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent shall have received notice to the
contrary from such Lender prior to the making of such Loan.  The Administrative Agent may consult with legal counsel (who may
be counsel for the Company), independent accountants and other experts selected by it, and shall not be liable for any action taken or
not taken by it in accordance with the advice of any such counsel, accountants or experts.

 

SECTION
9.05.  Delegation of Duties.  The Administrative Agent may perform any and all of its duties and exercise
its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative
Agent.  The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers
by or through their respective Related Parties.  The exculpatory provisions of this Article shall apply to any such sub-agent
and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to the respective activities of all such
Persons in connection with the syndication of the credit facility provided for herein as well as activities as the Administrative Agent.

 

SECTION
9.06.  Resignation of Administrative Agent.  The Administrative Agent may at any time give notice of its resignation
to the Lenders and the Company.  Upon receipt of any such notice of resignation, the Required Lenders shall have the right,
with the consent of the Company, to appoint a successor, which shall be a bank with an office in the United States, or an Affiliate of
any such bank with an office in the United States.  If no such successor shall have been so appointed by the Required Lenders
and

 

    64 

     

    

shall have accepted such appointment
within 30 days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may on
behalf of the Lenders, and with the consent of the Company, appoint a successor Administrative Agent meeting the qualifications set forth
above; provided that if the retiring Administrative Agent shall notify the Company and the Lenders that no qualifying Person has
accepted such appointment, then such resignation shall nonetheless become effective in accordance with such notice and (1) the retiring
Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents and (2) all payments,
communications and determinations provided to be made by, to or through the retiring Administrative Agent shall instead be made by or
to each Lender directly, until such time as the Required Lenders appoint a successor Administrative Agent as provided for above in this
Section.  Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor shall succeed
to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Administrative Agent, and the
retiring Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents
(if not already discharged therefrom as provided above in this Section).  The fees payable by the Company to a successor Administrative
Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Company and such successor.  After
the retiring Administrative Agent’s resignation hereunder and under the other Loan Documents, the provisions of this Article and
Sections 10.05 and 10.09 shall continue in effect for the benefit of the retiring Administrative Agent, its sub-agents and their respective
Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting
as the retiring Administrative Agent.

 

If
the Person serving as the Administrative Agent has become, or any Person as to which the Administrative Agent is, directly or indirectly,
a subsidiary has become, the subject of a Bankruptcy Event, the Required Lenders may, to the extent permitted by applicable laws, by
notice in writing to the Company and such Person, remove such Person as Administrative Agent and, with the consent of the Company, appoint
a successor, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United
States.  If no such successor shall have been appointed by the Required Lenders and shall have accepted such appointment within
30 days (or such earlier day as shall be agreed by the Required Lenders) (the “Removal Effective Date”), then
such removal shall nonetheless become effective in accordance with such notice on the Removal Effective Date.

 

SECTION
9.07.  Acknowledgments of Lenders.  (a) Each Lender acknowledges that it has, independently and without reliance
upon the Administrative Agent, any Arranger or any other Lender or any of their Related Parties and based on such documents and information
as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement.  Each Lender also acknowledges
that it will, independently and without reliance upon the Administrative Agent, any Arranger or any other Lender or any of their Related
Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions
in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished
hereunder or thereunder.

 

    65 

     

    

(b)  (i)
Each Lender hereby agrees that (x) if the Administrative Agent notifies such Lender that the Administrative Agent has determined in its
sole discretion that any funds received by such Lender from the Administrative Agent or any of its Affiliates (whether as a payment,
prepayment or repayment of principal, interest, fees or otherwise; individually and collectively, a “Payment”) were
erroneously transmitted to such Lender (whether or not known to such Lender), and demands the return of such Payment (or a portion thereof),
such Lender shall promptly, but in no event later than one Business Day thereafter, return to the Administrative Agent the amount of
any such Payment (or portion thereof) as to which such a demand was made in same day funds, together with interest thereon in respect
of each day from and including the date such Payment (or portion thereof) was received by such Lender to the date such amount is repaid
to the Administrative Agent at the NYFRB Rate, and (y) to the extent permitted by applicable law, such Lender shall not assert, and hereby
waives, as to the Administrative Agent, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand,
claim or counterclaim by the Administrative Agent for the return of any Payments received, including without limitation any defense based
on “discharge for value” or any similar doctrine.  A notice of the Administrative Agent to any Lender under this
Section 9.07(b) shall be conclusive, absent manifest error.

 

(ii)
Each Lender hereby further agrees that if it receives a Payment from the Administrative Agent or any of its Affiliates (x) that is in
a different amount than, or on a different date from, that specified in a notice of payment sent by the Administrative Agent (or any
of its Affiliates) with respect to such Payment (a “Payment Notice”) or (y) that was not preceded or accompanied by
a Payment Notice, it shall be on notice, in each such case, that an error has been made with respect to such Payment.  Each
Lender agrees that, in each such case, or if it otherwise becomes aware a Payment (or portion thereof) may have been sent in error, such
Lender shall promptly notify the Administrative Agent of such occurrence and, upon demand from the Administrative Agent, it shall promptly,
but in no event later than one Business Day thereafter, return to the Administrative Agent the amount of any such Payment (or portion
thereof) as to which such a demand was made in same day funds, together with interest thereon in respect of each day from and including
the date such Payment (or portion thereof) was received by such Lender to the date such amount is repaid to the Administrative Agent
at the NYFRB Rate.

 

(iii)
The Company hereby agrees that (x) in the event an erroneous Payment (or portion thereof) is not recovered from any Lender that has received
such Payment (or portion thereof) for any reason (such unrecovered amount, an “Erroneous Payment Return Deficiency”),
upon the Administrative Agent’s notice to such Lender at any time, (i) such Lender shall be deemed to have assigned its Loans (but
not its Commitment) with respect to which such erroneous Payment was made in an amount equal to the Erroneous Payment Return Deficiency
(or such lesser amount as the Administrative Agent may specify) (such assignment of such Loans (but not Commitments), the “Erroneous
Payment Deficiency Assignment”) on a cashless basis at par plus any accrued and unpaid interest (with the assignment fee to
be waived by the Administrative Agent in such instance), and is hereby

 

    66 

     

    

(together
with the Company) deemed to execute and deliver an Assignment and Assumption with respect to such Erroneous Payment Deficiency Assignment,
and such Lender shall deliver any Notes evidencing such Loans to the Company or the Administrative Agent (but the failure of such Lender
to deliver any such Notes shall not affect the effectiveness of the foregoing assignment), (ii) the Administrative Agent as the assignee
Lender shall be deemed to acquire the Erroneous Payment Deficiency Assignment, (iii) upon such deemed acquisition, the Administrative
Agent as the assignee Lender shall become a Lender hereunder with respect to such Erroneous Payment Deficiency Assignment and the assigning
Lender shall relinquish its rights as a Lender hereunder with respect to such Erroneous Payment Deficiency Assignment, excluding, for
the avoidance of doubt, its obligations under the indemnification provisions of this Agreement and its Commitment, which shall survive
as to such assigning Lender, (iv) the Administrative Agent and the Company shall each be deemed to have waived any consents required
under this Agreement to any such Erroneous Payment Deficiency Assignment and (v) the Administrative Agent may reflect in the Register
its ownership interest in the Loans subject to the Erroneous Payment Deficiency Assignment; provided that, for the avoidance of
doubt, no Erroneous Payment Deficiency Assignment will reduce the Commitment of any Lender and such Commitment shall remain available
in accordance with the terms of this Agreement and (y) an erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy
any obligations of the Company under the Loan Documents; provided that, for the avoidance of doubt, clauses (x) and (y) above
shall not apply to the extent any such Payment is, and solely with respect to the amount of such Payment that is, comprised of funds
received by the Administrative Agent from the Company for the purpose of making such Payment.

 

(iv)
Subject to Section 10.01 (but excluding, in all events, any assignment consent or approval requirements (other than any required consent
of the Company)), the Administrative Agent may, in its discretion, sell any Loans acquired pursuant to an Erroneous Payment Deficiency
Assignment and upon receipt of the proceeds of such sale, the Erroneous Payment Return Deficiency owing by the applicable Lender shall
be reduced by the net proceeds of the sale of such Loan (or portion thereof), and the Administrative Agent shall retain all other rights,
remedies and claims against such Lender (and/or against any recipient that receives funds on its respective behalf). In addition, an
Erroneous Payment Return Deficiency owing by the applicable Lender (x) shall be reduced by the proceeds of prepayments or repayments
of principal and interest, or other distribution in respect of principal and interest, received by the Administrative Agent on or with
respect to any such Loans acquired from such Lender pursuant to an Erroneous Payment Deficiency Assignment (to the extent that any such
Loans are then owned by the Administrative Agent) and (y) may, in the sole discretion of the Administrative Agent, be reduced by any
amount specified by the Administrative Agent in writing to the applicable Lender from time to time.

 

(v)
Each party’s obligations under this Section 9.07(b) shall survive the resignation or replacement of the Administrative Agent or
any transfer of rights or

 

    67 

     

    

obligations
by, or the replacement of, a Lender, the termination of the Commitments or the repayment, satisfaction or discharge of all obligations
under the Loan Documents.

 

SECTION
9.08.  No Other Duties, Etc.  Notwithstanding anything herein to the contrary, none of the Arrangers, the
Syndication Agent or the Documentation Agents shall have any powers, duties or responsibilities under this Agreement or any of the other
Loan Documents, except in its capacity, as applicable, as Administrative Agent or a Lender, but all such Persons shall have the benefit
of the indemnities and exculpatory provisions provided for hereunder and under the other Loan Documents.

 

SECTION
9.09.  Administrative Agent May File Proofs of Claim.  In case of the pendency of any proceeding under any
Debtor Relief Law or any other judicial proceeding relating to the Company, the Administrative Agent (irrespective of whether the principal
of any Loan shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative
Agent shall have made any demand on the Company) shall be entitled and empowered, by intervention in such proceeding or otherwise:

 

(a)
to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other obligations
of the Company under the Loan Documents that are owing and unpaid and to file such other documents as may be necessary or advisable in
order to have the claims of the Lenders and the Administrative Agent (including any claim for the reasonable compensation, expenses,
disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts
due the Lenders and the Administrative Agent hereunder) allowed in such judicial proceeding; and

 

(b)
to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;

 

and any custodian,
receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such proceeding is hereby authorized by each Lender
to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such
payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements
and advances of the Administrative Agent and their agents and counsel, and any other amounts due the Administrative Agent hereunder.

 

Nothing
contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any
Lender any plan of reorganization, arrangement, adjustment or composition affecting the obligations of the Company under the Loan Documents
or the rights of any Lender to authorize the Administrative Agent to vote in respect of the claim of any Lender in any such proceeding.

 

SECTION
9.10.  Certain ERISA Matters.

 

    68 

     

    

(a)  Each
Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such
Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative
Agent and not, for the avoidance of doubt, to or for the benefit of the Company, that at least one of the following is and will be true:

 

(i)
such Lender is not using “plan assets” (within the meaning of Section 3(42) of ERISA or otherwise) of one or more Benefit
Plans with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments
or this Agreement,

 

(ii)
the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by
independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company
general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38
(a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions
determined by in-house asset managers), is applicable with respect to such Lender’s entrance into, participation in, administration
of and performance of the Loans, the Commitments and this Agreement,

 

(iii)
(A) such Lender is an investment fund managed by a “Qualified Professional Asset Manager” (within the meaning of Part VI
of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate
in, administer and perform the Loans, the Commitments and this Agreement, (C) the entrance into, participation in, administration of
and performance of the Loans, the Commitments and this Agreement satisfies the requirements of sub-sections (b) through (g) of Part I
of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with
respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments and this
Agreement, or

 

(iv)
such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion,
and such Lender.

 

(b)  In
addition, unless either (1) sub-clause (i) in paragraph (a) of this Section is true with respect to a Lender or (2) a Lender has provided
another representation, warranty and covenant in accordance with sub-clause (iv) in paragraph (a) of this Section, such Lender further
(x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person
became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent
and not, for the avoidance of doubt, to or for the benefit of the Company, that the Administrative Agent is not a fiduciary with respect
to the assets of such Lender involved in such Lender’s entrance into, participation in, administration of and performance of the
Loans, the Commitments and this Agreement (including in connection

 

    69 

     

    

with the reservation or exercise of
any rights by the Administrative Agent under this Agreement, any Loan Document or any documents related hereto or thereto).

 

SECTION
9.11.  Posting of Communications.  (a)   The Company agrees that the Administrative Agent may, but
shall not be obligated to, make any Communications available to the Lenders by posting the Communications on a Platform.

 

(b)  Although
the Platform and its primary web portal are secured with generally-applicable security procedures and policies implemented or modified
by the Administrative Agent from time to time (including, as of the Closing Date, a user ID/password authorization system) and the Platform
is secured through a per-deal authorization method whereby each user may access the Platform only on a deal-by-deal basis, each of the
Lenders and the Company acknowledges and agrees that the distribution of material through an electronic medium is not necessarily secure,
that the Administrative Agent is not responsible for approving or vetting the representatives or contacts of any Lender that are added
to the Platform, and that there may be confidentiality and other risks associated with such distribution.  Each of the Lenders
and the Company hereby approves distribution of the Communications through the Platform and understands and assumes the risks of such
distribution.

 

(c)  THE
PLATFORM AND THE COMMUNICATIONS ARE PROVIDED “AS IS” AND “AS AVAILABLE”. THE APPLICABLE PARTIES (AS DEFINED BELOW)
DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE COMMUNICATIONS, OR THE ADEQUACY OF THE PLATFORM AND EXPRESSLY DISCLAIM LIABILITY FOR
ERRORS OR OMISSIONS IN THE PLATFORM AND THE COMMUNICATIONS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS,
IS MADE BY THE APPLICABLE PARTIES IN CONNECTION WITH THE COMMUNICATIONS OR THE PLATFORM. IN NO EVENT SHALL THE ADMINISTRATIVE AGENT,
THE ARRANGERS OR ANY OF THEIR RESPECTIVE RELATED PARTIES (COLLECTIVELY, “APPLICABLE PARTIES”) HAVE ANY LIABILITY TO THE COMPANY,
ANY LENDER OR ANY OTHER PERSON FOR DAMAGES OF ANY KIND, INCLUDING DIRECT OR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, LOSSES
OR EXPENSES (WHETHER IN TORT, CONTRACT OR OTHERWISE) ARISING OUT OF THE COMPANY’S OR THE ADMINISTRATIVE AGENT’S TRANSMISSION
OF COMMUNICATIONS THROUGH THE INTERNET OR THE PLATFORM, EXCEPT TO THE EXTENT THAT SUCH LIABILITIES ARE DETERMINED BY A COURT OF COMPETENT
JURISDICTION BY A FINAL AND NONAPPEALABLE JUDGMENT TO HAVE RESULTED FROM THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF SUCH APPLICABLE
PARTY; PROVIDED, HOWEVER, THAT IN NO EVENT SHALL ANY APPLICABLE PARTY HAVE ANY LIABILITY TO THE COMPANY, ANY LENDER OR
ANY OTHER PERSON FOR INDIRECT, SPECIAL, INCIDENT, CONSEQUENTIAL OR PUNITIVE DAMAGES (AS OPPOSED TO DIRECT OR ACTUAL DAMAGES).

 

    70 

     

    

(d)  Each
Lender agrees that notice to it (as provided in the next sentence) specifying that Communications have been posted to the Platform shall
constitute effective delivery of the Communications to such Lender for purposes of the Loan Documents.  Each Lender agrees
(i) to notify the Administrative Agent in writing (which could be in the form of electronic communication) from time to time of such
Lender’s email address to which the foregoing notice may be sent by electronic transmission and (ii) that the foregoing notice
may be sent to such email address.

 

(e)  Each
of the Lenders and the Company agrees that the Administrative Agent may, but (except as may be required by applicable law) shall not
be obligated to, store the Communications on the Platform in accordance with the Administrative Agent’s generally applicable document
retention procedures and policies.

 

(f)  Nothing
herein shall prejudice the right of the Administrative Agent or any Lender to give any notice or other communication pursuant to any
Loan Document in any other manner specified in such Loan Document.

 

ARTICLE
X

Miscellaneous

 

SECTION
10.01.  Assignments and Participations.  (a)  The provisions of this Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that (i) other
than pursuant to a consolidation or merger not prohibited under Section 7.04, the Company may not assign or otherwise transfer any of
its rights or obligations hereunder without the prior written consent of the Administrative Agent and each Lender, and (ii) no Lender
may assign or otherwise transfer any of its rights or obligations hereunder except (A) to an Eligible Assignee in accordance with the
provisions of subsection (b) of this Section, (B) by way of participation in accordance with the provisions of subsection (d) of this
Section, or (C) by way of pledge or assignment of a security interest subject to the restrictions of subsection (f) of this Section (and
any other attempted assignment or transfer by any party hereto shall be null and void).  Nothing in this Agreement, expressed
or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted
hereby, Participants to the extent provided in subsection (e) of this Section and, to the extent expressly contemplated hereby, the sub-agents
of the Administrative Agent and each of the Lender-Related Persons) any legal or equitable right, remedy or claim under or by reason
of this Agreement.

 

(b)  Any
Lender may at any time assign to one or more Eligible Assignees all or a portion of its rights and obligations under this Agreement (including
all or a portion of its Commitment and the Loans and other amounts at the time owing to it); provided that (i) except in the case
of an assignment of the entire remaining amount of the assigning Lender’s Commitment or Loans at the time owing to it or in the
case of an assignment to a Lender or an Affiliate of a Lender or an Approved Fund with respect to a Lender, the aggregate amount of the
Commitment or Loans subject to each such assignment,

 

    71 

     

    

determined
as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade
Date” is specified in the Assignment and Assumption, as of the Trade Date, shall not be less than US$10,000,000 or an integral
multiple of US$5,000,000 in excess thereof, unless each of the Administrative Agent and, so long as no Event of Default under Section
8.01(a), (b), (g) or (h) has occurred and is continuing, the Company otherwise consents (each such consent not to be unreasonably withheld
or delayed); (ii) each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s
rights and obligations under this Agreement with respect to the Commitment or Loans assigned, provided that this clause (ii) shall
not be construed to prohibit the assignment of (A) a proportionate part of all the assigning Lender’s rights and obligations in
respect of its Commitment without assigning a proportionate part of the assigning Lender’s Loans or (B) a proportionate part of
all the assigning Lender’s rights and obligations in respect of its Loans without assigning a proportionate part of the assigning
Lender’s Commitment; (iii) any assignment of a Commitment or a Loan must be approved (which approval shall not be unreasonably
withheld or delayed) by the Administrative Agent (whether or not the proposed assignee would otherwise qualify as an Eligible Assignee);
(vi) the parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with
a processing and recordation fee of US$3,500; and (iv) the assignee shall deliver to the Administrative Agent a completed Administrative
Questionnaire (unless the assignee shall already be a Lender hereunder).  Subject to acceptance and recording thereof by the
Administrative Agent pursuant to subsection (c) of this Section, from and after the effective date specified in each Assignment and Assumption,
the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption,
have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest
assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment
and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be
a party hereto but shall continue to be entitled to the benefits of Sections 3.01, 3.04, 3.05, 10.05 and 10.09 with respect to facts
and circumstances occurring prior to the effective date of such assignment).  Any assignment or transfer by a Lender of rights
or obligations under this Agreement that does not comply with this subsection shall be treated for purposes of this Agreement as a sale
by such Lender of a participation in such rights and obligations in accordance with subsection (d) of this Section.  Notwithstanding
the foregoing, the Administrative Agent shall not be obligated to consent to an assignment hereunder until it is satisfied it has complied
with all necessary “know your customer” or other similar checks under all applicable laws and regulations in relation to
the assignment to such assignee Lender.    

 

(c)  The
Administrative Agent, acting solely for this purpose as a non-fiduciary agent of the Company, shall maintain at one of its offices a
copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders,
and the Commitment of, and principal amounts of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”).  The
entries in the Register shall be conclusive, absent manifest error, and the Company, the Administrative Agent and the Lenders may treat
each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this

 

    72 

     

    

Agreement,
notwithstanding notice to the contrary.  The Register shall be available for inspection by the Company and, as to entries pertaining
to it, any Lender, at any reasonable time and from time to time upon reasonable prior notice.

 

(d)  Any
Lender may at any time, without the consent of, or (except as set forth below in this subsection (d)) notice to, the Company or the Administrative
Agent, sell participations to any Person (other than a natural person, or a holding company, investment vehicle or trust for, or owned
and operated for the primary benefit of, a natural person, or the Company or the Company’s Affiliates or Subsidiaries) (each, a
“Participant”) in all or a portion of such Lender’s rights and/or obligations under this Agreement (including
all or a portion of its Commitment or the Loans owing to it); provided that (i) such Lender’s obligations under this Agreement
shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations
and (iii) the Company, the Administrative Agent and the other Lenders shall continue to deal solely and directly with such Lender in
connection with such Lender’s rights and obligations under this Agreement.  Each Lender selling a participation shall
notify the Company of the identity of the Participant and the amount of the participation; provided that the failure of any Lender
to give such notice shall not affect the validity of such sale or the rights of the Participant hereunder.  Any agreement or
instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce
this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement and the other Loan Documents;
provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree
to any amendment, waiver or other modification described in clause (ii) of the first proviso to Section 10.06(a) that directly affects
such Participant.  Subject to subsection (e) of this Section, the Company agrees that each Participant shall be entitled to
the benefits of Sections 3.01, 3.04 and 3.05 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant
to subsection (b) of this Section.  To the extent permitted by law, each Participant also shall be entitled to the benefits
of Section 10.03 as though it were a Lender; provided such Participant agrees to be subject to Section 2.11(c) as though it were
a Lender.

 

(e)  A
Participant shall not be entitled to receive any greater payment under Section 3.01 than the applicable Lender would have been entitled
to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made
with the Company’s prior written consent.  No Participant shall be entitled to the benefits of Section 3.05 unless the
Company is notified of the participation sold to such Participant and such Participant agrees, for the benefit of the Company, to provide
such forms, certificates or other evidence, if any, with respect to withholding Tax matters as required under Section 3.05 and otherwise
complies with the requirements of Section 3.05 as though it were a Lender.

 

(f)  Any
Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement (including under
any Note) to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank or
any other central bank; provided that no such pledge or

 

    73 

     

    

assignment
shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party
hereto.

 

(g)  Each
Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Company, maintain a register
on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s
interest in the Loans or other obligations under the Loan Documents (the “Participant Register”); provided
that, except as set forth in paragraph (d) of this Section, no Lender shall have any obligation to disclose all or any portion of the
Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any
Commitments, Loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary
to establish that such Commitment, Loan or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury
Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person
whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding
any notice to the contrary.  For the avoidance of doubt, the Administrative Agent (in its capacity as such) shall not have
any responsibility for maintaining a Participant Register.

 

SECTION
10.02.  Notices; Effectiveness; Electronic Communication.  (a)  General.  Except
in the case of notices and other communications expressly permitted to be given by telephone (and except as provided in subsection (b)
below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier
service, mailed by certified or registered mail or sent by e-mail, and all notices and other communications expressly permitted hereunder
to be given by telephone shall be made to the applicable telephone number, as follows:

 

(i) if
to the Company, to V.F. Corporation, 105 Corporate Center Boulevard, Greensboro, North Carolina 27408, Attn: Anthony T. Cottonaro, Vice
President-Treasurer (telephone: (716) 510-3529; e-mail address: Tony_Cottonaro@vfc.com);

 

(ii)
if to the Administrative Agent, to JPMorgan Chase Bank, N.A. 10 South Dearborn, Floor L2, Suite IL1-0480, Chicago, IL, 60603-2300, Attn:
Ashley Love (telephone: (980) 296-6579, e-mail address: ashley.love@chase.com) with a copy to JPMorgan Chase Bank, N.A., Middle Market
Servicing, 10 South Dearborn, Floor L2, Suite IL1-0480, Chicago, IL, 60603-2300, Attn: Commercial Banking Group (e-mail addresses: jpm.agency.cri@jpmorgan.com,
jpm.agency.servicing.1@jpmorgan.com); and

 

(iii)
if to any other Lender, to it at its address set forth in its Administrative Questionnaire.

 

Notices sent by
hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received.  Notices
delivered through e-mail or

 

    74 

     

    

other electronic
communications to the extent provided in subsection (b) below shall be effective as provided in such subsection (b).

 

(b)  Electronic
Communications.  Notices and other communications to the Lenders hereunder may be, in addition to e-mail, delivered or
furnished by other electronic communication or using the Platform pursuant to procedures approved by the Administrative Agent; provided
that the foregoing shall not apply to notices under Article II to any Lender if such Lender has notified the Administrative Agent
that it is incapable of receiving notices under such Article by such electronic communication.  Each of the Administrative
Agent and the Company may, in its discretion and in addition to e-mail, agree to accept notices and other communications to it hereunder
by other electronic communications pursuant to procedures approved by it; provided that approval of such procedures may be limited
to particular notices or communications.

 

Unless
the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received
upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested”
function, as available, return e-mail or other written acknowledgement); provided that if such notice or other communication is
not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening
of business on the next business day for the recipient, and (ii) notices or communications posted to the Platform shall be deemed received
upon the receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that such notice
or communication is available and identifying the website address therefor.

 

(c)  Change
of Address, Etc.  Each of the Company and the Administrative Agent may change its address, telephone number or e-mail address
for notices and other communications hereunder by notice to the other parties hereto.  Each Lender may change its address,
telephone number or e-mail address for notices and other communications hereunder by notice to the Company and the Administrative Agent.  In
addition, each Lender agrees to notify the Administrative Agent from time to time to ensure that the Administrative Agent has on record
(i) an effective address, contact name, telephone number and e-mail address to which notices and other communications may be sent and
(ii) accurate wire instructions for such Lender.  Furthermore, each Public Lender agrees to cause at least one individual at
or on behalf of such Public Lender to at all times have selected the “Private Side Information” or similar designation on
the content declaration screen of the Platform in order to enable such Public Lender or its delegate, in accordance with such Public
Lender’s compliance procedures and applicable law, including United States Federal and state securities laws, to make reference
to Company Materials that are not made available through the “Public Side Information” portion of the Platform and that may
contain MNPI.

 

(d)  Reliance
by Administrative Agent and Lenders.  The Administrative Agent and the Lenders shall be entitled to, but shall have no
obligation to, rely and act upon any notices (including telephonic notices) purportedly given by the Company even if (i) such notices
were not made in a manner specified herein, were incomplete or were not

 

    75 

     

    

preceded
or followed by any other form of notice specified herein or (ii) the terms thereof, as understood by the recipient, varied from any confirmation
thereof.  The Company shall indemnify the Administrative Agent, each Lender and the Related Parties of each of them from all
Liabilities and expenses resulting from the reliance by such Person on each notice purportedly given by the Company, except to the extent
that such Liabilities or expenses are determined by a court of competent jurisdiction by a final and nonappealable judgment to have resulted
from the gross negligence or willful misconduct of such Person; provided that in no event shall any such Person have any Liability,
on any theory of liability, to the Company, any Lender or any other Person for indirect, special, incidental, consequential or punitive
damages (as opposed to direct or actual damages).  All telephonic notices to and other telephonic communications with the Administrative
Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording.

 

SECTION
10.03.  Right of Set-off; Adjustments.  Upon the occurrence and during the continuance of any Event of Default
and following notice to the Lenders from the Administrative Agent or the Required Lenders authorizing the exercise of the rights set
forth in this Section 10.03, each Lender and each of its Affiliates shall hereby be authorized at any time and from time to time, to
the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final)
at any time held and other indebtedness at any time owing by such Lender or such an Affiliate to or for the credit or the account of
the Company against any and all of the obligations of the Company now or hereafter existing under this Agreement and any other Loan Document
held by such Lender, irrespective of whether or not such Lender shall have made any demand under this Agreement or any other Loan Document
and although such obligations may be unmatured.  Each Lender agrees promptly to notify the Company after any such set-off and
application made by such Lender; provided, however that the failure to give such notice shall not affect the validity of
such set-off and application.  The rights of each Lender under this Section 10.03 are in addition to other rights and remedies
(including, without limitation, other rights of set-off) that such Lender or any of its Affiliates may have.

 

SECTION
10.04.  Survival.  All covenants, agreements, representations and warranties made herein shall survive the
making by the Lenders of the Loans and the execution and delivery to the Lenders of this Agreement and the other Loan Documents and shall
continue in full force and effect until the Facility Termination Date; provided that the provisions of Sections 3.01, 3.04,
3.05, 10.05, 10.08 and 10.09 and Article IX shall survive and remain in full force and effect regardless of the Facility Termination
Date.

 

SECTION
10.05.  Expenses.  The Company agrees to pay on demand all reasonable out-of-pocket costs and expenses of
the Administrative Agent, the Arrangers and their respective Affiliates in connection with the preparation, execution, delivery, administration,
modification, and amendment of this Agreement, the other Loan Documents, and the other documents to be delivered hereunder and the structuring,
arrangement and syndication of the credit facility established hereby, including, without limitation, the reasonable fees and expenses
of counsel for the Administrative Agent with respect thereto and with respect to advising the Administrative Agent as to its rights and
responsibilities under the Loan Documents.  If an Event of Default occurs, the Company

 

    76 

     

    

further
agrees to pay on demand all reasonable out-of-pocket costs and expenses of the Administrative Agent and the Lenders (including, without
limitation, reasonable attorneys’ fees and expenses) in connection with the enforcement (whether through negotiations, legal proceedings,
or otherwise) of the Loan Documents and the other documents to be delivered hereunder. For the avoidance of doubt, no amount shall be
payable pursuant to this Section 10.05 in respect of Taxes other than any Taxes that represent losses, claims or damages arising from
any non-Tax claim.

 

SECTION
10.06.  Amendments and Waivers.  (a)  Except as provided in Section 10.06(b), any provision of this
Agreement or any other Loan Document may be amended or waived if, but only if, such amendment or waiver is in writing and is signed by
the Company and the Required Lenders or, as to Loan Documents other than this Agreement, the Administrative Agent at the direction of
and on behalf of the Required Lenders; provided that (i) any provision of this Agreement or any other Loan Document may be amended
by an agreement in writing entered into by the Company and the Administrative Agent to cure any ambiguity, omission, defect or inconsistency
so long as, in each case, (A) such amendment does not adversely affect the rights of any Lender or (B) the Lenders shall have received
at least five Business Days’ prior written notice thereof and the Administrative Agent shall not have received, within five Business
Days of the date of such notice to the Lenders, a written notice from the Required Lenders stating that the Required Lenders object to
such amendment and (ii) no such amendment or waiver shall (A) increase the Commitment of any Lender or change the currency in which Loans
are available thereunder without the written consent of such Lender, (B) reduce the principal of or rate or amount of interest on any
Loan or any fees payable hereunder (in each case, other than as a result of any waiver of any default interest applicable pursuant to
Section 2.10(d), without the written consent of each Lender affected thereby, (C) postpone any date fixed for the payment of any
scheduled installment of principal of or interest on any Loan or any fees payable hereunder, or the scheduled date for termination or
expiration of any Commitment, without the written consent of each Lender affected thereby, (D) change the percentage set forth in the
definition of the term “Required Lenders” or the percentage of the Commitments or of the unpaid principal amount of the Loans,
or the number of Lenders, which shall be required for the Lenders or any of them to take any action under this Section 10.06 or any other
provision of this Agreement, without the written consent of each Lender, (E) change Section 2.06, 2.11 or 8.05 in a manner that would
alter the pro rata sharing of payments or the pro rata reduction of the Commitments required thereby (or, in the case of Section 8.05,
the order of the application of payments required thereby), without the written consent of each Lender or (F) amend this Section 10.06,
without the written consent of each Lender; and, provided further that no amendment, waiver or consent shall, unless in writing
and signed by the Administrative Agent in addition to the Lenders required above, affect the rights or duties of the Administrative Agent
under this Agreement or any other Loan Document.

 

(b)  Notwithstanding
anything to the contrary in paragraph (a) of this Section:

 

(i)  this
Agreement and the other Loan Documents may be amended in a manner provided in Sections 2.06(d), 2.13 and 3.02(b); and

 

    77 

     

    

(ii)  no
consent with respect to any amendment, waiver or other modification of this Agreement or any other Loan Document shall be required of
any Defaulting Lender, except with respect to any amendment, waiver or other modification referred to in clause (A), (B) or (C) of Section
10.06(a)(ii) and then only in the event such Defaulting Lender shall be affected by such amendment, waiver or other modification.

 

(c)  The
Administrative Agent may, but shall have no obligation to, with the concurrence of any Lender, execute amendments, waivers or other modifications
on behalf of such Lender. Any amendment, waiver or other modification effected in accordance with this Section 10.06 shall be binding
upon each Person that is at the time thereof a Lender and each Person that subsequently becomes a Lender.

 

(d)  No
notice to or demand on the Company in any case shall entitle the Company to any other or further notice or demand in similar or other
circumstances, except as otherwise expressly provided herein.  No failure, delay or omission by the Administrative Agent or
any Lender in exercising any right, remedy or option shall operate as a waiver of such or any other right, remedy or option or of any
Default or Event of Default.  

 

SECTION
10.07.  Counterparts; Electronic Execution.  (a) This Agreement and any Loan Document may be executed in any
number of counterparts, each of which when so executed and delivered shall be deemed an original, and it shall not be necessary in making
proof of this Agreement or any Loan Document to produce or account for more than one such fully-executed counterpart.

 

(b)  Delivery
of an executed counterpart of a signature page of (i) this Agreement, (ii) any other Loan Document and/or (iii) any document, amendment,
approval, consent, information, notice (including, for the avoidance of doubt, any notice delivered pursuant to Section 10.02), certificate,
request, statement, disclosure or authorization related to this Agreement, any other Loan Document and/or the transactions contemplated
hereby and/or thereby (each, an “Ancillary Document”) that is an Electronic Signature transmitted by emailed .pdf
or any other electronic means that reproduces an image of an actual executed signature page shall be effective as delivery of a manually
executed counterpart of this Agreement, such other Loan Document or such Ancillary Document, as applicable.  The words “execution”,
“signed”, “signature”, “delivery” and words of like import in or relating to this Agreement, any
other Loan Document and/or any Ancillary Document shall be deemed to include Electronic Signatures and deliveries or the keeping of records
in any electronic form (including deliveries by emailed .pdf or any other electronic means that reproduces an image of an actual executed
signature page), each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical
delivery thereof or the use of a paper-based recordkeeping system, as the case may be; provided that, without limiting the foregoing,
(A) to the extent the Administrative Agent has agreed to accept any Electronic Signature, the Administrative Agent and each of the Lenders
shall be entitled to rely on such Electronic Signature purportedly given by or on behalf of the Company without further verification
thereof and without any obligation to review the appearance or form of any such Electronic Signature

 

    78 

     

    

and
(B) upon the request of the Administrative Agent or any Lender, any Electronic Signature shall be promptly followed by a manually executed
counterpart.  Without limiting the generality of the foregoing, the Company hereby (1) agrees that, for all purposes, including,
without limitation, in connection with any workout, restructuring, enforcement of remedies, bankruptcy proceedings or litigation among
the Administrative Agent, the Lenders and the Company, Electronic Signatures transmitted by emailed .pdf or any other electronic means
that reproduce an image of an actual executed signature page and/or any electronic images of this Agreement, any other Loan Document
and/or any Ancillary Document shall have the same legal effect, validity and enforceability as any paper original and (2) agrees that
the Administrative Agent and each of the Lenders may, at its option, create one or more copies of this Agreement, any other Loan Document
and/or any Ancillary Document in the form of an imaged electronic record in any format, which shall be deemed created in the ordinary
course of such Person’s business, and destroy the original paper document (and all such electronic records shall be considered
an original for all purposes and shall have the same legal effect, validity and enforceability as a paper record).

 

SECTION
10.08.  Termination.  The termination of this Agreement shall not affect any rights of the Company, the Lenders
or the Administrative Agent or any obligation of the Company, the Lenders or the Administrative Agent arising prior to the effective
date of such termination and the provisions hereof shall continue to be fully operative until all transactions entered into or rights
created or obligations incurred prior to such termination have been fully disposed of, concluded or liquidated and the obligations of
the Company hereunder (other than any such obligations in the nature of continuing indemnities or expense reimbursement obligations not
yet due and payable, which shall continue) arising prior to or after such termination have been irrevocably paid in full. The rights
granted to the Administrative Agent for the benefit of the Lenders under the Loan Documents shall continue in full force and effect,
notwithstanding the termination of this Agreement, until all of the obligations of the Company hereunder have been paid in full after
the termination hereof (other than any such obligations in the nature of continuing indemnities or expense reimbursement obligations
not yet due and payable, which shall continue) or the Company has furnished the Lenders and the Administrative Agent with an indemnification
satisfactory to the Administrative Agent and each Lender with respect thereto.  Notwithstanding the foregoing, if after receipt
of any payment of all or any part of the obligations of the Company hereunder, any Lender is for any reason compelled to surrender such
payment to any Person because such payment is determined to be void or voidable as a preference, impermissible setoff, a diversion of
trust funds or for any other reason, this Agreement shall continue in full force, and the Company shall be liable to, and shall indemnify
and hold the Administrative Agent or such Lender harmless for, the amount of such payment surrendered until the Administrative Agent
or such Lender shall have been finally and irrevocably paid in full.  The provisions of the foregoing sentence shall be and
remain effective notwithstanding any contrary action which may have been taken by the Administrative Agent or the Lenders in reliance
upon such payment, and any such contrary action so taken shall be without prejudice to the Administrative Agent or the Lenders’
rights under this Agreement and shall be deemed to have been conditioned upon such payment having become final and irrevocable.

 

    79 

     

    

SECTION
10.09.  Indemnification; Limitation of Liability.  (a)  The Company, to the maximum extent permitted
by applicable law, agrees to indemnify and hold harmless each Lender-Related Person (each such Person, an “Indemnified Party”)
from and against any and all Liabilities and expenses (including, without limitation, reasonable attorneys’ fees) that may be incurred
by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection with or by reason of (including,
without limitation, in connection with any Proceeding or preparation of defense in connection therewith) (i) in the case of the Arrangers,
the Administrative Agent and their Related Parties only, the structuring, arrangement or syndication of the credit facility established
hereby (and all related commitment and fee letters and the execution, delivery or performance thereof) and (ii) this Agreement and the
other Loan Documents and the transactions contemplated herein or the actual or proposed use of the proceeds of the Loans, except, in
each case, to the extent such Liabilities or expenses are found in a final, non-appealable judgment by a court of competent jurisdiction
to have resulted from the gross negligence or willful misconduct of such Indemnified Party or any Related Party of such Indemnified Party.  In
the case of a Proceeding to which the indemnity in this Section 10.09 applies, such indemnity shall be effective whether or not such
Proceeding is brought by the Company or any of its directors, shareholders or creditors or an Indemnified Party or any other Person or
any Indemnified Party is otherwise a party thereto and whether or not the transactions contemplated hereby are consummated.  This
paragraph shall not apply with respect to Taxes other than any Taxes that represent losses, claims or damages arising from any non-Tax
claim.

 

(b)  The
Company agrees that no Lender-Related Person shall have any Liability (whether direct or indirect, in contract or tort or otherwise)
to it, any of its Subsidiaries, any guarantor, or any security holders or creditors thereof arising out of, related to or in connection
with the transactions contemplated herein, except, subject to the immediately following sentence, to the extent that such Liability is
found in a final non-appealable judgment by a court of competent jurisdiction to have directly resulted from the gross negligence or
willful misconduct of such Lender-Related Person or its Affiliates or their officers, directors or employees.  To the extent
permitted by applicable law, the Company shall not assert, and the Company hereby waives, (i) any claim against any Lender-Related Person,
on any theory of liability, for any Liabilities arising from the use by others of information or other materials (including any personal
data) obtained through telecommunications, electronic or other information transmission systems (including the Internet), except to the
extent such Liability is determined in a final, non-appealable judgment by a court of competent jurisdiction to have resulted from the
gross negligence or willful misconduct of such Lender-Related Person or its Affiliates or their officers, directors or employees and
(ii) any Liabilities against any Lender-Related Person, on any theory of liability, for special, indirect, consequential or punitive
damages (as opposed to direct or actual damages) arising out of or otherwise relating to this Agreement, any other Loan Document or any
of the transactions contemplated herein or the actual or proposed use of the proceeds of the Loans.

 

(c)  To
the extent that the Company fails to pay any amount required to be paid by it under Section 10.05 or 10.09(a) to the Administrative Agent
(or any sub-agent thereof) or any of its Related Parties, each Lender severally agrees to pay to the

 

    80 

     

    

Administrative
Agent (or any such sub-agent) or such Related Party, as the case may be, such Lender’s pro rata share (determined as of the time
that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount; provided that the unreimbursed
expense or Liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or such sub-agent)
in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent)
in connection with such capacity.  For purposes of this Section 10.09(c), a Lender’s “pro rata share” shall
be determined based upon its percentage of the aggregate principal amount of the Loans and the Commitments at the time (or most recently
outstanding and in effect).

 

SECTION
10.10.  Severability.  If any provision of this Agreement or the other Loan Documents shall be determined
to be illegal or invalid as to one or more of the parties hereto, then such provision shall remain in effect with respect to all parties,
if any, as to whom such provision is neither illegal nor invalid, and in any event all other provisions hereof shall remain effective
and binding on the parties hereto, and the invalidity of a particular provision in a particular jurisdiction shall not invalidate such
provision in any other jurisdiction.

 

SECTION
10.11.  Integration.  This Agreement, together with the other Loan Documents and any separate agreements with
respect to fees payable to the Administrative Agent, comprises the complete and integrated agreement of the parties on the subject matter
hereof and thereof and supersedes all prior agreements, written or oral, on such subject matter.  In the event of any conflict
between the provisions of this Agreement and those of any other Loan Document, the provisions of this Agreement shall control; provided
that the inclusion of supplemental rights or remedies in favor of the Administrative Agent or the Lenders in any other Loan Document
executed on or after the date of this Agreement shall not be deemed a conflict with this Agreement.

 

SECTION
10.12.  Governing Law; Waiver of Jury Trial.

 

(a)  THIS
AGREEMENT AND THE OTHER LOAN DOCUMENTS SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE
TO CONTRACTS EXECUTED, AND TO BE FULLY PERFORMED, IN SUCH STATE.

 

(b)  EACH
OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE JURISDICTION OF THE UNITED STATES
DISTRICT COURT OF THE SOUTHERN DISTRICT OF NEW YORK AND THE SUPREME COURT OF THE STATE OF NEW YORK SITTING IN NEW YORK
COUNTY, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY
OTHER LOAN DOCUMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, AND EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY
AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH SUIT, ACTION OR 

 

    81 

     

    

PROCEEDING
BROUGHT BY IT SHALL BE INSTITUTED IN, AND HEARD AND DETERMINED EXCLUSIVELY BY, SUCH FEDERAL COURT OR, IN THE EVENT SUCH FEDERAL COURT
LACKS SUBJECT MATTER JURISDICTION, SUCH NEW YORK STATE COURT.  EACH PARTY HERETO HEREBY EXPRESSLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE IN, OR TO THE EXERCISE OF
JURISDICTION OVER IT AND ITS PROPERTY BY, ANY SUCH COURT IN ANY SUCH SUIT, ACTION OR PROCEEDING. EACH OF THE PARTIES HERETO AGREES THAT
A FINAL JUDGMENT IN ANY SUCH SUIT, ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE
JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW.

 

(c)  EACH
OF THE PARTIES HERETO IRREVOCABLY AGREES THAT SERVICE OF PROCESS MAY BE MADE BY PERSONAL SERVICE OF A COPY OF THE SUMMONS AND COMPLAINT
OR OTHER LEGAL PROCESS IN ANY SUCH SUIT, ACTION OR PROCEEDING, OR BY REGISTERED OR CERTIFIED MAIL (POSTAGE PREPAID) IN THE MANNER PROVIDED
FOR NOTICES IN SECTION 10.02.  Nothing in the Agreement or any other Loan Document
will affect the right of any party to this Agreement or such other Loan Document to serve process in any other manner permitted by law.

 

(d)  IN
ANY ACTION, SUIT OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS OR REMEDIES UNDER OR RELATED TO ANY LOAN DOCUMENT OR ANY AMENDMENT, INSTRUMENT,
DOCUMENT OR AGREEMENT DELIVERED OR THAT MAY IN THE FUTURE BE DELIVERED IN CONNECTION THEREWITH, THE COMPANY, THE ADMINISTRATIVE AGENT
AND THE LENDERS HEREBY AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THAT ANY SUCH ACTION, SUIT OR PROCEEDING SHALL BE TRIED
BEFORE A COURT AND NOT BEFORE A JURY AND HEREBY IRREVOCABLY WAIVE, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT SUCH PERSON MAY
HAVE TO TRIAL BY JURY IN ANY SUCH ACTION, SUIT OR PROCEEDING.

 

(e)  EACH
PARTY HERETO HEREBY EXPRESSLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION IT MAY HAVE THAT ANY COURT TO
WHOSE JURISDICTION IT HAS SUBMITTED PURSUANT TO THE TERMS HEREOF IS AN INCONVENIENT FORUM.

 

SECTION
10.13.  Confidentiality.  Each of the Administrative Agent and the Lenders agrees to maintain the confidentiality
of the Information (as defined below), except that Information may be disclosed (a) to its Related Parties, including accountants, legal
counsel and other advisors (it being understood that the Persons to whom such disclosure is made will be informed of the confidential
nature of such Information and

 

    82 

     

    

instructed
to keep such Information confidential or shall be subject to a professional obligation of confidentiality), (b) to the extent requested
by any regulatory authority (including, for the avoidance of doubt, any central bank, the Federal Reserve Bank or self-regulatory authority),
(c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto,
(e) in connection with the exercise of any remedies hereunder or under or any other Loan Document or any suit, action or proceeding relating
to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing
provisions substantially the same as those of this Section, to (i) any assignee of or Participant in, or any prospective assignee of
or Participant in, any of its rights or obligations under this Agreement or (ii) any actual or prospective counterparty (or its Related
Parties) to any swap or derivative transaction relating to the Company or any Subsidiary and its obligations, (g) with the consent of
the Company, (h) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section or
(y) becomes available to the Administrative Agent, any Lender or any Affiliate of any of the foregoing on a nonconfidential basis from
a source other than the Company, (i) on a confidential basis to the CUSIP Service Bureau or any similar agency in connection with
the issuance and monitoring of CUSIP numbers with respect to this Agreement and (j) to market data collectors, including league table
providers, and other services providers to the lending industry, in each case, information of the type routinely provided to such service
providers.  For the purposes of this Section, “Information” means all information received from the Company
or any of its Subsidiaries relating to the Company, any Subsidiary or any of their respective businesses, other than any such information
that is available to the Administrative Agent or any Lender on a nonconfidential basis prior to disclosure by the Company or any of its
Subsidiaries.  Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered
to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of
such Information as such Person would accord to its own confidential information.  

 

SECTION
10.14.  “Know Your Customer” Checks; Certain Notices.  (a)   If (i) the introduction
of or any change in (or in the interpretation, administration or application of) any law or regulation made after the date of this Agreement,
(ii) any change in the status of the Company after the date of this Agreement, or (iii) a proposed assignment or transfer by
a Lender of any of its rights and/or obligations under this Agreement to a party that is not a Lender prior to such assignment or transfer,
obliges the Administrative Agent or any Lender (or, in the case of clause (iii) above, any prospective new Lender) to comply with “know
your customer” or similar identification procedures in circumstances where the necessary information is not already available to
it, the Company shall promptly upon the request of the Administrative Agent or any Lender supply, or procure the supply of, such documentation
and other evidence as is reasonably requested by the Administrative Agent (for itself or on behalf of any Lender) or any Lender (for
itself or, in the case of the event described in clause (iii) above, on behalf of any prospective new Lender) in order for the Administrative
Agent, such Lender or, in the case of the event described in clause (iii) above, any prospective new Lender to carry out and be satisfied
it has complied with all necessary “know your customer” or other similar checks under all

 

    83 

     

    

applicable
laws and regulations pursuant to the transactions contemplated in the Loan Documents.

 

(b)  Each
Lender shall promptly upon the request of the Administrative Agent supply, or procure the supply of, such documentation and other evidence
as is reasonably requested by the Administrative Agent (for itself) in order for the Administrative Agent to carry out and be satisfied
it has complied with all necessary “know your customer” or other similar checks under all applicable laws and regulations
pursuant to the transactions contemplated in the Loan Documents.

 

(c)  
Each Lender that is subject to the USA PATRIOT Act and/or the Beneficial Ownership Regulation and the Administrative Agent (for itself
and not on behalf of any Lender) hereby notifies the Company that pursuant to the requirements of the USA PATRIOT Act and/or the Beneficial
Ownership Regulation, it is required to obtain, verify and record information that identifies the Company, which information includes
the name and address of the Company and other information that will allow such Lender or the Administrative Agent, as applicable, to
identify the Company in accordance with the USA PATRIOT Act and/or the Beneficial Ownership Regulation.

 

SECTION
10.15.  Interest Rate Limitation.  Notwithstanding anything herein to the contrary, if at any time the interest
rate applicable to any Loan, together with all fees, charges and other amounts that are treated as interest on such Loan under applicable
law (collectively the “Charges”), shall exceed the maximum lawful rate (the “Maximum Rate”) that
may be contracted for, charged, taken, received or reserved by the Lender holding such Loan in accordance with applicable law, the rate
of interest payable in respect of such Loan hereunder, together with all Charges payable in respect thereof, shall be limited to the
Maximum Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of such Loan but were not payable
as a result of the operation of this Section shall be cumulated and the interest and Charges payable to such Lender in respect of other
Loans or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with interest thereon
at the Federal Funds Effective Rate to the date of repayment, shall have been received by such Lender.

 

SECTION
10.16.  No Fiduciary Relationship.  The Company, on behalf of itself and the Subsidiaries, agrees that in
connection with all aspects of the transactions contemplated hereby and any communications in connection therewith, the Company and its
Affiliates, on the one hand, and the Administrative Agent, the Arrangers, the Lenders and their respective Affiliates, on the other hand,
will have a business relationship that does not create, by implication or otherwise, any fiduciary duty on the part of the Administrative
Agent, the Arrangers, the Lenders or their respective Affiliates, and no such duty will be deemed to have arisen in connection with any
such transactions or communications. The Company acknowledges that the Administrative Agent, the Arrangers, the Lenders and their respective
Affiliates may be providing debt financing, equity capital or other services (including financial advisory services) to other companies
that have or may in the future have interests conflicting with the Company’s own interests.

 

    84 

     

    

SECTION
10.17.  Acknowledgement and Consent to Bail-In of Affected Financial Institutions.  Notwithstanding anything
to the contrary in this Agreement, any other Loan Document or any related agreement, arrangement or understanding among the parties hereto,
each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document may be subject
to the Write-Down and Conversion Powers of a Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound
by:

 

(a)  the
application of any Write-Down and Conversion Powers by a Resolution Authority to any such liabilities arising hereunder that may be payable
to it by any party hereto that is an Affected Financial Institution; and  

 

(b)  the
effects of any Bail-in Action on any such liability, including, if applicable:

 

(i)  a
reduction in full or in part or cancellation of any such liability;

 

(ii)  a
conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution,
its parent entity, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments
of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document;
or

 

(iii)  the
variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of any Resolution Authority.

 

[Signatures on following
pages]

 

     

     

    

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the
day and year first above written.

 

	 	V.F. CORPORATION
	 	 
	 	by
	 	 	/s/ Steven E. Rendle
	 	 	Name: Steven E. Rendle
	 	 	Title:   Chairman, President and CEO
	 	 	 
	 	 	 
	 	by

	 	 	 /s/ Matthew H. Puckett
	 	 	Name:  Matthew H. Puckett
	 	 	Title:    Executive Vice President and CFO

 

[Signature Page to the V.F. Corporation Term Loan
Agreement]

     

     

    

	 	jpmorgan chase bank, n.a.,
    as the Administrative Agent and a Lender
	 	 
	 	by
	 	 	 /s/ James Kyle O'Donnell
	 	 	Name: James Kyle O'Donnell
	 	 	Title:   Vice President

 

[Signature Page to the V.F. Corporation Term Loan
Agreement]

     

     

    

SIGNATURE PAGE TO

V.F. CORPORATION

TERM LOAN AGREEMENT

 

	Name
of Lender:
	 
	WELLS FARGO BANK, N.A.	 
	 	 
	 
	by 
	 
	 	 	/s/ Carl Hinrichs	 
	 	 	Name:  Carl Hinrichs	 
	 	 	Title:    Director	 

 

 

     

     

    

SIGNATURE PAGE TO

V.F. CORPORATION

TERM LOAN AGREEMENT

 

	Name
of Lender:
	 
	PNC Bank, National Association	 
	 	 
	 
	by 
	 
	 	 	/s/ Dawn Kondrat	 
	 	 	Name:  Dawn Kondrat	 
	 	 	Title:    Senior Vice President	 

 

 

 

     

     

    

SIGNATURE PAGE TO

V.F. CORPORATION

TERM LOAN AGREEMENT

 

	Name
of Lender:
	 
	TD BANK, N.A.	 
	 	 
	 
	by 
	 
	 	 	/s/ Steve Levi	 
	 	 	Name:  Steve Levi	 
	 	 	Title:    Senior Vice President	 

  

 

 

     

     

    

SIGNATURE PAGE TO

V.F. CORPORATION

TERM LOAN AGREEMENT

 

	Name
of Lender:
	 
	TRUIST BANK	 
	 	 
	 
	by 
	 
	 	 	/s/ David Felty	 
	 	 	Name:  David Felty	 
	 	 	Title:    Managing Director	 

 

  

 

     

     

    

SIGNATURE PAGE TO

V.F. CORPORATION

TERM LOAN AGREEMENT

 

	Name
of Lender:
	 
	U.S. Bank National Association	 
	 	 
	 
	by 
	 
	 	 	/s/ Adam J. Kultgen	 
	 	 	Name:  Adam J. Kultgen	 
	 	 	Title:    Vice President	 

 

 

 

     

     

    

SIGNATURE PAGE TO

V.F. CORPORATION

TERM LOAN AGREEMENT

 

	Name
of Lender:
	 
	BNP Paribas	 
	 	 
	 
	by 
	 
	 	 	/s/ Emma Petersen	 
	 	 	Name:  Emma Petersen	 
	 	 	Title:    Managing Director	 

 

 

 

	 
	by
	 
	 	 	/s/ David Foster	 
	 	 	Name:  David Foster	 
	 	 	Title:    Director	 

 

 

 

     

     

    

SIGNATURE PAGE TO

V.F. CORPORATION

TERM LOAN AGREEMENT

 

	Name
of Lender:
	 
	CREDIT SUISSE AG, New York Branch	 
	 	 
	 
	by 
	 
	 	 	/s/ Doreen Barr	 
	 	 	Name:  Doreen Barr	 
	 	 	Title:    Authorized Signatory	 

 

 

 

	 
	by
	 
	 	 	/s/ Wing Yee Lee-Cember	 
	 	 	Name:  Wing Yee Lee-Cember	 
	 	 	Title:    Authorized Signatory	 

 

 

 

     

     

    

SIGNATURE PAGE TO

V.F. CORPORATION

TERM LOAN AGREEMENT

 

	Name
of Lender:
	 
	The Bank of Nova Scotia	 
	 	 
	 
	by 
	 
	 	 	/s/  Sarah Shaikh	 
	 	 	Name:  Sarah Shaikh	 
	 	 	Title:    Managing Director	 

 

 

     

     

    

Schedule 2.01

 

Commitments

 

	Lender	Commitment
	Wells
    Fargo Bank, National Association	$190,000,000.00
	JPMorgan
    Chase Bank, N.A.	$150,000,000.00
	PNC
    Bank National Association	$150,000,000.00
	TD
    Bank, N.A.	$150,000,000.00
	Truist
    Bank	$150,000,000.00
	U.S.
    Bank National Association	$150,000,000.00
	BNP
    Paribas	$20,000,000.00
	Credit
    Suisse AG, New York Branch	$20,000,000.00
	The
    Bank of Nova Scotia	$20,000,000.00
	Total	$1,000,000,000.00

 

     

     

    

EXHIBIT A

 

[FORM OF] ASSIGNMENT
AND ASSUMPTION

 

This
Assignment and Assumption (this “Assignment and Assumption”) is dated as of the Effective Date set forth below and
is entered into by and between [Insert name of Assignor] (the “Assignor”) and [Insert name of Assignee] (the “Assignee”).
Capitalized terms used but not defined herein shall have the meanings given to them in the Credit Agreement identified below (the “Credit
Agreement”), receipt of a copy of which is hereby acknowledged by the Assignee. The Standard Terms and Conditions set forth
in Annex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption
as if set forth herein in full.

 

For
an agreed consideration, the Assignor hereby irrevocably sells and assigns to the Assignee, and the Assignee hereby irrevocably purchases
and assumes from the Assignor, subject to and in accordance with the Standard Terms and Conditions and the Credit Agreement, as of the
Effective Date inserted by the Administrative Agent as contemplated below, (a) all of the Assignor’s rights and obligations in
its capacity as a Lender under the Credit Agreement and any other documents or instruments delivered pursuant thereto to the extent related
to the amount and percentage interest identified below of all of such outstanding rights and obligations of the Assignor under the credit
facility identified below and (b) to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and
any other right of the Assignor (in its capacity as a Lender) against any Person, whether known or unknown, arising under or in connection
with the Credit Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or
in any way based on or related to any of the foregoing, including, but not limited to, contract claims, tort claims, malpractice claims,
statutory claims and all other claims at law or in equity related to the rights and obligations sold and assigned pursuant to clause
(a) above (the rights and obligations sold and assigned pursuant to clauses (a) and (b) above being referred to herein collectively as,
the “Assigned Interest”). Such sale and assignment is without recourse to the Assignor and, except as expressly provided
in this Assignment and Assumption, without representation or warranty by the Assignor.

 

		i.	Assignor:                                                     

 

		ii.	Assignee:                                                    
                                            [and is an Affiliate/Approved Fund of [identify Lender]]1

 

		iii.	Borrower:V.F. Corporation.

 

		iv.	Administrative Agent: JPMorgan Chase
                                            Bank, N.A., as the administrative agent under the Credit Agreement

 

		v.	Credit Agreement:
                                            The Term Loan Agreement dated as of [●], 2022, among V.F. Corporation, JPMorgan
                                            Chase Bank, N.A., as

 

 

 1
Select as applicable.

 

     

     

    

Administrative
Agent, and the Lenders party thereto from time to time (as from time to time amended, restated, supplemented or otherwise modified).

 

		vi.	Assigned Interest:

 

	Facility Assigned	Aggregate Amount
    of [Commitment][Loans] for all Lenders*	Amount of [Commitment][Loans]
    Assigned*	Percentage Assigned of the
    Aggregate Amount of [Commitments][Loans] of all Lenders2
	Commitment	$	$	%
	Loans	 	 	 
	 	 	 	 

 

* Amount to be
adjusted by the counterparties to take into account any payments or prepayments made between the Trade Date and the Effective Date.

 

		vii.	[Trade
                                            Date.                                                    ,
                                            20     ]3

 

		viii.	Effective
                                            Date:                                                     ,
                                            20       [TO BE INSERTED BY THE ADMINISTRATIVE AGENT
                                            AND WHICH SHALL BE THE EFFECTIVE DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.]

 

 

2 Set
forth, to at least 9 decimals, as a percentage of the Commitments or Loans, as applicable, of all Lenders.

 

3 To be completed if the Assignor and the Assignee intend
that the minimum assignment amount is to be determined as of the Trade Date.

 

     

     

    

The terms set forth in this Assignment
and Assumption are hereby agreed to: ________________, as Assignor

 

	  by	 
	 	_____________________________
	 	Name:
	 	Title:
	 	 

 

________________, as Assignee

 

	  by	 
	 	_____________________________
	 	Name:
	 	Title:

Consented to and Accepted:

 

JPMORGAN CHASE BANK, N.A., as Administrative
Agent

 

	by	 
	 	_____________________________
	 	Name:
	 	Title:

 

[Consented to:

 

V.F. CORPORATION

 

	by	 
	      	_____________________________
	 	Name:
	 	Title:
	 	 
	by	 
	 	_____________________________
	 	Name:
	 	Title: ]4

 

	   

 

4 To be added
only if the consent of the Company is required pursuant to the definition of “Eligible Assignee” or Section 10.01(b) of the
Credit Agreement.

 

     

     

    

ANNEX 1 TO

ASSIGNMENT AND ASSUMPTION

 

 

STANDARD TERMS AND
CONDITIONS FOR

ASSIGNMENT AND ASSUMPTION

 

1.       Representations
and Warranties.

 

1.1       Assignor.  The
Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of the Assigned Interest, (ii) the Assigned Interest
is free and clear of any lien, encumbrance or other adverse claim and (iii) it has full power and authority, and has taken all action
necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby; and (b) assumes
no responsibility with respect to (i) any statements, warranties or representations made in or in connection with the Credit Agreement
or any other Loan Document, other than its representations and warranties set forth in this Assignment and Assumption, (ii) the execution,
legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any collateral thereunder, (iii) the financial
condition of the Company, any Subsidiary or any other Affiliate of the Company or any other Person obligated in respect of any Loan Document,
(iv) any requirements under applicable law for the Assignee to become a Lender under the Credit Agreement or to charge interest at the
rate set forth therein from time to time or (v) the performance or observance by the Company, any Subsidiary or any other Affiliate of
the Company or any other Person of any of their respective obligations under any Loan Document.

 

1.2       Assignee.  The
Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver
this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement,
(ii) it meets all requirements of an Eligible Assignee under the Credit Agreement (subject to receipt of such consents as may be required
under the Credit Agreement) and it satisfies any requirements under applicable law that are required to be satisfied by it in order to
acquire the Assigned Interest and become a Lender, (iii) from and after the Effective Date, it shall be bound by the provisions of the
Credit Agreement as a Lender thereunder and, to the extent of the Assigned Interest, shall have the obligations of a Lender thereunder,
(iv) it is sophisticated with respect to decisions to acquire assets of the type represented by the Assigned Interest and either it,
or the Person exercising discretion in making its decision to acquire the Assigned Interest, is experienced in acquiring assets of such
type, (v) it has received a copy of the Credit Agreement, together with copies of the most recent financial statements delivered pursuant
to Section 5.04 or 6.01 thereof, as applicable, and such other documents and information as it has deemed appropriate to make its own
credit analysis and decision to enter into this Assignment and Assumption and to purchase the Assigned Interest on the basis of which
it has made such analysis and decision independently and without reliance on the Administrative Agent, any Arranger, the Assignor or
any other Lender or any of their respected Related Parties and (vi) attached to this Assignment and Assumption is any documentation required
to be delivered by it pursuant to the terms of the Credit Agreement (including Section 3.05 thereof), duly completed and executed by
the Assignee; and (b) agrees that (i) it will, independently and without reliance on the Administrative Agent, any Arranger, the Assignor
or any other Lender, and based on such documents and information

 

     

     

    

as it shall deem appropriate at the
time, continue to make its own credit decisions in taking or not taking action under the Loan Documents, and (ii) it will perform in
accordance with their terms all of the obligations which by the terms of the Loan Documents are required to be performed by it as a Lender.

 

2.       Payments.  From
and after the Effective Date, the Administrative Agent shall make all payments in respect of the Assigned Interest (including payments
of principal, interest, fees and other amounts) to the Assignee for amounts which have accrued to but excluding the Effective Date and
to the Assignee for amounts which have accrued from and after the Effective Date. The Assignor and the Assignee shall make all appropriate
adjustments of payments by the Administrative Agent for periods prior to the Effective Date or with respect to the making of this assignment
directly between themselves.

 

3.       General
Provisions.  This Assignment and Assumption shall be binding upon, and inure to the benefit of, the parties hereto and
their respective successors and assigns. This Assignment and Assumption may be executed in any number of counterparts, which together
shall constitute one instrument. Acceptance and adoption of the terms of this Assignment and Assumption by the Assignee and the Assignor
by Electronic Signature or delivery of an executed counterpart of a signature page of this Assignment and Assumption by any electronic
system shall be effective as delivery of a manually executed counterpart of this Assignment and Assumption. This Assignment and Assumption
shall be governed by, and construed in accordance with, the laws of the State of New York.

 

     

     

    

EXHIBIT B

 

[FORM OF] BORROWING
NOTICE

 

JPMorgan Chase Bank, N.A.

10 South Dearborn,
Floor L2

Suite IL1-0480

Chicago, IL, 60603-2300

Attention: Ashley Love

Email: ashley.love@chase.com

 

With copy(s) to:

 

JPMorgan Chase Bank, N.A.

Middle Market
Servicing

10 South Dearborn, Floor L2

Suite IL1-0480

Chicago, IL, 60603-2300

Attention: Commercial Banking Group

Email: jpm.agency.cri@jpmorgan.com

   jpm.agency.servicing.1@jpmorgan.com

 

[Date]

 

Ladies and Gentlemen:

 

Reference
is made to the Term Loan Agreement dated as of [●], 2022, among V.F. Corporation, JPMorgan Chase Bank, N.A., as Administrative
Agent, and the Lenders party thereto from time to time (as from time to time amended, restated, supplemented or otherwise modified, the
“Credit Agreement”).  Capitalized terms used but not otherwise defined herein shall have the meanings specified
in the Credit Agreement.

 

This
notice constitutes a Borrowing Notice and the Company hereby gives you notice, pursuant to Section 2.03 of the Credit Agreement, that
it requests a Borrowing under the Credit Agreement, and in that connection specifies the following information with respect to such Borrowing:

 

		(a)	Type
                                            of Borrowing:1

 

		(b)	Aggregate
                                            principal amount of Borrowing2:  US$ _______________

 

		(c)	Date of Borrowing (which is a Business
                                            Day): _______________

 

 

1
Specify Term SOFR Borrowing or ABR Borrowing.

 

2 Must comply with Section 2.02(c) of the Credit
Agreement.

 

     

     

    

		(d)	Interest
                                            Period and the last day thereof3:   ____________________

 

		(e)	Location and number of the Company’s
                                            account to which proceeds of the requested Borrowing are to be disbursed (give name of bank
                                            and account number):  [         ] (Account
                                            No.: ______________)

 

 

 3
Applicable to Term SOFR Borrowings only. Shall be subject to the definition of “Interest Period” and Section 2.02(d) of the
Credit Agreement and can be a period of one, three or six months.

 

     

     

    

 

	 	Very truly yours,
	 	 
	 	V.F. Corporation
	 	 
	 	by
	 	 	 
	 	 	Name:
	 	 	Title:

     

     

    

EXHIBIT C

 

[FORM OF] INTEREST
ELECTION REQUEST

 

JPMorgan Chase Bank, N.A.

10 South Dearborn,
Floor L2

Suite IL1-0480

Chicago, IL, 60603-2300

Attention: Ashley Love

Email: ashley.love@chase.com

 

With copy(s) to:

 

JPMorgan Chase Bank, N.A.

Middle Market
Servicing

10 South Dearborn, Floor L2

Suite IL1-0480

Chicago, IL, 60603-2300

Attention: Commercial Banking Group

Email: jpm.agency.cri@jpmorgan.com

   jpm.agency.servicing.1@jpmorgan.com

 

Ladies and Gentlemen:

 

Reference
is made to the Term Loan Agreement dated as of [●], 2022, among V.F. Corporation, a Pennsylvania corporation (the “Company”),
JPMorgan Chase Bank, N.A., as Administrative Agent, and the Lenders party thereto from time to time (as from time to time amended, restated,
supplemented or otherwise modified, the “Credit Agreement”).  Capitalized terms used and not otherwise defined
herein have the meanings specified in the Credit Agreement.

 

This
notice constitutes an Interest Election Request and the Company  hereby gives notice, pursuant to Section 2.05 of the Credit
Agreement, that it requests the conversion or continuation of a Borrowing under the Credit Agreement, and in that connection the Company
specifies the following information with respect to such Borrowing and each resulting Borrowing:

 

1.       Borrowing
to which this request applies:

 

Principal Amount:  _______________________________

Type:  _______________________________ 

Interest Period:1  _______________________________

 

2.       Effective
date of this election:2  _______________________________

 

 

1 In the case
of a Term SOFR Borrowing, specify the last day of the current Interest Period therefor.

 

2 Must be a Business Day.

 

     

     

    

3.Resulting Borrowing[s]3

 

Principal Amount: ______________________________

Type:  _______________________________

Interest Period:4  _______________________________

 

	 	Very truly yours,
	 	 
	 	V.F. CORPORATION,
	 	by
	 	 	 
	 	 	Name:
	 	 	Title:

 

 

3 If different options
are being elected with respect to different portions of the Borrowing, provide the information required by this item 3 for each resulting
Borrowing.  Each resulting Borrowing shall be in an aggregate amount that is an integral multiple of, and not less than, the
amount specified for a Borrowing of such Type in Section 2.02(c) of the Credit Agreement.

 

4 Applicable only if the resulting Borrowing is to be a
Term SOFR Borrowing.  In the case of a Term SOFR Borrowing, shall be subject to the definition of “Interest Period”
and Section 2.02(d) of the Credit Agreement and can be a period of one, three or six months.  If an Interest Period is not
specified, then the Company shall be deemed to have selected an Interest Period of one month’s duration.  In no case
may such Borrowing extend beyond the Maturity Date.

 

     

     

    

EXHIBIT D

 

[[FORM
OF] ACCESSION AGREEMENT dated as of [                  ],
20__ (this “Agreement”), among V.F. CORPORATION, a Pennsylvania corporation (the “Company”), [                       ]
(each, an “Increasing Lender”), and JPMORGAN CHASE BANK, N.A., as Administrative Agent.

 

Reference
is made to the Term Loan Agreement dated as of [●], 2022, among the Company, JPMorgan Chase Bank, N.A., as Administrative Agent,
and the Lenders party thereto from time to time (as from time to time amended, restated, supplemented or otherwise modified, the “Credit
Agreement”).  Capitalized terms used and not otherwise defined herein have the meanings specified in the Credit Agreement.

 

The
Company desires, pursuant to Section 2.06(d) of the Credit Agreement, to increase the aggregate amount of the Commitments by US$[          ]
to US$[          ] (the “Commitment Increase”).  The date
of effectiveness of the Commitment Increase in accordance with Section 2.06(d) of the Credit Agreement is referred to herein as the “Commitment
Increase Effective Date”.

 

[Each
Increasing Lender that, prior to the Commitment Increase Effective Date, is a Lender hereby agrees that, effective as of the Commitment
Increase Effective Date, (a) the Commitment of such Increasing Lender shall be increased by (or, if such Increasing Lender does not,
immediately prior to the Commitment Increase Effective Date have a Commitment, such Increasing Lender shall have a Commitment in) an
amount equal to the amount set forth opposite the name of such Increasing Lender on Schedule I hereto under the caption “Commitment
Increase Amount” and (b) such Increasing Lender shall have all of the rights and obligations of a Lender under the Credit Agreement
in respect of the amount of such increase in the Commitment of (or the amount of the Commitment of) such Increasing Lender (as well as
all the rights and obligations of such Increasing Lender in respect of its Commitment and Loans, if any, in effect immediately prior
to the Commitment Increase Effective Date).]

 

[Each
Increasing Lender that, prior to the Commitment Increase Effective Date, is not a Lender hereby (a) represents and warrants that such
Increasing Lender is an Eligible Assignee and (b) agrees that, effective as of the Commitment Increase Effective Date, (i) such Increasing
Lender shall have a Commitment in an amount equal to the amount set forth opposite the name of such Increasing Lender on Schedule I hereto
under the caption “Commitment Increase Amount” and (ii) such Increasing Lender shall be party to the Credit Agreement as
a Lender for all purposes of the Credit Agreement and the other Loan Documents, and shall have all the rights and obligations of a Lender
under the Credit Agreement, and agrees to be bound by all provisions of the Credit Agreement applicable to it as a Lender thereunder.]

 

[The
Administrative Agent hereby approves the identity of each Increasing Lender that, prior to the Commitment Increase Effective Date, is
not a Lender.]

 

This
Agreement shall be construed in accordance with and governed by the laws of the State of New York. This Agreement may be executed in
counterparts (and by

 

     

     

    

different parties hereto on different
counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.

 

[Remainder of page
intentionally left blank]

 

     

     

    

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their duly authorized officers, all as of the day
and year first above written.

 

	 	V.F. CORPORATION
	 	 
	 	by
	 	 	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	by
	 	 	 
	 	 	Name:
	 	 	Title:

 

 

	 	
 JPMORGAN CHASE BANK, N.A.,

                                            as Administrative Agent

	 	 
	 	by
	 	 	 
	 	 	Name:
	 	 	Title:

 

 

	 	[Insert Name of increasing Lender]
	 	 
	 	by
	 	 	 
	 	 	Name:
	 	 	Title:

     

     

    

Schedule I

 

Commitment Increase

 

	Increasing Lender	Commitment Increase
    Amount]1
	 	 
	 	 

 

 

1 Amount
must be equal to US$20,000,000 or an integral multiple of US$5,000,000 in excess thereof.

 

     

     

    

Schedule 1

 

[FORM OF] COMPLIANCE
CERTIFICATE

 

JPMorgan Chase Bank, N.A.

10 South Dearborn,
Floor L2

Suite IL1-0480

Chicago, IL, 60603-2300

Attention: Ashley Love

Email: ashley.love@chase.com

 

With copy(s) to:

 

JPMorgan Chase Bank, N.A.

Middle Market
Servicing

10 South Dearborn, Floor L2

Suite IL1-0480

Chicago, IL, 60603-2300

Attention: Commercial Banking Group

Email: jpm.agency.cri@jpmorgan.com

   jpm.agency.servicing.1@jpmorgan.com

 

Reference
is made to the Term Loan Agreement dated as of [●], 2022, among V.F. Corporation, JPMorgan Chase Bank, N.A., as Administrative
Agent, and the Lenders party thereto from time to time (as from time to time amended, restated, supplemented or otherwise modified, the
“Credit Agreement”).  Capitalized terms used but not otherwise defined herein shall have the respective
meanings therefor set forth in the Credit Agreement.

 

The
undersigned, a duly authorized and acting Authorized Representative, hereby certifies to the Administrative Agent as follows:

 

		I.	Calculations:

 

A.Compliance
with Section 7.01: Consolidated Net Indebtedness to Consolidated Net Capitalization as of [                         ],
20__ 1 (the “Determination Date”):

 

	4.Consolidated Net Indebtedness
    as of the Determination Date	US$[                         ]
	 	 
	5.Consolidated Net Worth as of the Determination
    Date 	US$[                         ]

 

 

1 The Determination Date
is the last day of the fiscal quarter or fiscal year covered by the financial statements that are being delivered concurrently with the
delivery of this Compliance Certificate pursuant to Section 6.01(a) or 6.01(b) of the Credit Agreement.

 

     

     

    

	6.Consolidated Net Capitalization
    as of the Determination Date (sum of A.1 and A.2)	US$[                         ]

     

	 	 
	7.Ratio of A.1 to A.3*	_________ to 1.00
	 	 
	*Required: A.4 must not be greater than (i) with respect to any Determination
    Date ending on or prior to the fiscal quarter ending on or about March 31, 2023, 0.70 to 1.00, (ii) with respect to any Determination
    Date thereafter and ending on or prior to the fiscal quarter ending on or about March 31, 2024, 0.65 to 1.00 and (iii) with respect
    to any Determination Date thereafter, 0.60 to 1.00.

 

B.Compliance
with Section 7.02(j): Liens

 

	1.Consolidated Net Worth as of the Determination
    Date 	US$[                         ]
	 	 
	2.B.1 X 15% 	US$[                         ]
	 	 
	3.Is the aggregate principal
    amount of Indebtedness secured by Liens not permitted under Sections 7.02(a) through 7.02(i) less than B.2? 	Yes	No
	 	 	 
	4.B.1 x 20%	US$[                         ]
	 	 
	5.Is the sum of (1) the aggregate principal
    amount of Indebtedness secured by the Liens not permitted under Sections 7.02(a) through 7.02(i) and (2) the aggregate principal
    amount of Indebtedness incurred in accordance with Section 7.03(f) less than B.4?	Yes	No

 

C.Compliance
with Section 7.03(f): Indebtedness of Subsidiaries

 

	1.Is the aggregate principal amount of Indebtedness not permitted under
    Sections 7.03(a) through 7.03(e) less than B.2?	Yes	No

 

		II.	No Default:

 

     

     

    

No Default
or Event of Default has occurred and is continuing on the date of this Compliance Certificate[, except as set forth below]2.

 

[Remainder
of page intentionally left blank]

 

 

2 Set forth the details
of any Default or Event of Default and the action that the Company is taking or proposes to take with respect thereto.

 

     

     

    

IN
WITNESS WHEREOF, I have executed this Compliance Certificate this [            ]
day of [                      ],
20__.

 

	 	V.F. CORPORATION
	 	 
	 	by
	 	 	 
	 	 	Name:
	 	 	Title:Exhibit 10.1

 

CERTAIN INFORMATION IDENTIFIED IN THIS DOCUMENT,
MARKED BY BRACKETS AND ASTERISKS (“[***]”), HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

 

EXECUTION VERSION

 

 

 

 

 

 

 

 

 

 

 

 

EXCLUSIVE SUBLICENSE AGREEMENT

 

BY AND BETWEEN

 

CLS Therapeutics Ltd

 

AND

 

Xenetic Biosciences, Inc.

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

    	 	 	 

     

    

 

EXCLUSIVE SUBLICENSE AGREEMENT

 

This Exclusive Sublicense Agreement, made this 26th day
of April, 2022 (the “Effective Date”), is by and between CLS Therapeutics LTD, a company organized under the laws of
Guernsey with principal offices located at of PO Box 175, Frances House, Sir William Place, St Peter Port, Guernsey, GY1 4HQ, UK (“CLS”)
and Xenetic Biosciences, Inc., a Nevada corporation, with offices located at 40 Speen St. Ste 102, Framingham, MA 01701 (“XBIO”).
Each of XBIO and CLS may be referred to, individually, as a “Party”, and, collectively, as the “Parties”.

 

RECITALS

 

WHEREAS, CLS owns or controls certain patent
rights and know-how related to the use of Deoxyribonuclease enzyme for treatment of cancer;

 

WHEREAS, XBIO is interested in obtaining
an exclusive sublicense under such patent rights and to such know-how to develop and commercialize pharmaceutical products and methods
incorporating Deoxyribonuclease enzyme, and CLS is willing to grant XBIO such a sublicense, in each case on the terms and conditions set
forth in this Agreement.

 

NOW, THEREFORE, in consideration of the
foregoing and the mutual covenants contained in this Agreement, CLS and XBIO, intending to be legally bound, hereby agree as follows:

 

ARTICLE
I

DEFINITIONS

 

When used in this Agreement, each of the following
capitalized terms, whether used in the singular or plural, shall have the meaning set forth in this Article I.

 

1.1.          
“Affiliate” of an entity means any person or entity which, directly or indirectly, controls, is controlled by
or is under common control with such entity. For the purposes of this definition, “control” refers to any of the following:
(i) direct or indirect ownership of fifty percent (50%) or more of the voting securities entitled to vote for the election of directors
in the case of a corporation, or of fifty percent (50%) or more of the equity interest with the power to direct management in the case
of any other type of legal entity; (ii) status as a general partner in any partnership; or (iii) any other arrangement where a person
or entity possesses, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of
voting securities, by contract or otherwise.

 

1.2.          
“Agreement” means this Exclusive Sublicense Agreement, including any and all exhibits, schedules, appendices
and other addenda to it and as it may be amended from time to time in accordance with the provisions of this document.

 

1.3.          
“Business Day” means Monday through Friday, except the legal public holidays specified in 5 U.S.C. 6103, any
day declared to be a holiday by federal statute or executive order, or any day with respect to which the U.S. Office of Personnel Management
has announced that Federal agencies in the Washington, DC, area are closed.

 

1.4.          
“Calendar Day” means the period of elapsed time, using Coordinated Universal Time or local time that begins
at midnight and ends 24 hours later at the next midnight.

 

 

 

    	 	2	 

     

    

 

1.5.          
“CLS Improvement” means an Improvement made by CLS or its Affiliates.

 

1.6.          
“Combination Product” means any pharmaceutical product containing both a Licensed Product component and one
or more other active pharmaceutical ingredients.

 

1.7.          
“Commercially Reasonable Efforts” means the level of efforts and resources, including financial resources, at
least equal to those normally used by a company in the pharmaceutical or biotechnology industry to conduct the relevant activity, including,
in the case of research, development or commercialization, the level of effort and resources at least equal to those normally used by
such a company to research, develop, manufacture or commercialize, as the case may be, a product owned by such company or to which it
has rights, which product is at a similar stage in its development or product life and is of a similar market and profitability potential
to Licensed Product, taking into account all relevant factors including the patent and other proprietary position of the product, product
labeling or anticipated labeling, market potential, financial return, medical and clinical considerations, regulatory environment and
competitive market conditions, and other technical, legal, scientific, medical or commercial factors that such a company would deem to
be relevant.

 

1.8.          
“Compound” means a human recombinant Deoxyribonuclease I.

 

1.9.          
“Confidential Information” shall mean any and all confidential and proprietary information, including chemical
or biological materials, chemical structures, sequence information, commercialization plans, correspondence, customer lists, data, development
plans, formulae, improvements, Know-How, processes, regulatory filings, clinical trial designs, clinical trial protocols, data read-outs
from clinical trials, reports, strategies, techniques, or other information, in each case that are disclosed by or on behalf of a Party
or its Affiliates (the “Disclosing Party”) to the other Party or its Affiliates (the “Receiving Party”)
pursuant to this Agreement, regardless of whether any of the foregoing are marked “confidential” or “proprietary”
or communicated to the other Party by or on behalf of the Disclosing Party in oral, written, visual, graphic, or electronic form. Confidential
Information shall not include any information that: (w) is already known to the Receiving Party at the time of disclosure (as evidenced
by written records or other competent evidence) without any obligation to keep it confidential or any restriction on its use, prior to
disclosure by the Disclosing Party; or (x) is generally available to the public or becomes publicly known through no wrongful act of the
Receiving Party or its representatives; or (y) is subsequently received by the Receiving Party from a Third-Party lawfully in possession
thereof and without any obligation to keep it confidential or any restriction on its use; or (z) is developed independently by the Receiving
Party without reference or reliance upon the Disclosing Party’s Confidential Information (as evidenced by written records or other
competent evidence). Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because
individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination
itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party.

 

1.10.        
“Control” or “Controlled”, other than for purposes of Section 1.1, means the possession of
the right to grant licenses or sublicenses or to disclose proprietary or trade secret information without violating the terms of any agreement
or other arrangement with a Third Party and without misappropriating or infringing the proprietary or trade secret information of a Third
Party.

 

1.11.        
“Cover”, “Covering” or “Covered” means, with respect to a Licensed Patent
and invention, that, in the absence of ownership of, or a license under, such Licensed Patent, the practice of such invention would infringe
a Valid Claim of such Licensed Patent (including in the case of a Licensed Patent that is a patent application, a Valid Claim of such
patent application as if such patent application were an issued patent).

 

1.12.        
“EIRGEN Agreement” means that certain Exclusive Sublicense Agreement between CLS and EirGen Pharma Ltd. (“EirGen”)
dated as of February 22, 2022, under which EirGen sublicensed its rights to certain of the Licensed Technology and Licensed Know-how to
CLS for use of the Compound for treatment of cancer, neurodegenerative disease and stroke.

 

 

 

    	 	3	 

     

    

 

1.13.        
“EMA” means the European Medicines Agency or any successor agency thereto.

 

1.14.        
“EU” means the countries of the European Union, as it is constituted as of the Effective Date and as it may
be expanded from time to time.

 

1.15.        
“FDA” means the United States Food and Drug Administration or any successor agency thereto.

 

1.16.        
“Field” means therapeutic, prophylactic or palliative, uses in humans for treating a cancer.

 

1.17.        
“First Commercial Sale”, as to a particular country, means the first arms-length commercial sale of a Licensed
Product by XBIO, its Affiliates or Sublicensees to a Third Party in such country after approval of the NDA, or if approval of an NDA is
not required in such country, then following receipt of Marketing Approval required to market such Licensed Product in such country.

 

1.18.        
“GAAP” means U.S. generally accepted accounting principles applied on a consistent basis, or any other accounting
principles generally accepted for public companies, such as International Financial Reporting Standards. Unless otherwise defined or stated,
financial terms shall be calculated under GAAP.

 

1.19.        
“Improvements” means any development, modification or improvement arising out of or relating to the technology
described in the Licensed Technology, including the Compound and uses thereof, that enhances the usability, functionality, efficiency,
performance or another characteristic of the Licensed Technology.

 

1.20.        
“Know-how” means all present and future technical information, methods, knowledge, data information and know-how,
patentable or otherwise, in written or electronic form.

 

1.21.        
“Licensed Know-how” means any Know-how listed on Exhibit B attached hereto and any CLS Know-how developed following
the Effective Date that relate to or incorporate any information and/or know-how necessary to research, develop, make, use, offer to sell,
sell or export a Licensed Product.

 

1.22.        
“Licensed Patents” means:

 

(a)            The
patents and patent applications listed on Exhibit A attached hereto and incorporated herein by reference;

 

(b)            the
patents and patent applications included in the CLS Improvements and listed on Exhibit A attached hereto;

 

(c)            any
patents and patent applications that Cover any CLS Improvements developed by CLS following the Effective Date that are necessary or useful
to research, develop, make, use, offer to sell, sell or export a Licensed Product and that are necessary to practice the inventions disclosed
or claimed by the patents and patent applications listed on Exhibit A; and

 

(d)            all
continuations, continuations-in-part, patents of addition, divisions, renewals, reexaminations, reissues and extensions (including any
patent term extension under 35 USC §156) of any of the foregoing patents and patent applications; and any Supplementary Protection
Certificate (within the meaning of such term under Council Regulation (EU) No. 1768/92) or any other similar statutory protection in
relation to the relevant Licensed Product before or after the Effective Date.

 

 

 

    	 	4	 

     

    

 

1.23.       
“Licensed Product” means any product comprising, incorporating or containing the Compound, including, but not
limited to, a pharmaceutically acceptable salt, polymorph, crystal form, prodrug, or solvate of the Compound, all to the extent such product
or its use, manufacture or importation is Covered by a Licensed Patent or relies upon, references or incorporates the Licensed Know-How
or CLS Improvements.

 

1.24.       
“Licensed Technology” means the Licensed Patents and CLS Improvements.

 

1.25.       
“Major EU Markets” means the United Kingdom, France, Italy, Spain and Germany.

 

1.26.       
“Marketing Approval” means any approval, including price approval, registration, license or authorization from
any Regulatory Authority required to market and sell a Licensed Product in a jurisdiction and shall include an approval, registration,
license or authorization granted in connection with an NDA.

 

1.27.       
“Material Adverse Effect” means any change in or effect on the business of XBIO that is, or could reasonably
be expected to be, materially adverse to the business, assets (including intangible assets), liabilities (contingent or otherwise), condition
(financial or otherwise) or results of operations of XBIO.

 

1.28.       
“NDA” means a New Drug Application, Biologics License Application or equivalent submission filed with the FDA
in connection with seeking Marketing Approval of a Licensed Product, or an equivalent application filed with any equivalent regulatory
agency or governmental authority in any jurisdiction other than the United States.

 

1.29.       
“Net Sales” means the gross amount invoiced on sales of Licensed Product in the Territory by XBIO, its Affiliates
or, for the purposes of Section 1.38, Sublicensees, less the following deductions with respect to the sale of such Licensed Product:

 

(i)             customary
trade, cash and quantity discounts and other customary discounts actually given to customers in the ordinary course of business;

 

(ii)            rebates,
credits and allowances given by reason of rejections, returns, damaged or defective product or recalls;

 

(iii)           government-mandated
rebates and any other compulsory payments, credits, adjustments and rebates actually paid or deducted;

 

(iv)           price
adjustments, allowances, credits, chargeback payments, discounts, rebates, fees, reimbursements or similar payments granted to managed
care organizations, group purchasing organizations or other buying groups, pharmacy benefit management companies, health maintenance
organizations and any other providers of health insurance coverage, health care organizations or other health care institutions (including
hospitals), health care administrators or patient assistance or other similar programs, or to federal, state/provincial, local and other
governments, including their agencies, or to wholesalers, distributors or other trade customers;

 

(v)            reasonable
and customary freight, shipping, insurance and other transportation expenses, if actually borne by XBIO, its Affiliates or, for the purposes
of Section 1.38, Sublicensees without reimbursement from any Third Party;

 

 

 

    	 	5	 

     

    

 

(vi)           sales,
value-added, excise taxes, tariffs and duties, and other taxes and government charges directly related to the sale, delivery or use of
Licensed Product (but not including taxes assessed directly against the income derived from such sale) net of any credits or allowances
received by XBIO, its Affiliates or, for the purposes of Section 1.38, Sublicensees with respect to such taxes or charges;

 

(vii)          amounts
previously included in Net Sales of Licensed Product that are written off as uncollectible after reasonable collection efforts, in accordance
with standard practices of the applicable party; and

 

(viii)         any
item, substantially similar in character or substance to any of the foregoing, calculated in accordance with GAAP consistently applied
and customary in the pharmaceutical industry to be deducted in the definition of net sales in a license agreement of this type.

 

Net Sales will be determined from books and records
maintained in accordance with GAAP, consistently applied throughout the organization and across all products of the entity whose sales
of Licensed Product are giving rise to Net Sales.

 

Disposition of Licensed Product for, or use of the
Licensed Product in, clinical trials or other scientific testing, as free samples, or under compassionate use, patient assistance, or
test marketing programs or other similar programs or studies where a Licensed Product is supplied without charge shall not result in any
Net Sales, however if XBIO, its Affiliates or, for the purposes of Section 1.38, Sublicensees charges for such Licensed Product, the amount
billed will be included in the calculation of Net Sales.

 

In the event a Licensed Product is sold in the form
of a Combination Product, then the Net Sales for any such Combination Product shall be determined by multiplying the Net Sales of the
Combination Product during the applicable royalty Reporting Period, by the fraction, A/(A+B), where A is the weighted (by sales volume)
average sale price of the Licensed Product when sold separately in finished form in the country in which the Combination Product is sold,
and B is the weighted (by sales volume) average sale price of the other active pharmaceutical ingredients included in the Combination
Product when sold separately in finished form in the country in which the Combination Product is sold, in each case during the applicable
royalty Reporting Period or, if sales of both the Licensed Product and the other active pharmaceutical ingredients did not occur in such
period, then in the most recent royalty Reporting Period during the preceding twelve (12) months in which sales of both occurred, if any.
In the event that such average sale price cannot be determined for both the Licensed Product and all other active pharmaceutical ingredients
included in the Combination Product, then the Parties will in good faith discuss and agree on a pro-rata allocation of the Net Sales that
reflects the Licensed Product’s contribution to the Combination Product on an equitable basis. XBIO covenants that neither it nor
any of its Affiliates or, for the purposes of Section 1.38, Sublicensees will intentionally manipulate the fraction A/(A+B) to avoid or
reduce royalty payments or obligations that would otherwise be due for sales of Licensed Product in combination form or otherwise.

 

1.30.         “Regulatory
Authority” means any federal, national, multinational, state, county, city, provincial, or local regulatory agency, department,
bureau or other governmental entity with authority over the marketing, commercialization, manufacture or sale of a pharmaceutical product
in the Territory, including the FDA in the United States and the EMA in the EU.

 

1.31.         “Reporting
Period” shall mean each three month period ending March 31, June 30, September 30 and December 31.

 

 

1.32.         “Royalty
Term” has the meaning set forth in Section 3.5.

 

1.33.         “Royalty
Sublicense Income” shall mean royalties received from a Sublicensee.

 

 

 

    	 	6	 

     

    

 

1.34.        “SciVac
Agreement” means that certain exclusive Sublicense Agreement between OPKO Ireland Global Holdings Ltd., and SciVac Ltd. (now
VBI Vaccines Inc. and hereinafter, “SciVac”) dated as of May 5, 2016, under which SciVac Ltd. sublicensed its rights to certain
of the Licensed Technology and Licensed Know-how to OPKO Ireland Global Holdings Ltd. for use of the Compound for all indications, uses
and treatments.

 

1.35.         “SciVac
Improvement” means an Improvement made by SciVac or its Affiliates.

 

1.36.         “Sublicensee”
means a Third Party to whom XBIO or any of its Affiliates or Sublicensee(s) grants an express sublicense under the Licensed Patents,
CLS Improvements and/or Licensed Know-how to develop, manufacture, commercialize or use Licensed Product in the Field in the Territory;
provided that the term “Sublicensee” excludes any Third Party who acts solely as a promoter, agent, marketer and/or distributor
for and on behalf of XBIO or any of its Affiliates or Sublicensees for the distribution and/or marketing of Licensed Product.

 

1.37.        “Sublicense
Income” means consideration received by XBIO or any of its Affiliates from a Sublicensee in connection with or otherwise attributable
to a grant to such Sublicensee of an express sublicense under the Licensed Patents, CLS Improvements and/or Licensed Know-how to develop,
manufacture, commercialize or use Licensed Product in the Field in the Territory, including without limitation, (a) lump sum license
fees; (b) proceeds of sale of the Licensed Technology, CLS Improvements and/or Licensed Know-how; (c) signing fees; and (d) milestone
payments relating to the Milestones or other milestones; provided, however, that Sublicense Income shall not include Royalty Sublicense
Income.

 

1.38.         “Sublicensee
Net Sales” shall mean any Net Sales generated by a Sublicensee.

 

1.39.         “Sublicense
Percentage” shall equal [***].

 

1.40.         “Tax”
or “Taxes” means any present or future taxes, levies, imposts, duties, charges, assessments or fees of any nature
(including interest, penalties and additions thereto) that are imposed by a government authority, but not including a Party’s income
taxes.

 

1.41.         “Term”
means the term of this Agreement determined in accordance with Section 9.1.

 

1.42.         “Territory”
means worldwide.

 

1.43.         “Third
Party” means any person other than a Party or any of its Affiliates or their respective employees.

 

1.44.         “Third
Party Payments” means all royalties, upfront fees, milestones and other payments paid by XBIO or its Affiliates to Third Parties
under licenses to intellectual property or to acquire intellectual property that is necessary for the development, manufacture, import,
sale or use of Licensed Product in the Field in the Territory. For purposes of this definition, the term “necessary” shall
mean that, in the reasonable determination of XBIO or its Affiliates, the intellectual property of the Third Party were reasonably necessary
or useful to the manufacture, use or sale of Licensed Product in the Territory.

 

1.45.         “United
States” or “U.S.” means the United States of America and its territories and possessions.

 

1.46.         “Valid
Claim” means (i) a claim of an issued and unexpired patent that has not been revoked or held unenforceable or invalid by a
decision of a court or other governmental agency of competent jurisdiction from which no appeal can be taken or with respect to which
an appeal is not taken within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable
through reissue, disclaimer or otherwise or been dedicated to the public, and (ii) a claim in a pending patent application that is being
prosecuted and that has not been abandoned, disclaimed, allowed to lapse or finally determined to be unallowable by the applicable governmental
authority in a decision from which no appeal can be taken or from which no appeal is taken within the time allowed for appeal.

 

 

 

    	 	7	 

     

    

  

ARTICLE
II

LICENSE GRANT

 

2.1.           License
Grant. Effective as of the Effective Date hereof, and subject to the terms and conditions of this Agreement, CLS grants to XBIO:
(a) an exclusive, royalty-bearing, fully transferrable (in accordance with Section 11.5) license under the Licensed Technology (the “Patent
License”), and (b) an exclusive, royalty-bearing, fully transferable (in accordance with Section 11.5) license under the Licensed
Know-how (the “Know-how License”), in each case with the right to grant sublicenses, to the extent provided in Section
2.2, to research, develop, make, have made, use, import, export, market, offer for sale, sell and have sold, Licensed Product in the
Territory within the Field.

 

2.2.           Sublicenses.

 

(a)            Sublicensing. XBIO shall have the right to grant subsequent sublicenses under the Patent License and Know-how License only
with the prior written consent of CLS, not to be unreasonably withheld. Any subsequent sublicenses shall be in writing and include substantially
the same non-financial terms and be in substantially the same form as this Agreement. In the event of termination of the Patent License
(except for the passage of time), any existing agreements that contain a subsequent sublicense of, or other grant of right with respect
to, Licensed Technology shall terminate to the extent of such subsequent sublicense or other grant of right; provided, however, that,
for each Sublicensee, upon termination of the subsequent sublicense agreement with such Sublicensee, if such Sublicensee is not then in
material breach of such sublicense agreement such that XBIO would not have the right to terminate such subsequent sublicense, CLS shall
be obligated, at the request of such Sublicensee, to preserve the effectiveness, scope and validity of such subsequent sublicense or other
grant of right for up to ninety (90) days while CLS enters into a new agreement with such Sublicensee on substantially the same terms
as those contained in such sublicense agreement, and provided further that such terms shall be amended, if necessary, to the extent required
to ensure that such sublicense agreement does not impose any obligations or liabilities on CLS which are not included in this Agreement
or adversely affect the consideration due to CLS hereunder. In the event that CLS and such Sublicensee are unable to enter into a new
sublicense agreement within the ninety (90) day period mentioned above following a good faith negotiation by both CLS and Sublicensee,
then XBIO’s agreement with such Sublicensee shall terminate upon expiration of such ninety (90) day period.

 

(b)           Performance by Sublicensees. XBIO shall be fully responsible for performance of each Sublicensee of its obligations under
this Agreement. Each sublicense granted by XBIO pursuant to this Section 2.2 will contain terms and conditions not inconsistent with those
sections of this Agreement applicable to Sublicensees. Each sublicense agreement will contain the following provisions: (i) a requirement
that any Sublicensee selling Licensed Product submit applicable sales or other reports to XBIO to the extent necessary or relevant to
the reports required to be made or records required to be maintained under this Agreement; (ii) an audit requirement as to those Sublicensees
selling Licensed Product consistent with that set forth in Section 4.3; and (iii) a requirement that such Sublicensee comply with the
confidentiality provisions and restrictions on use of Confidential Information consistent with Article VI with respect to Confidential
Information of CLS. If XBIO becomes aware of a material breach by a Sublicensee of the rights granted to XBIO under Section 2.1, XBIO
will promptly notify CLS of the particulars of the same, and will use Commercially Reasonable Efforts to enforce the terms of such sublicense.

 

2.3.          Responsibility;
Decision-making. During the Term, XBIO will, including through its Affiliates and Sublicensees and their respective contractors,
have sole responsibility for and sole decision-making authority with respect to, the research, development, manufacture, marketing, sale
and use of Licensed Product in the Field in the Territory and will be responsible for all of the costs and expenses associated with such
activities during the Term. XBIO shall keep CLS reasonably informed as to XBIO’s progress in these efforts and XBIO will use good
faith efforts to confer with CLS, on at least a quarterly basis, with respect to the development of the Licensed Product. Without limiting
the foregoing, XBIO will use good faith efforts to confer with CLS on significant product development decisions (such as design and conduct
of clinical trials, entering into research and development collaborations, and entering into license or sublicense agreements) in advance
of making such decisions.

 

 

 

    	 	8	 

     

    

 

2.4.          Diligence.
XBIO will, including through its Affiliates and Sublicensees, use Commercially Reasonable Efforts during the Term to develop and obtain
Marketing Approval for a Licensed Product in the United States and in each Major EU Market, and to commercialize such Licensed Product
in the United States and each Major EU Market if the relevant Marketing Approval is obtained. In addition, XBIO will, including through
its Affiliates and Sublicensees, use Commercially Reasonable Efforts to secure any data and market exclusivity for a Licensed Product
for which Marketing Approval is obtained, to the extent available from the applicable Regulatory Authorities. XBIO agrees to register
this Agreement with any foreign governmental agency, which requires such registration and where the failure to so register would have
a material adverse impact on commercialization of Licensed Product in a Major EU Market, and XBIO shall pay all costs and legal fees
in connection therewith. XBIO shall not be relieved of any of its obligations under this Agreement by any failure to register this Agreement
in any country, and, specifically, shall not be relieved of its obligation to make any payment due to CLS where such payment is blocked
due to any failure to register this Agreement. CLS shall cooperate with XBIO in the preparation of each submission for Marketing Approvals
for the Licensed Product(s) in the Territory and in obtaining and maintaining Marketing Approvals within the Territory.

 

(a)           Ownership
of Clinical Trial Data. All data (including all pre-clinical, clinical and/or marketing data) developed by XBIO during the Term and
relating to a Licensed Product and the Field shall be and remain the property of XBIO; provided, however, that XBIO hereby grants to
CLS and its Affiliates a perpetual non-exclusive license and right of reference to, and a right to copy, access and otherwise use, all
such data solely to support CLS’ and its Affiliates’ seeking marketing approval of one or more products outside the Field.
All data (including all pre-clinical, clinical and/or marketing data) developed by CLS during the Term relating to a Compound outside
the Field shall be and remain the property of CLS; provided, however, that CLS hereby grants to XBIO, its Affiliates and Sublicensees
a perpetual non-exclusive license and right of reference to, and a right to copy, access and otherwise use, all such data solely to support
XBIO’s, its Affiliates’ and Sublicensees’ seeking Marketing Approval of one or more products within the Field.

 

(b)           Clinical
Studies. XBIO shall have the exclusive right to conduct any clinical trials or studies, prior to or after relevant Marketing Approval,
with respect to the Licensed Product in the Territory and in the Field.

 

ARTICLE
III

FINANCIAL PROVISIONS

 

3.1.          Consideration
Given by XBIO. Subject to the terms and conditions of that certain Subscription Agreement to be entered into by the Parties concurrently
herewith, XBIO will grant to CLS on the date hereof 375,000 (three hundred seventy-five thousand) shares of Common Stock of XBIO (the
“Shares”). Of the Shares, 250,000 (two hundred fifty thousand) shall be issued directly by XBIO to EirGen in satisfaction
of the requirements of Section 3.2 of the EIRGEN Agreement, and XBIO shall promptly deliver to CLS written evidence of such issuance.
EirGen is an intended third-party beneficiary of this Section 3.1 only and shall not be considered an intended third-party beneficiary
of any other portion or provision of this Exclusive Sublicense Agreement.

 

3.2.          Milestone
Payments. As additional consideration for the licenses granted to XBIO under Section 2.1 above, XBIO will pay non-refundable and
non-creditable milestone payments to CLS in the amounts and upon the occurrence of the events set forth below (each a “Milestone”),
irrespective of whether such Milestone was achieved by XBIO or its Affiliates. Each such payment shall be made within forty-five (45)
Calendar Days after a Milestone has occurred. Each milestone payment will be payable only one time and shall not be subject to any royalty
provisions set forth in Section 3.3(a). Notwithstanding the terms of this Section 3.2, if XBIO enters into a sublicense with a Sublicensee,
then the sole payments due by XBIO to CLS with respect to any Milestone shall be pursuant to Section 3.4(b) and XBIO shall be under no
obligation to make any further milestone payments pursuant to this Section 3.2.

 

	Milestone	Milestone Payment
	[***]	
    950,000 shares of Common Stock of XBIO

    [***]

	[***]	$[***]
	[***]	$[***]
	[***]	$[***]

[***]

 

 

    	 	9	 

     

    

 

3.3.          Royalty.

 

(a)            As
partial consideration for the licenses granted to XBIO under Section 2.1 above, XBIO will pay to CLS an amount equal to Net Sales for
a Licensed Product within the Territory multiplied by the Applicable Percentage, as set forth below by each Licensed Product.

 

	Annual Net Sales of Licensed Products	Applicable Percentage
	Up to and including  [***] per calendar year	[***]
	Over [***] per calendar year	[***]
	Over  [***] per calendar year	[***]

 

(b)            The
Parties agree that the applicable royalty upon Net Sales payable under Section 3.3(a) above, shall apply to Net Sales during the Royalty
Term (as defined below). At the end of the applicable Royalty Term no royalties shall be paid under the Patent License.

 

(c)            To
the extent that that a Licensed Product is sublicensed to a Sublicensee, no further royalties will be due under this Section 3.3 and
all payments due to CLS shall be made pursuant to Section 3.4.

 

3.4.           Sublicense
Income.

 

(a)            As
additional consideration for the licenses granted to XBIO under Section 2.1 above, XBIO will pay to CLS an amount equal to the Sublicense
Percentage multiplied by the Royalty Sublicense Income (the “Sublicense Royalty Payment”); [***].

 

(b)           As
additional consideration for the licenses granted to XBIO under Section 2.1 above, XBIO will also pay to CLS an amount equal to the Sublicense
Percentage multiplied by the Sublicense Income.

 

3.5.           Patent
License Royalty Term. Royalties payable for the Patent License under Section 3.3 shall be payable on a country-by-country and Licensed
Product-by-Licensed Product basis during the period commencing on the First Commercial Sale of such Licensed Product in the Field in
such country, and ending on a country-by-country basis upon (i) the expiration of the last Valid Claim Covering such Licensed Product
in such country, or (ii) five (5) years from the date of First Commercial Sale in such country, whichever is later (the “Royalty
Term”).

 

3.6.           Third
Party Payments. XBIO will have the right to deduct from the royalty otherwise payable under Sections 3.3, fifty percent (50%) of
Third Party Payments, provided that in no event will the royalty payment be reduced as a result of application of this paragraph, to
less than fifty percent (50%) of the amount otherwise payable under Section 3.3. Third Party Payments available for offset under this
Section 3.6 and not used as a credit against the royalty payable hereunder in a given calendar quarter may be carried over to future
calendar quarters until fully utilized.

 

3.7.           Payments;
Reports. Following the First Commercial Sale in any country in the Territory, XBIO will pay royalties due on Net Sales in a calendar
quarter within sixty (60) days of the end of such calendar quarter and shall be accompanied by a report as set forth in Article 4 below.

 

3.8.           Taxes.
All payments shall be made by XBIO under this Agreement without deduction or withholding of taxes owed by CLS except to the extent that
any such deduction or withholding is required by applicable law to be made on account of Taxes, as determined by XBIO in good faith.
To the extent that amounts are so withheld, such withheld amounts shall be treated for all purposes of this Agreement has having been
delivered and paid to CLS. The Parties will cooperate with respect to all documentation required by any relevant government taxing authority
or reasonably requested by either Party to secure a reduction in the rate of applicable withholding Taxes. XBIO shall not be liable for
any excess Taxes withheld, and in the event of an overwithholding, CLS’s sole recourse shall be to apply for a refund from the
appropriate taxing authority.

 

 

 

    	 	10	 

     

    

 

3.9.           United
States Dollars. All dollar ($) amounts specified in this Agreement are United States dollar amounts.

 

3.10.         Currency
Conversion. All payments to be made hereunder will be made in U.S. Dollars, to a bank account designated by CLS. In the case of sales
outside the United States, payments received by XBIO, its Affiliates or Sublicensees will be expressed in the U.S. Dollar equivalent
calculated on a quarterly basis in the currency of the country of sale and converted to their U.S. Dollar equivalent using the average
of the rate of exchange as quoted in the Wall Street Journal (WSJ) for the relevant quarter. If the WSJ does not publish such rate, a
comparable rate publication shall be agreed from time to time by the Parties, and with respect to any country for which such rate is
not published by the WSJ or a comparable publication, the Parties will use the prevailing rate for bank cable transfers for such date,
as quoted by the leading United States banks in New York City dealing in the foreign exchange market.

 

3.11.         Late
Payments. The payments due under this Agreement shall, if overdue, bear interest at a rate per annum equal to two percent (2%) above
the prime rate in effect on the due date as reported by The Wall Street Journal, such interest rate being compounded on the last day
of each Reporting Period, not to exceed the maximum permitted by law. Any such overdue payments when made shall be accompanied by all
interest so accrued. Said interest and the payment and acceptance thereof shall not preclude CLS from exercising any other rights it
may have as a consequence of the lateness of any payment. This Section 3.11 shall not apply to any payments that are disputed in good
faith by either Party until thirty (30) Calendar Days after the resolution of any such dispute.

 

ARTICLE
IV

MAINTENANCE OF BOOKS AND RECORDS

 

4.1.           Reporting.

 

(a)            XBIO shall report to CLS the date on which it achieves a Milestone within forty (40) Calendar Days of each such occurrence.

 

(b)           XBIO
shall report to CLS the date on which it achieves the First Commercial Sale in each country of the Territory within thirty (30) Calendar
Days of each such occurrence. For each country in the Territory, following the First Commercial Sale of Licensed Product, XBIO shall
deliver reports to CLS within sixty (60) Calendar Days after the end of each Reporting Period. Each report under this Section 4.1(b)
shall be certified as correct by an officer of XBIO and shall contain at least the following information as may be pertinent to a royalty
accounting hereunder for the immediately preceding Reporting Period:

 

(i)             the
total number of units of Licensed Products sold by XBIO, its Affiliates and Sublicensees in each country;

 

(ii)            the
amounts billed, invoiced and received by XBIO, its Affiliates and Sublicensees for each Licensed Product, in each country, and total
billings or payments due or made for all Licensed Products;

 

(iii)           calculation
of Net Sales for the applicable Reporting Period in each country, including an itemized listing of permitted offsets and deductions;
and

 

(iv)           total
royalties payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion.

 

4.2.           If
no amounts are due to CLS for any Reporting Period, the report shall so state.

 

 

 

    	 	11	 

     

    

 

4.3.           XBIO
shall maintain and shall cause each of its Affiliates and Sublicensees to maintain, complete and accurate records relating to the rights
and obligations under this Agreement and any royalties payable to CLS in relation to this Agreement, which records shall contain sufficient
information to permit CLS and its representatives to confirm the accuracy of such royalties and reports delivered to CLS and compliance
in all other respects with this Agreement. XBIO shall maintain, and shall cause each of its Affiliates and Sublicensees to maintain,
accurate records regarding Licensed Products, including Net Sales thereof, and shall retain such records over a period of at least six
(6) years. CLS will have the right, once annually at its own expense, to have a nationally recognized, independent, certified public
accounting firm, which shall be mutually agreed upon by the Parties, review any such records of XBIO and its Affiliates and Sublicensees
(the “Audited Party”) in the location(s) where such records are maintained by the Audited Party upon reasonable written
notice (which shall be no less than fifteen (15) Business Days’ prior written notice) and during regular business hours and under
obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of payments made under Section 3.2. If any
examination conducted by CLS or its representatives pursuant to the provisions of this Section show an underreporting or underpayment
of five percent (5%) or more in any payment due to CLS hereunder in a Reporting Period, the Audited Party shall bear the full cost of
such audit and shall remit any amounts due to CLS (including interest due in accordance with Section 3.10) within thirty (30) days of
receiving notice thereof from CLS.

 

ARTICLE
V

INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION

AND RELATED MATTERS

 

5.1.           Prosecution
and Maintenance of Licensed Patents. XBIO shall have responsibility for filing, prosecuting and maintaining all Licensed Patents
and shall be responsible for all related expenses and costs. XBIO shall also be responsible, at its cost, for defending all such Licensed
Patents, including the defense of any oppositions or reexaminations or similar proceedings, and shall use Commercially Reasonable Efforts
in the conduct of such activities. XBIO will provide to CLS copies of all prosecution filings and material submissions related to such
Licensed Patents and will use reasonable efforts to provide CLS with a draft of each such filing or material submission in advance of
such submission and will consider in good faith any comments that CLS may timely provide. If XBIO decides not to file, prosecute or maintain
patent applications or patents within the Licensed Patents that Cover the Licensed Product and/or its use, CLS shall have the right,
but not the obligation, to file, prosecute and maintain such invention at its cost and expense.

 

5.2.           Ownership
of Improvements. Should XBIO its Affiliates or Sublicensees develop any Improvements to the Licensed Patents or Licensed Know-how,
XBIO shall be the sole and exclusive owner of such Improvements (the “XBIO Improvements”). To the extent XBIO decides at
its sole discretion to file for patent protection of an XBIO Improvement, XBIO shall have the responsibility for filing, prosecuting
and maintaining all such patent applications and any patents that issue therefrom (the “XBIO Patents”) at its sole expense
and cost. XBIO shall also be responsible, at its cost, for defending all such XBIO Patents, including the defense of any oppositions
or reexaminations or similar proceedings.

 

5.3.           Third
Party Infringement.

 

(a)            Notices.
Each Party will promptly report in writing to the other Party any (i) known or suspected infringement of any Licensed Patents, or (ii)
unauthorized use or misappropriation of any Licensed Know-how by a Third Party, of which such Party becomes aware, in each case only
to the extent relevant to Licensed Product or the development, manufacture, commercialization or use of Licensed Product in the Field
in the Territory, and will provide the other Party with all available information evidencing such infringement, or unauthorized use or
misappropriation.

 

 

 

    	 	12	 

     

    

 

(b)           XBIO
First Right to Enforce Certain Licensed Patents. XBIO or, as applicable its Affiliate or Sublicensee will have the first right, but
not the obligation, to initiate a suit or take other appropriate action that it believes is reasonably required to prevent or abate actual
or threatened infringement or misappropriation of, or otherwise protect or enforce, the Licensed Patents against a Third Party who is
researching, developing, making, using or selling a product in the Field in a country within the Territory. CLS and its Affiliates will
join such suit if the relevant court would lack jurisdiction if CLS or such Affiliate were absent from such suit and CLS and such Affiliates
will execute such legal papers and cooperate in the prosecution of such suit as may be reasonably requested by XBIO; provided, that XBIO
will promptly reimburse all out-of-pocket expenses (including reasonable attorneys’ fees and expenses) incurred by CLS and such
Affiliates in connection with such requested cooperation.

 

(c)            CLS
Rights if XBIO Elects Not to Proceed. If XBIO does not initiate a suit or take other appropriate action pursuant to Section 5.3(b)
within one hundred twenty (120) days after having received or sending notice written notice of such infringement or misappropriation
or, in the case of receipt of a notice letter sent by a Third Party pursuant to the requirements of 21 U.S.C. § 355(b)(2)(A)(iv)
or 355(j)(2)(A)(vii)(IV) or under any analogous provisions, within ten (10) days before any statutory or regulatory deadline for filing
such suit, then CLS will have the immediate right to initiate a suit or take other appropriate action that it believes is reasonably
required to prevent or abate actual or threatened infringement or misappropriation of, or otherwise to protect or enforce the relevant
Licensed Patent. XBIO and, as applicable its Affiliates will join such suit if the relevant court would lack jurisdiction if XBIO or
such Affiliates were absent from such suit and XBIO and such Affiliates will execute such legal papers and cooperate in the prosecution
of such suit as may be reasonably requested by CLS; provided, that CLS will promptly reimburse all out-of-pocket expenses (including
reasonable attorneys’ fees and expenses) incurred by XBIO and such Affiliates in connection with such requested cooperation.

 

(d)           Enforcement
Against Other Infringement of Licensed Patents. Except as provided in Section 5.3(b), as between the Parties CLS will have the sole
right, but not the obligation, to initiate a suit or take other appropriate action that it believes is reasonably required to prevent
or abate actual or threatened infringement or misappropriation of, or otherwise to protect or enforce, the Licensed Patents outside of
the Field during the Term.

 

(e)            Right
to Enforce Licensed Know-how. Responsibility for preventing or abating actual or threatened infringement or misappropriation of,
or otherwise protecting or enforcing Licensed Know-how will be determined in the same manner as the right to enforce Licensed Patents
under paragraphs (b) and (c). XBIO shall keep CLS informed of the status of all enforcement activities, and shall consider in good faith
all CLS’s comments regarding any aspect of such enforcement.

 

(f)            Conduct
of Certain Actions; Costs. XBIO will have the sole and exclusive right to select counsel for any suit initiated by it pursuant to
this Section. XBIO will assume and pay all of its own out-of-pocket costs incurred in connection with any litigation or proceedings initiated
by it pursuant to this Section, including the fees and expenses of the legal counsel selected by it.

 

(g)           Recoveries.

 

(i)             If
XBIO initiates suit as permitted in accordance with Sections 5.3(b) with respect to Licensed Patents and/or Licensed Know-how, any damages,
settlements, accounts of profits, or other financial compensation actually paid to XBIO by a Third Party based upon such suit, after
deducting and reimbursing XBIO and CLS’s actual out of pocket expenses (including reasonable attorneys’ fees and expenses)
incurred in pursuing such suit (such net amount, the “Recovery”), will be treated as Net Sales, and will be subject
to the royalty payment obligations under Section 3.2, with XBIO retaining the balance after such payment.

 

(ii)            If
CLS initiates suit pursuant to Section 5.2(c) with respect to Licensed Patents or Licensed Know-how, any damages, settlements, accounts
of profits, or other financial compensation actually paid to CLS by a Third Party based upon such suit, after deducting and reimbursing
CLS’s and XBIO’s actual out of pocket expenses (including reasonable attorneys’ fees and expenses) incurred in pursuing
such suit, will be shared equally by the Parties.

 

 

 

    	 	13	 

     

    

 

5.4.          Patent
Invalidity Claim. Each of the Parties will promptly notify the other Party in the event of any legal or administrative action by
any Third Party against a Licensed Patent, or any certification filed pursuant to 21 U.S.C. § 355(b)(2)(A)(iv) or 355(G)(2)(A)(vii)(IV)
or any notice under any analogous provisions, with respect to such Licensed Patents, of which it becomes aware, including any nullity,
revocation, reexamination or compulsory license proceeding. Responsibility for defending against any such action shall be determined
in the same manner as enforcement of the relevant Licensed Patents pursuant to Section 5.2.

 

5.5.          Patent
Marking. XBIO agrees to comply with the patent marking statutes in each country in which the Licensed Product is sold by XBIO or
its Affiliates or Sublicensees.

 

5.6.          Title
to and Ownership of Marketing Approvals. XBIO or its designee shall be the owner of all Marketing Approvals for the Licensed Product(s)
in the Territory and in the Field; provided, however, that XBIO hereby grants to CLS and its Affiliates a perpetual non-exclusive license
and right of reference to, and a right to copy, access and otherwise use, all such Marketing Approvals solely to support CLS’ and
its Affiliates’ seeking marketing approval of one or more products outside the Field. CLS agrees to have transferred any Licensed
Product Marketing Approvals in the Field that are owned by CLS or its Affiliates to XBIO or its designees.

 

ARTICLE
VI

CONFIDENTIALITY

 

6.1.          Confidential
Information. During the Term and for a period of seven (7) years after any termination or expiration of this Agreement, the Receiving
Party agrees (i) to keep in confidence and not to disclose the Disclosing Party’s Confidential Information to any Third Party without
the prior written consent of the Disclosing Party except for disclosures expressly permitted pursuant to this Section 6.1, and (ii) not
to use the Disclosing Party’s Confidential Information for any purpose, except pursuant to, and in order to carry out, the terms
and objectives of this Agreement (which includes activities contemplated by the licenses granted in Section 2.1) or as otherwise specifically
permitted under this Agreement. The terms of this Agreement will be considered Confidential Information of both Parties, subject to permitted
disclosures as set forth in this Article VI. In addition, if the Receiving Party is required to disclose Confidential Information of
the Disclosing Party by regulation, law or legal process, including by the rules or regulations of the United States Securities and Exchange
Commission (“SEC”), United Kingdom Financial Services Authority (“FSA”) or similar regulatory agency in a country
other than the United States, United Kingdom or of any stock exchange, the Receiving Party shall provide prior written notice and a copy
of such intended disclosure to the Disclosing Party and agrees to consult with the Disclosing Party with respect to the preparation and
submission of a confidential treatment request for this Agreement and will disclose only such Confidential Information of the Disclosing
Party as is required to be disclosed by the rules or regulations of the United States Securities and Exchange Commission (“SEC”),
United Kingdom Financial Services Authority (“FSA”) or similar regulatory agency in a country other than the United States,
United Kingdom or of any stock exchange and will cooperate in the disclosing Party’s efforts to obtain a protective order or to
limit the scope of the required disclosures.

 

6.2.          Permitted
Disclosures. The Receiving Party agrees that it and its Affiliates will provide or permit access to the Disclosing Party’s
Confidential Information only to the Receiving Party’s employees, consultants, advisors and bona fide potential acquirors, and
to service providers, investigators, Third Party contractors, potential and existing Sublicensees and distributors, in each case who,
in such Party’s reasonable judgment, have a need to know such Confidential Information to assist the Receiving Party with the activities
contemplated by this Agreement or in connection with a potential business relationship or investment that would encompass Licensed Product,
and who are subject to obligations of confidentiality and non-use with respect to such Confidential Information similar to the obligations
of confidentiality and non-use of the Receiving Party under Section 6.1 CLS and XBIO shall each remain responsible for any failure by
its Affiliates, and its and its Affiliates’ respective employees, consultants, advisors and permitted contractors, Sublicensees
and distributors, to treat such Confidential Information as required under Section 6.1 (as if such Affiliates, employees, consultants,
advisors, contractors, sublicensees and distributors were Parties directly bound to the requirements of Section 6.1). XBIO and CLS may
also disclose Confidential Information of the other Party to Regulatory Authorities and other governmental authorities, but solely in
connection with the activities contemplated by this Agreement.

 

 

 

    	 	14	 

     

    

 

6.3.           Publicity.
Neither Party will issue a press release or public announcement relating to the terms of this Agreement without the prior written approval
of the other Party, which approval shall not be unreasonably withheld or delayed, except that a Party may issue such a press release
or public announcement if required by applicable law, including by the rules or regulations of the United States Securities and Exchange
Commission (SEC), United Kingdom Financial Services Agency or similar regulatory agency in a country other than the United States or
of any stock exchange; provided that such Party complies with the notice and review provisions set forth in this Section.

 

6.4.           Publications.
XBIO and its Affiliates and Sublicensees shall have the right to publish the results of development, manufacture, commercialization and
use of Licensed Product in the Field during the Term, provided that it provides CLS with a copy of the publication at least sixty (60)
days prior to the intended publication date and agrees to delay publication up to an additional thirty (30) days if requested by CLS
in order to protect confidential information and/or intellectual property rights.

 

6.5.           Return
of Confidential Information. Upon termination of this Agreement prior to the end of the Term, the Receiving Party shall, at the request
of, and as directed by, the Disclosing Party, return or destroy Confidential Information of the Disclosing Party in the Receiving Party’s
possession, and shall destroy any reports or notes in Receiving Party’s possession to the extent containing the Disclosing Party’s
Confidential Information, and any electronic copies of any of the foregoing, provided that (i) the Receiving Party may retain one copy
of Confidential Information of the Disclosing Party for archival purposes, and (ii) neither Party shall be required to return or destroy
copies of the other Party’s Confidential Information stored on automatically created system back-up media.

 

ARTICLE
VII

REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS

 

7.1.           Mutual
Representations. Each Party hereby represents and warrants to the other Party, as of the Effective Date, as follows:

 

(a)            It
is duly organized and validly existing under the laws of its jurisdiction of incorporation and has the corporate power and authority
to execute and deliver this Agreement and to perform its obligations hereunder.

 

(b)           The
execution, delivery and performance of this Agreement by such Party has been duly and validly authorized and approved by proper corporate
action on the part of such Party. Such Party has taken all other action required by applicable law, its certificate of incorporation
or by-laws or any agreement to which it is a party or by which it or its assets are bound, to authorize such execution, delivery and
performance. Assuming due authorization, execution and delivery on the part of the other Party, this Agreement constitutes a legal, valid
and binding obligation of such Party.

 

(c)            The
execution and delivery of this Agreement, and the performance as contemplated hereunder, by such Party will not violate any applicable
law.

 

(d)           Neither
the execution and delivery of this Agreement nor the performance hereof by such Party requires such Party to obtain any permit, authorization
or consent from any governmental authority (except for any Marketing Approvals, pricing or reimbursement approvals, manufacturing-related
approvals or similar approvals necessary for development, manufacture or commercialization of Licensed Products), or from any other person,
and such execution, delivery and performance by such Party, including the granting of the licenses granted under this Agreement, will
not result in the breach of or give rise to any conflict, termination of, rescission, renegotiation or acceleration under or trigger
any other rights under any agreement or contract to which such Party may be a party existing as of the Effective Date.

 

 

 

    	 	15	 

     

    

 

(e)            Neither
Party nor any of its Affiliates has been debarred or is subject to debarment, and CLS has not used in any capacity in connection with
the development or manufacture of Licensed Product prior to the Effective Date, any person or entity who has been debarred pursuant to
Section 306 of the United States Federal Food, Drug, and Cosmetic Act, or who is the subject of a conviction described in such section.

 

7.2.           CLS’s
Representations and Warranties. CLS hereby makes the following representations and warranties to XBIO as of the Effective Date:

 

(a)            CLS
has the right to grant to XBIO the rights and licenses described in this Agreement.

 

(b)            Exhibit
A contains a complete and correct list of all existing patents and patent applications Controlled by CLS and its Affiliates that are
necessary or useful to research, develop, make, use, import, export, market, offer for sale, sell and have sold Licensed Product in the
Territory in the Field.

 

(c)            To
CLS’s knowledge, no Third Party is infringing any of the Licensed Patents identified on Exhibit A.

 

(d)            To
CLS’s knowledge, the making, using or selling of a Licensed Product in the Field will not infringe any Third Party patent rights.

 

(e)            CLS
has not received any written notice of (i) any claim that any patent or trade secret right owned or controlled by a Third Party would
be infringed or misappropriated by the manufacture, use, sale, offer for sale or importation of Licensed Products in the Field in the
Territory, or (ii) any threatened claims or litigation seeking to invalidate or otherwise challenge the Licensed Patents or CLS’s
rights therein.

 

(f)             CLS
is the exclusive owner or licensee of the Licensed Patents and the Licensed Know-how listed in Exhibit B. CLS’s rights to the Licensed
Patents and Licensed Know-how are held free and clear of any liens, security interests and similar encumbrances.

 

(g)            To
CLS’ knowledge, the SciVac Agreement is in full force and effect and is binding and enforceable against the parties thereto in
accordance with its terms. To CLS’s knowledge, neither party to the SciVac Agreement has received or sent any notice of breach
or default thereunder. The EIRGEN Agreement is in full force and effect and is binding and enforceable against the parties thereto in
accordance with its terms. Neither CLS nor, to CLS’s knowledge has any party to the EIRGEN Agreement received or sent any notice
of such breach or default thereunder.

 

(h)            To
CLS’s knowledge, there have been no inventorship or ownership challenges with respect to any of the Licensed Patents.

 

(i)             Neither
CLS nor its Affiliates has received written notice from any Regulatory Authority threatening any proceedings with respect to the research,
development or manufacture of any Licensed Product in the Field in the Territory.

 

(j)             CLS
represents that it has such knowledge and experience in business or financial matters that it is capable of evaluating the merits and
risks of an investment in the Shares.

 

7.3.           XBIO
Representations and Warranties.

 

(a)            Neither
XBIO nor any of its Affiliates or subsidiaries is in violation or default of any provision of its or their certificate of incorporation
or bylaws (or equivalent organization documents), or in breach of or default with respect to any provision of any agreement, judgment,
decree, order, lease, franchise, license, permit or other instrument to which it or they are a party or by which it or they or any of
its or their properties are bound except for any violation or default that would not reasonably be expected to have a Material Adverse
Effect.

 

 

 

    	 	16	 

     

    

 

(b)            There
are no legal or governmental actions, suits or proceedings pending and there are no inquiries or investigations pending, or, to XBIO’s
knowledge, any legal or governmental actions, suits, or proceedings threatened, against XBIO or any of its Affiliates or subsidiaries
or of which property owned or leased by the XBIO or any of its Affiliates or subsidiaries is or may be the subject, which actions, suits
or proceedings, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. Neither XBIO nor any
of its Affiliates or subsidiaries is party to or subject to the provisions of any injunction, judgment, decree or order of any court,
regulatory body, administrative agency or other governmental body specifically naming XBIO or any of its Affiliates or subsidiaries that
would reasonably be expected to have a Material Adverse Effect.

 

7.4.           No
Warranty. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY HERETO MAKES ANY REPRESENTATIONS AND NEITHER PARTY
EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT
(INCLUDING ANY LICENSED PRODUCT), INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE. EXCEPT
AS EXPRESSLY PROVIDED IN THIS AGREEMENT, CLS MAKES NO WARRANTY OR REPRESENTATION AS TO THE VALIDITY OR SCOPE OF THE LICENSED PATENTS
OR LICENSED KNOW HOW, OR THAT ANY LICENSED PRODUCT WILL BE FREE FROM AN INFRINGEMENT ON PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS
OF THIRD PARTIES. XBIO AND CLS DISCLAIM ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF LICENSED
PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL OR THAT, IF COMMERCIALIZED, ANY PARTICULAR SALES LEVEL WILL BE ACHIEVED.

 

ARTICLE
VIII

INDEMNIFICATION

 

8.1.           Indemnification
by XBIO. XBIO will indemnify, hold harmless, and defend CLS, its Affiliates, and their respective directors, officers, employees
and agents (the “CLS Indemnitees”) from and against any and all damages, liabilities, costs, expenses and amounts
paid in settlement (collectively, “Losses”) incurred in connection with any Third Party claim arising out of or resulting
from, directly or indirectly; (i) any breach of, or inaccuracy in, any representation or warranty made by XBIO in this Agreement, or
any breach or violation of any term of this Agreement by XBIO; (ii) the negligence or willful misconduct of XBIO, its Affiliates and
their respective Sublicensees, and their respective directors, officers, employees and agents; and (iii) the research, development, manufacture,
commercialization, or use of Licensed Product by XBIO and its Affiliates and Sublicensees in the Territory under this Agreement. Notwithstanding
the foregoing or anything in this Agreement to the contrary, XBIO will have no obligation to indemnify the CLS Indemnitees for any other
Losses as to which CLS is obligated to indemnify XBIO under Section 8.2.

 

8.2.           Indemnification
by CLS. CLS will indemnify, hold harmless, and defend XBIO, its Affiliates and their respective directors, officers, employees and
agents (the “XBIO Indemnitees”) from and against any and all Losses incurred in connection with any Third Party Claim
arising out of or resulting from, directly or indirectly, (i) any breach of, or inaccuracy in, any representation or warranty made by
CLS in this Agreement, or any breach or violation of any term of this Agreement or the EIRGEN Agreement by CLS; (ii) the negligence or
willful misconduct of any CLS Indemnitee; or (iii) the research, development, manufacture, commercialization, or use of Licensed Product
by CLS or any of its Affiliates or licensees (other than XBIO ) outside the Field. Notwithstanding the foregoing, or anything in this
Agreement to the contrary, CLS will have no obligation to indemnify XBIO Indemnitees for any Losses as to which XBIO is obligated to
indemnify CLS under Section 8.1.

 

8.3.           Indemnification
Procedure. In the event of any such claim against any XBIO Indemnitee or CLS Indemnitee (individually, an “Indemnitee”),
the indemnified Party shall promptly notify the other Party in writing of the claim and the indemnifying Party shall manage and control,
at its sole expense, the defense of the claim and its settlement. The indemnified Party will cooperate with the indemnifying Party and
assist in good-faith the defense of the claim and its settlement and may, at the indemnifying Party’s option and expense, be represented
in any such action or proceeding. The indemnifying Party will not be liable for any settlements, litigation costs or expenses incurred
by any Indemnitee without the indemnifying Party’s prior written authorization. Notwithstanding the foregoing, if the indemnifying
Party believes that any exceptions to its obligation of indemnification of the Indemnitees may apply, the indemnifying Party will promptly
notify the Indemnitees, who shall then have the right to be represented in any such action or proceeding by separate counsel at their
expense; provided that the indemnifying Party will be responsible for payment of such expenses if the Indemnitees are ultimately determined
to be entitled to indemnification from the indemnifying Party.

 

 

 

    	 	17	 

     

    

 

8.4.           Limitation
of Liability. NEITHER PARTY HERETO WILL BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF THIS
AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS
OF ANY NOTICE OF SUCH DAMAGES, EXCEPT AS A RESULT OF A PARTY’S WILLFUL MISCONDUCT. NOTHING IN THIS SECTION 8.4 IS INTENDED TO LIMIT
OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY.

 

8.5.           Insurance.
During the Term and for a period of at least two (2) years after the last commercial sale of a Licensed Product in the Territory under
this Agreement, XBIO will maintain insurance, with a reputable, insurer rated at least “A” by AmBest in an amount appropriate
for its business and products of the type that are the subject of this Agreement, and for its obligations under this Agreement, including,
commencing immediately prior to the first human clinical trial, product and clinical trial liability insurance of at least $2,000,000
per occurrence and $2,000,000 in the aggregate on a worldwide basis.

 

ARTICLE
IX

TERM AND TERMINATION

 

9.1.           Term.
This Agreement will become effective as of the Effective Date and will continue in full force and effect on a country-by-country and
Licensed Product-by-Licensed Product basis until terminated in accordance with this Article IX (“Term”). Upon expiration
of the Royalty Term in a country of the Territory (but not earlier termination of this Agreement) the Patent License granted to XBIO
under Section 2.1(a) will convert to perpetual, fully paid-up, royalty-free licenses on a country-by-country and Licensed Product-by-Licensed
Product basis with the same scope as set forth in such Section.

 

9.2.           Termination
for Convenience. XBIO will have the right to terminate this Agreement at any time and for any reason upon at least three (3) months’
prior written notice to CLS.

 

9.3.           Termination
for Cause. This Agreement may be terminated at any time during the Term upon written notice by either Party if the other Party is
in material breach of its obligations hereunder, and has not cured such material breach within sixty (60) days after written notice describing
the nature of such material breach is provided to the breaching Party. Additionally, if XBIO ceases all development activities for a
period of twelve (12) consecutive months, and does not cure such failure or cessation within sixty (60) days of receiving written notice
thereof from CLS, then CLS will have the right to terminate this Agreement in its entirety by providing written notice of termination
to XBIO.

 

9.4.           CLS Termination. To the extent permitted by applicable law, CLS may terminate this Agreement upon written notice of termination
to XBIO upon or after the filing of bankruptcy of XBIO or the making by XBIO of any assignment for the benefit of creditors.

 

9.5.           Patent
Challenge. CLS has the right to terminate this Agreement upon written notice to XBIO in the event that XBIO or any of its Affiliates
or Sublicensees directly or indirectly challenges in a legal or administrative proceeding the patentability, enforceability or validity
of any Licensed Patent or the scope or construction of any Valid Claim (each, a “Patent Challenge”); provided that
this Section 9.5 will not apply to any such Patent Challenge that is first made by XBIO or any of its Affiliates or Sublicensees in defense
of a claim of patent infringement brought by CLS or its Affiliates under the applicable Licensed Patent.

 

 

 

    	 	18	 

     

    

 

9.6.           Effect
of Termination.

 

(a)            Pre-Termination
Obligations; Transfer of Information and Filings. Upon the termination of this Agreement for any reason, nothing herein shall be
construed to release either Party from any obligation that matured prior to the effective date of such termination. XBIO shall remain
obligated to provide an accounting for and to pay royalties earned. Subject to Section 9.1, in the event of termination, (i) the licenses
granted hereunder shall terminate; (ii) XBIO shall have no further right under Licensed Patents or Licensed Know-how to develop, manufacture
or market the Licensed Product or any product containing Licensed Product, or otherwise to use the Licensed Patents or Licensed Know
How; (iii) all XBIO sublicenses shall be subject to CLS’s obligation in Section 2.2(a); and (iv) except as otherwise set forth
in Section 2.4(a), all rights granted to XBIO hereunder shall revert to CLS for the benefit of CLS. Notwithstanding the foregoing, XBIO
shall be entitled to sell any completed inventory of Licensed Product which remain on hand as of the date of the termination to the extent
necessary to satisfy its contractual and legal obligations, so long as XBIO pays to CLS the royalties applicable to said subsequent sales
in accordance with the terms and conditions as set forth in this Agreement; provided that no sales shall be permitted after the expiration
of six (6) months after the date of termination. XBIO will execute all documents and take all such further actions, as may be reasonably
requested by CLS in order to give effect to the preceding sentences as soon as practicable.

 

(b)           Post-Termination
Royalty by CLS. If this Agreement is terminated by CLS for cause in accordance with Section 9.3, or by XBIO for convenience in accordance
with Section 9.2, then XBIO shall, at CLS’s request, grant to CLS or CLS’s designee a perpetual, non-exclusive license to
use solely in the Field: (a) all governmental or regulatory correspondence, conversation logs, filings and approvals (including all Marketing
Approvals and pricing and reimbursement approvals) owned or otherwise Controlled by XBIO and relating to the development, manufacture
or commercialization of the Licensed Product in the Territory and all product trademarks then being used in connection with Licensed
Product, other than XBIO corporate trademarks; and (b) all safety data and other adverse event data owned or otherwise Controlled by
XBIO; with all rights granted subject to the terms of any subsequent sublicense XBIO entered into providing a Sublicensee rights to the
property set forth in both (a) and (b) above. For purposes of clarity, if the Sublicensee has exclusive rights to the property set forth
in (a) and (b) above, then CLS shall have not right to sublicense those rights to a third-party, nor shall CLS have a right to use such
property set forth in (a) and (b) above for its own development or commercial purposes. In exchange for the license set forth in this
section 9.6(b), CLS shall pay to XBIO on a quarterly basis an amount equal to [***] of all proceeds received by CLS or any of its Affiliates,
successors, or assigns arising from or relating to any Licensed Product, Licensed Patent, or Licensed Know-how.

 

9.7.           Survival.
Any expiration or termination of this Agreement will be without prejudice to the rights of either Party against the other accrued or
accruing under this Agreement prior to expiration or termination, including payment obligations arising prior to such expiration or termination.
The provisions of Sections 2.4(a) and 5.6, and Articles V, VI, VII, VIII and IX will survive any expiration or termination of this Agreement
and all other provisions contained in this Agreement that by their explicit terms survive expiration or termination of this Agreement,
will survive. Except as set forth in this Article IX, upon termination or expiration of this Agreement all other rights and obligations
of the Parties under this Agreement terminate.

 

ARTICLE
X

DISPUTE RESOLUTION

 

10.1.         Continuance of Rights and Obligations During Pendency of Dispute Resolution. If there are any disputes in connection with
this Agreement, including disputes related to termination of this Agreement under Article IX, all rights and obligations of the Parties
shall continue until such time as any dispute has been resolved in accordance with the provisions of this Article X.

 

 

 

    	 	19	 

     

    

 

10.2.         Referral
of Unresolved Matters to Senior Executives. In the event that the Parties are unable to resolve a dispute within twenty-five (25)
days from the date such dispute is first brought to the other Party’s attention, the matter shall be referred to a senior executive
of each Party to be resolved by negotiation in good faith as soon as is practicable but in no event later than thirty (30) days after
referral.

 

10.3.         Arbitration.
Any dispute, controversy or claim arising out of or relating to this Agreement during the preclinical and clinical trial development
of a Licensed Product which the Parties have not resolved under Section 10.2, will be decided by arbitration in accordance with the Rules
of the Conflict Prevention and Resolution Institute (“CPR”) in effect at the time the dispute arises, unless the Parties
hereto mutually agree otherwise. To the extent such rules are inconsistent with this provision, this provision will control. The following
rules will apply to any such arbitration:

 

(a)            Any
demand for arbitration must be made in writing to the other Party.

 

(b)            There
will be three arbitrators, one of whom shall be appointed by each party and a third of whom shall be the chairman of the panel and be
appointed by mutual agreement of the two arbitrators appointed by the Parties, and with the mutual written consent of the Parties, with
such consent not to be unreasonably withheld. If the two arbitrators cannot agree on the appointment of the third arbitrator within thirty
(30) days, then the CPR shall select the arbitrator, who shall be approved following the mutual written consent of the Parties, with
such consent not to be unreasonably withheld. Any arbitration involving patent rights, other intellectual property rights or intellectual
property will be heard by arbitrators who are expert in such areas.

 

(c)            The
arbitration will be held in the State of Delaware, or such other place as the Parties agree. The arbitrators will apply the substantive
law of the Delaware.

 

(d)            Neither
Party will have the right independently to seek recourse from a court of law or other authorities in lieu of arbitration, but each Party
has the right before or during the arbitration to seek and obtain from the appropriate court provisional remedies to avoid irreparable
harm, maintain the status quo or preserve the subject matter of the arbitration. There shall be a stenographic record of the proceedings.
The decision of the arbitrators will be final and binding upon both Parties. The arbitrators will render a written opinion setting forth
findings of fact and conclusions of law.

 

(e)             The
expenses of the arbitration will be borne by the Parties in proportion as to which each Party prevails or is defeated in arbitration.
Each Party will bear the expenses of its counsel and other experts.

 

10.4.         Litigation.
Any dispute, controversy or claim arising out of or relating to this Agreement following approval of a Licensed Product, which the Parties
have not resolved under Section 10.2, will be decided by a court of the appropriate jurisdiction in the State of Delaware.

 

10.5.         Equitable
Relief. Notwithstanding anything to the contrary, each of the Parties hereby acknowledges that a breach of their respective obligations
under this Agreement may cause irreparable harm and that the remedy or remedies at law for any such breach may be inadequate. Each of
the Parties hereby agrees that, in the event of any such breach, in addition to all other available remedies hereunder, the non-breaching
Party shall have the right, through the arbitration process described in Section 10.3, to seek equitable relief to enforce the provisions
of this Agreement.

 

ARTICLE
XI

MISCELLANEOUS

 

11.1.         Governing
Law and Jurisdiction. The validity, construction and performance of this Agreement will be governed by and construed in accordance
with the substantive laws of the State of Delaware excluding any conflicts or choice of law rule or principle that might otherwise refer
construction or interpretation of this Agreement to the substantive law of another jurisdiction.

 

 

 

    	 	20	 

     

    

 

11.2.         Force
Majeure. Except for each Party’s confidentiality and indemnity obligations, the obligations of either Party under this Agreement
shall be excused during each period of delay caused by matters such as acts of God, pandemics, epidemics, strikes, supplier delays, failure
of utilities or common carriers, shortages of raw materials, government orders, sufferance of or voluntary compliance with acts of government
or governmental regulation, or acts of war or terrorism, which are reasonably beyond the control of the Party obligated to perform. Force
majeure shall not include a lack of funds, bankruptcy or other financial cause or disadvantage, and force majeure shall not excuse or
delay any Party’s payment obligations under this Agreement. Nothing contained in this Agreement shall affect either Party’s
ability or discretion regarding any strike or other employee dispute or disturbance and all such strikes, disputes or disturbances shall
be deemed to be beyond the control of such Party. A condition of force majeure shall be deemed to continue only so long as the affected
Party shall be taking all reasonable actions necessary to overcome such condition. If either Party shall be affected by a condition of
force majeure, such Party shall give the other Party prompt notice thereof, which notice shall contain the affected Party’s estimate
of the duration of such condition and a description of the steps being taken or proposed to be taken to overcome such condition of force
majeure. Any delay occasioned by any such cause shall not constitute a default, breach or failure under this Agreement, and the obligations
of the Parties shall be suspended during the period of delay so occasioned. During any period of force majeure, the Party that is not
directly affected by such condition of force majeure may take any reasonable action necessary to mitigate the effects of such condition
of force majeure.

 

11.3.         Further
Assurances. Each Party hereto agrees to perform such acts, execute such further instruments, documents or certificates, and provide
such cooperation in proceedings and actions as may be reasonably requested by the other Party in order to carry out the intent and purpose
of this Agreement.

 

11.4.         Notices.
Any notice required or permitted to be given under this Agreement will be in writing and will be deemed to have been properly given if
delivered in person by an internationally recognized overnight courier, or by fax (and promptly confirmed by overnight courier), to the
addresses given below or such other addresses as may be designated in writing by the Parties from time to time during the Term.

 

In the case of CLS:

 

CLS Therapeutic Limited

PO Box 175, Frances
House,

Sir William
Place, St Peter Port

Guernsey,
Channel Islands

GY1 4HQ

Attention: Mrs. Anne Le Cheminant

Facsimile: +44 (0) 1481 722674

Email: AnneLeCheminant@equiomgroup.com

 

With a copy to:

 

CLS Therapeutics, Inc.

Attn: Chief Executive Officer

101 6th Avenue, Floor 3

New York, NY 10013, U.S.A.

 

 

 

    	 	21	 

     

    

 

In the case of XBIO:

 

Xenetic Biosciences,
Inc.

40 Speen Street, Suite 102

Framingham, Massachusetts01701

Attn: Chief Executive
Officer

Email: j.eisenberg@xeneticbio.com

 

With a copy to:

 

Holland & Knight LLP

701 Brickell Avenue, Suite 3300

Miami, FL 33131

Attention: Danielle Price, Esq.

Email: danielle.price@hklaw.com

 

11.5.         Assignment.
This Agreement may not be assigned or otherwise transferred by either Party, without the written consent of the other Party such consent
not to be unreasonably withheld, conditioned or delayed; provided, however, that either Party may, without such consent, assign this
Agreement, in whole or in part, (i) to any of its Affiliates, and (ii) to a Third Party successor or purchaser of all or substantially
all of its business or assets to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other similar transaction,
provided that, the Third Party successor or purchaser provides written notice to the other Party that such Third Party agrees to be bound
by the terms of this Agreement. Any purported assignment in violation of this Section 11.5 will be void. Any permitted assignee shall
assume all obligations of its assignor under this Agreement.

 

11.6.         Affiliate
Performance. Any obligation of XBIO or CLS under or pursuant to this Agreement may be satisfied, met or fulfilled, in whole or in
part, either by XBIO or CLS directly or by any Affiliate or Sublicensee of either party.

 

11.7.         Amendment.
The Parties hereto may amend, modify or alter any of the provisions of this Agreement, but only by a written instrument duly executed
by both Parties hereto.

 

11.8.         Entire
Agreement. This Agreement, along with all schedules and exhibits attached hereto, contains the entire understanding of the Parties
with respect to the subject matter hereof and supersedes all prior agreements, whether written or oral. Each Party confirms that it is
not relying on any representations, warranties or covenants of the other Party except as specifically set out in this Agreement.

 

11.9.         No
Benefit to Third Parties. The provisions of this Agreement are for the sole benefit of the Parties and their successors and permitted
assigns, and they shall not be construed as conferring any rights in any other person or entity.

 

11.10.       Waiver.
The failure of a Party to enforce at any time for any period any of the provisions of this Agreement will not be construed as a waiver
of such provisions or of the rights of such Party thereafter to enforce each such provision.

 

11.11.       No
Implied Licenses. Except as expressly and specifically provided under this Agreement, the Parties agree that neither Party is granted
any implied rights to or under any of the other Party’s current or future patents, trade secrets, copyrights, moral rights, trade
or service marks, trade dress, or any other intellectual property rights.

 

 

 

    	 	22	 

     

    

 

11.12.       Relationship
of the Parties. The Parties agree that their relationship established by this Agreement is that of independent contractors. Furthermore,
the Parties agree that this Agreement does not, is not intended to, and shall not be construed to, establish a partnership or joint venture,
and nor shall this Agreement create or establish an employment, agency or any other relationship. Except as may be specifically provided
in this Agreement, neither Party shall have any right, power or authority, nor shall they represent themselves as having any authority
to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act as
an agent for the other Party for any purpose.

 

11.13.       Severability.
If any provision of this Agreement is held unenforceable by a court or tribunal of competent jurisdiction in a final unappealable order
because it is invalid or conflicts with any law of any relevant jurisdiction, then such provision will be inoperative in such jurisdiction
and the remainder of this Agreement shall remain binding upon the Parties hereto.

 

11.14.       Interpretation.

 

(a)            General. Unless the context of this Agreement otherwise requires, (a) words of one gender include the other gender; and
(b) words using the singular or plural number also include the plural or singular number, respectively. Whenever this Agreement refers
to a number of days, unless otherwise specified, such number shall refer to Calendar Days.

 

(b)           Other
Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that agreement,
contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and
thereof.

 

(c)            Capitalization.
Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein, shall have the meaning as defined in this Agreement.

 

(d)           Date
References. References from or through any date mean, unless otherwise specified, from and including or through and including, respectively.

 

(e)            Schedules
and Exhibits. All Schedules and Exhibits annexed hereto or referred to herein are hereby incorporated in and made a part of this
Agreement as if set forth in full herein.

 

(f)            Person
References. References to any Person include the successors and permitted assigns of that Person.

 

(g)           References
to Parts of this Agreement. References to Articles, Sections, Schedules, and Exhibits are to Articles, Sections, Schedules, and Exhibits
of this Agreement unless otherwise specified.

 

(h)           Other
Definitional and Interpretative Provisions. The words “hereof”, “herein” and “hereunder” and
words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement.
Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be
deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words
of like import. The word “or” is used in the inclusive sense (and/or). “Writing”, “written” and comparable
terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form.

 

(i)             Headings.
The Article and Section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning
or interpretation of this Agreement.

 

 

 

    	 	23	 

     

    

 

(j)             Expenses.
Except as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other
experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of
this Agreement.

 

11.15.       Further
Assurances. Each Party agrees to execute, acknowledge and deliver such further documents and instruments and do any other acts, from
time to time, as may be reasonably necessary, to effectuate the purposes of this Agreement.

 

11.16.       Counterparts.
This Agreement may be executed in any number of counterparts (including by facsimile or electronic signature, including DocuSign), each
of which shall be deemed an original, but all of which together shall constitute one and the same document.

 

[Signature Page Follows]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	24	 

     

    

 

IN WITNESS WHEREOF, XBIO and CLS have caused this
Agreement to be duly executed by their authorized representatives under seal, in duplicate on the Effective Date.

 

 

 

CLS Therapeutics Ltd.

 

 

By: /s/ Jodi Langlois                        

Name: Virtus Directors Limited

Title: Director

 

Xenetic Biosciences, Inc.

 

By: /s/ Jeffrey Eisenberg                 

 

Name: Jeffrey Eisenberg

 

Title: Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature page to D15 Sublicense Agreement]

    	 	 	 

     

    

 

Exhibit A

Licensed Patents

 

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	 	 

     

    

Exhibit B

Licensed Know-how

 

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	 	 

     

    

 

Exhibit C

 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]